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Abstract 
This project aimed to investigate the main traditional use of the plant Hyptis crenata 
(HC) and evaluate its activity in a pre-clinical trial. A traditional use survey was carried 
out in two municipalities in Brazil, interviewing 20 people. The results showed that the 
main use of HC is for pain relief (19/20). The main method used for its preparation was 
decoction extract (11/20). The antinociceptive activity of HC decoction extract was 
evaluated showing that HC 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.) increased delay in 
withdrawal response in the Hargreaves thermal withdrawal test by 29% and 28% 
respectively and decreased writhing occurrences induced by acetic acid by 70% and 
71% (p<0.05), when compared to vehicle. These treatments were examined in the acetic 
acid writhing test for their effects on c-fos protein expression. The results showed that 
HC 150 mg/kg (p.o.) decreased c-fos expression in the hypothalamic paraventricular 
nucleus by 40% (p<0.05). This study also evaluated the HC doses 1 mg/kg (p.o.), 5 
mg/kg (p.o.) and 45 mg/kg (p.o.) to assess the dose-response effect. HC dose- 
dependently induced antinociception in both animal models from 0 mg/kg (p.o.) to 15 
mg/kg (p.o.), until a plateau response occurred between 15 mg/kg and 45 mg/kg 
(thermal withdrawal test p=0.0002 and writhing inhibition p=0.4725). Then, the 
decoction extract was fractionated and tested in an attempt to identify which HC 
compounds were active in inducing the antinociceptive effect. The hexane fraction had 
the highest activity (per dose) compared to the other fractions, indicating that it was 
enriched with the active compounds. Also, a preliminary COX inhibition assay was 
carried out; the results indicating possible COX-2 inhibition for HC treatments. 
Additionally, an investigation through behavioural analyses of whether HC and its 
fractions were affecting basal behaviour, such as muscle relaxation and sedation, 
showed no change of such behaviour. Overall, these data support the antinociceptive 
effect of Hyptis crenata and that there are specific compounds responsible for this effect. 
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1.1 Traditional Use of Medicinal Plants 
1.1.1 Historical background of herbal medicine 
The use of medicinal plants is not novel, in fact this form of medication has been used 
by humans for thousands of years. There are fossil records showing that since the 
middle Palaeolithic age at least 60,000 years ago plants were used for medicinal 
purposes (Leroi Gourhan, 1975). This timeline can also be affirmed by the discovery of 
a Neanderthal archaeological site in Iraq dated to 60,000 B.C. that revealed pollen of 
several species of medicinal plants being used (Gurib-Fakim, 2006). 
In relation to the history of herbal medicine, its origin and development, there are some 
distinctions involving continents, countries and cultures. For instance, African, Greek, 
Indian and Chinese each have distinct histories. The African continent is described as 
being the oldest and perhaps the most diverse application of medication, including 
phytotherapy. In the African continent, traditional medicines have varied forms, usually 
based on a holistic concept involving body and mind. The diagnoses made by the healer 
are for treatment of the psychological basis first and after medicine is prescribed to treat 
the symptoms (Gurib-Fakim, 2006). Also, in countries like South Africa, the traditional 
healer, known as Dingaka or Invanga, believed that preparations involving plant, animal 
and insect parts produce a powerful synergistic action for treatments (Louw et al., 2002). 
The ancient Greeks also played an important role in introducing phytotherapy as 
medicine, but this system incorporated a close relation between their Gods and the plant. 
As a result, some plants that are known today, such as Origanum dictamnus and 
Artemisa absinthium, were first named in dedication to the goddess Artemis-Diktynna a 
thousand years B.C. (Liolios et al., 2010). This “god-plant belief” together with Greek 
medicine were drastically decreased after the end of the Roman Empire due to the fact 
that this knowledge was not valued by the Christian Byzantines (Lardos, 2006). 
However, some of this ancient knowledge survived, and can be found in the classical 
documents written by Hippocrates (5th century B.C.), Dioscorides (1st century A.D.), 
and Galen (2nd century A.D.) (Karousou and Deirmentzoglou, 2011). 
Another nation that has made an important contribution to phytotherapy is India. This 
country has a very ancient practice of traditional medicine named Ayurveda. Unlike the 
ancient Greek, this medicine is still being practiced in India (Dwivedi, 2007). There are 
© Newcastle University 2013  3 
many plants reported for their therapeutic properties in the Ayurveda system and one of 
the oldest documents, dated to 100-500 B.C., describes 700 plants with descriptions of 
their therapeutic properties (Patwardhan, 2005; Patwardhan et al., 2005). 
Like Ayurveda, traditional Chinese medicine is also an ancient system of treatment and 
is dated to more than 5000 years old (Gurib-Fakim, 2006). It is distinguished from 
medicine which focuses on individual treatment, such as Western medicines, by the 
concept of traditional Chinese medicine that uses plants that will adjust the balance of 
the body, thereby improving its pathology (Xiang et al., 2008). This medical system has 
been disseminated to other Asian countries, including Japan where nowadays it is 
known as Kampo medicine (Ushiroyama, 2005). 
The various systems of medicine used by these cultures have been distributed and have 
spread to other continents when the process of colonisation took place. The outcome of 
this process was a fusion of knowledge between the coloniser and original inhabitant of 
the territory. An example of this applies to countries colonised in Central and South 
America. Using Brazil as an example, this country has a vast biodiversity of plant 
species that were used as medicine by the natives. Although the traditional indigenous 
use of herbs has predominated, the herbal medicine systems have undergone 
modification due to the process of colonisation carried out by Europeans that used the 
Western herbalism system that originated in Greece and Rome, and also the 
introduction of Africans during the slavery period (Monteiro et al., 2010; De Melo et al., 
2011). 
This is the historical background of medicinal plants, but it does not mean that use of 
medicinal plants belongs to the past. In fact, it is still in use worldwide and its demand 
has been progressively increasing in recent decades in the form of phytotherapy. The 
next section will describe the traditional medicine that is still in use and the 
commercialisation of phytotherapeutics. 
1.1.2 Current use of plants as medication 
As mentioned, some of the traditional medicine systems have contributed to the origin 
of different types of medicine that are still being used worldwide. They can be classified 
into four basic systems: (i) traditional Chinese herbalism or Kampo medicine in Japan; 
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(ii) traditional Indian medicine, Ayurvedic herbalism; (iii) Western herbalism; and (iv) 
traditional African, Arabic and Islamic medicine (Azaizeh et al., 2008). 
The traditional Chinese herbal medicine lists more than 11,228 plant species. This fact 
makes it the most comprehensive form of herbalism worldwide (Sucher, 2006). It has 
recently been reported that there are more than 600 plants being used by the Chinese 
pharmacopoeia (Zheng et al., 2011). 
With respect to Ayurvedic medicine, in India the use of this medicinal system provides 
healthcare to about 80% of the population in India, i.e. around 1 billion people (Jain et 
al., 2005; Tripathi et al., 2011). 
Ethnobotanical surveys from various places in Europe that use Western herbalism have 
shown that it is still widely practiced in these regions (Azaizeh et al., 2008). In Cyprus, 
for example, there are shops selling a variety of herbs that are used mainly for 
neuropsychiatric, gastrointestinal, and respiratory ailments (Karousou and 
Deirmentzoglou, 2011). In Navarra, in the Iberian Peninsula, with a population of 
144,674 inhabitants, the use of 90 medicinal plants belonging to 39 botanical families is 
reported. These species include Santolina squarrosa, Thymus vulgaris, Rosmarinus 
officinalis and Urtica dioica (Calvo et al., 2011). A systematic review of the traditional 
use of wild and cultivated plants in north-eastern Bosnia and Herzegovina, Southeast 
Europe, showed the use of 254 plant species with 1655 different preparation methods. 
The most frequently mentioned indications were disorders of the gastrointestinal tract, 
respiratory system, urogenital tract, skin, blood system, cardiovascular system, nervous 
system and rheumatism (Saric-Kundalic et al., 2011). 
Herbalism that has spread to or from North and South America is classified as Neo-
Western herbalism. As mentioned earlier this medicine system applies formulations 
prescribed in ancient pharmacopoeias from western medicines and also preparation 
methods indicated by indigenous origin. An example of this system is the use of the 
plant Echinacea as an immune stimulant for the treatment of colds (Elvin-Lewis, 2001). 
The Tehuacán-Cuicatlán Valley, in central Mexico, is reported to have 2800 plant 
species with 88 of these species used in traditional medicine (Pérez-Negrón and Casas, 
2007). In Latin America, social transmission of medicinal plant knowledge and skills is 
passed on by an experienced healer or elderly relatives, and some of them, due to their 
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spiritual beliefs, claim that the information is acquired through dreams (Vandebroek et 
al., 2004). 
As described above, the use of plants in Brazil has been influenced by its cultural 
mixing. However, another factor that plays an important role is the geographical 
conditions that will make possible for certain species to be available. Therefore, in 
Brazil the traditional use of medicinal plants can be divided into five categories 
according to its vegetation distribution and cultural background. These are North 
(Amazon Forest); Northeast (tropical forest and Caatinga which is a desert-like terrain); 
Southeast (Atlantic forest and Cerrado that is savannah-like vegetation); Central-West 
(Cerrado and Pantanal); and South (rainforest along the coast known as Mata Atlântica, 
tropical semi-deciduous forest known as Araucárias, and Pampas). The size of the area 
and the variety of different species caused by geographical variability contributes to the 
number of plant species being used. For instance, an ethnobotanical survey in the 
central west area showed that many species were being used in comparison with the 
relatively small number of people interviewed. As reported in the survey carried out in 
the Monjolinho settlement in Mato Grosso do Sul state that shows 210 different species 
being used by 35 people (da Cunha and Bortolotto, 2011). On the other hand a survey 
involving 92 people from Rio Grande do Norte in the Northeast region shows only 45 
species being used (Silva and Freire, 2010). 
In summary, these reports show that the concept of using medicinal plants as a form of 
treatment is an ancient knowledge that is still spreading worldwide. However the 
method of use and the plant species varies according to cultural belief, type of treatment 
needed and geographical influences that determine which species would be available to 
be used. 
1.2 Research on Medicinal Plants 
1.2.1 Pain relief drugs developed based on medicinal plants 
There are several medicinal plant compounds that have been utilised in pain relief drug 
discovery. Perhaps two of the most well-known would be morphine and salicylic acid. 
The former was isolated by a German pharmacist Friedrich Serturner in 1804. He 
named the compound and defined its class as an alkaloid (Klockgether-Radke, 2002). 
Morphine was extracted from the poppy Papaver somniferum and since its discovery it 
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has been used for pain therapy and currently is particularly used against cancer pain 
(Cherny, 2000). Salicylic acid was isolated from the white willow Salix alba and later 
synthesised as acetylsalicylic acid by the pharmaceutical company Bayer, which named 
it “Aspirin”, the change in the chemical structure enabled this drug to became more 
palatable (Mackowiak, 2000). In 1971 the pharmacologist John Vane studying the 
effects of aspirin identified that its mechanism involved inhibition of prostaglandins. He 
also suggested that the salicylate was more effective in inhibiting PGE1 than PGE2 
(Vane, 1971). Further research investigating the pain relief mechanism of morphine and 
salicylic acid led to the identification of the opioid receptors and the understanding of 
cyclooxygenase inhibition mechanisms that will be discussed later in this chapter. 
After Bayer’s work with salicylic acid other pharmaceutical companies, like Merck, 
also turned their attention towards chemical compounds from plants, and started 
screening plants used by traditional systems like the Chinese. However the aim was to 
find compounds that could be synthesised and modified into a drug in the same way as 
acetylsalicylic acid (Borris, 1996). 
In the course of time a different approach has been adopted in the search of compounds 
from medicinal plants, due to the high cost of compound synthesis and also because 
more people started looking for more natural forms of medication. Complementary and 
alternative medicines (CAM) became popular, using herbal therapy that has its focus on 
using the entire extract rather than a single compound (Desmarchelier, 2008; Zareba, 
2009). According to WHO the commercialisation of these products has generated 
income of US$ 5 billion in 2003-2004 for western societies and for China US$ 14 
billion in 2005. Another explanation for this increasing demand could be that herbal 
medicine represents a valuable resource in disease prevention rather than treatment, this 
is the case for therapy of diseases affecting the central nervous system, such as chronic 
neurodegenerative disorders, e.g. Alzheimer's disease and Parkinson's disease (Iriti et al., 
2010). 
In general, the compounds from medicinal plants have contributed greatly to the 
discovery and development of important drugs that have played crucial roles for human 
health. An example of this is the antimalarial agent artemisinin, which was extracted 
from sweet wormwood, Artemisia annua, and has been manufactured by many 
companies, including Merck and Bayer (Borris, 1996). The search for plant compounds 
still continues and one major focus for decades has been to find an efficient treatment 
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for cancer. The National Cancer Institute in United States launched a large project in 
1960 for screening anti-tumour agents from medicinal plant compounds, they evaluated 
35,000 plant species. As a result of this program, the compound taxol from the yew tree 
was identified and so far it has been very successful as an anti-tumour drug (Balunas 
and Kinghorn, 2005; Ghantous et al., 2010). 
1.2.2 The process of evaluation of plant activities and their pharmacological 
properties 
Many research groups have been evaluating medicinal plants with a history of 
traditional use and their compounds as a source of new clinically useful medicines 
(Srinivasan, 2005). However, there are concerns and criticisms regarding the reliability 
of results from much of the research on medicinal plants, mainly related to the quality 
and appropriateness of the methods used (Wirth et al., 2005; Chan and Chan, 2008). 
This would also apply for studies evaluating pain relief properties. 
When evaluating antinociceptive effects in animals it is important to use the right pain 
assessment methods and to check for false positive results that can occur, for example 
when muscular relaxation is interpreted as antinociception (Le Bars et al., 2001). 
However, studies of the effects of medicinal plants on pain in animal models differ 
conceptually from the use of the same models as part of the development of synthetic 
antinociceptives, and a failure to take this into account when developing the 
experimental protocols may render the results of the research irrelevant for either 
purpose. 
When evaluating medicinal plants in particular, any available information about 
traditional use of the plant species should be considered when deciding the methods of 
preparation and dosage (Fabricant et al., 2001). Testing a synthetic compound for pain 
relief in an animal model usually takes place at a stage where the mechanism is already 
known and the aim is to investigate dosages and toxicology of the compound. In 
contrast, in a medicinal plant evaluation the relevant doses can usually be estimated 
from information about the traditional use, while there is a need to evaluate the 
magnitude of the effects (if any) and assess which mechanisms may be involved. 
It is important to investigate the traditional use of medicinal plants to create a database 
and guidelines for methods of use and preparations, also such information could be used 
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to develop new drugs and contribute to medical treatments. In relation to traditional use 
of any medicinal plant, its long term use by humans gives some advantages when using 
its lead compounds to develop a new drug, due to the fact that their bioactive 
compounds have been used for many generations. Furthermore, as a result of their long 
term use it can be assumed that they are more likely to have a low toxicity for humans. 
Unfortunately, literature on medicinal plants used in traditional medicine usually do not 
report detail on the therapeutic uses and method of preparation (Chinsamy et al., 2011). 
There are relatively few studies that have evaluated through pharmacological trials the 
information obtained from a traditional use survey. Usually the pharmacological 
evaluation is made by other research groups. Furthermore, there are few traditional use 
studies that describe with detail the preparation methods for the plants mentioned. The 
majority of studies which have carried out surveys and performed pharmacological 
studies afterwards are the studies involving antiplasmodial activity (Sanon et al., 2003). 
Although this fact gives an impression that there is little integration between 
ethnobotanical and pharmacology areas, this might be a misleading concept. Some 
research groups that reported ethnobotanical studies might also be carrying out 
pharmacological trials, but publishing in separate documents. 
1.3 Pain 
The word "pain" was originated from the Latin “poena”, meaning a fine or a penalty 
(MedicineNet, 2010). As the word suggests it is a very unpleasant sensation but it is 
also crucial for the protection of the body and for the process of healing damaged 
tissues. However, pain can become chronic and abnormal, through pathophysiological 
processes causing problems not only for the patient but consequently for the public in 
general due to the total cost of pain for the national economy (Woolf and Salter, 2000). 
Reports from the British Pain Society show that in the United Kingdom millions of 
working days are lost due to pain caused by arthritis, and an large sum of money, £5 
billion is spent per annum to treat pain symptoms such as back pain (British Pain 
Society 2008). This type of pain or any other chronic pain still represents difficult 
challenges for medicine because in many of these cases there is no efficient treatment 
available. Therefore, the patients need to adapt to live with the problem for the rest of 
their lives. (Melzack and Wall, 1996). 
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1.3.1 Describing and classifying pain – Acute and chronic pain 
Although sense of pain has an established physiological basis, the sensation varies 
according to individual experience. The major classification of pain is according to its 
duration and the type of trigger that will transform into the pain sensation. The term 
acute pain is used for pain that lasts only for a relatively short period (hours-days). The 
purpose of this type of pain is to induce the individual to react and protect the part of the 
body injured until it is healed. After it is healed, the pain should disappear (Melzack and 
Wall, 1996). However in some cases the patient still suffers the pain sensation even 
after the original injury has healed and for this reason it becomes classified as chronic 
pain. This is an incessant noxious stimulus sensation that can be prolonged from months 
to years and is provoked by a dysfunction of the physiological pathway (Cheville et al., 
2000). This type of sensation can be categorised as hyperalgesia, that is “an increased 
amount of pain associated with a mild noxious stimulus or spontaneous pain without 
any precipitating stimulus” (Cheville et al., 2000; Rang et al., 2007). Some of the 
known types of chronic pain are: fibromyalgia (a generalised pain of muscles and 
tissues), back pain, neuropathic pain (arising from damage to the nervous system), 
arthritis and postoperative pain. Compared to arthritis and back pain, fibromyalgia is the 
least understood regarding its pathophysiology but is relatively common (2.4% of the 
population) with a preponderance of cases in women (incidence ratio of 9:1 
female:male) (McBeth and Mulvey, 2012). Postoperative pain can be common after 
surgery to remove a tumour, where the pain stimuli persist after it is healed. In the case 
of neuropathic pain, it can occur after central nervous system disorders, such as that 
caused by stroke. Chronic pain is known for its incessant suffering, no matter what is its 
cause. In the long term it is likely to induce psychiatric disorders like depression that 
consequently intensifies the complexity of the disease making the treatment even more 
challenging (Toates, 2007). 
1.3.2 The physiology of pain and pathways 
Pain is one of the sensory systems that has evolved along with human evolution and was 
crucial for species survival, in that specific and complex neural pathways developed to 
transmit a pain signal from sensory cells through the body to the brain and vice versa 
(Nicholls et al., 2001). Through these signals, it is possible to obtain limb movements 
(reflex withdrawal) and hence protect the body from harm. The spinal cord represents 
an important role in contributing to this motor mechanism, since each segment of the 
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spinal cord contains motor neurones that control a wide range of skeletal muscles that 
will enable withdrawal response to a painful stimulus (Matthews, 2001). 
In the pain pathway the afferent (incoming) signals enter the spinal cord via the dorsal 
roots and reflex motor pathways exit via ventral roots. In response to the incoming 
signals the cognitive systems in the brain will activate inhibitory or excitatory 
transmission through the system (Nicholls et al., 2001). There are several parts of the 
brain involved in the descending control of pain, some of these structures are the cortex, 
thalamus, midbrain and periaqueductal grey (Jones and Dunlop, 2007). These brain 
structures are involved in the process of detecting, suppressing or enhancing the pain 
sensation. For example, the lateral thalamus has been reported to be involved in the 
process of discerning the location of injury on the body after acute pain stimuli (Kandel 
et al., 2000; Squire et al., 2013). Neurons of somatosensory cortex and insular cortex 
are described as being involved in the aching sensation and overall pain response 
(Kandel et al., 2000; Squire et al., 2013). Periaqueductal grey interneurons are involved 
in suppressing pain response by inhibiting the release of neurotransmitters, such as 
glutamate originating in the primary nociceptive afferents. Injury or abnormality in the 
parts of the brain involved in the descending pain pathway may also affect perception of 
pain, as observed in clinical cases of thalamic pain syndrome (Dejerine-Roussy 
Syndrome) in which mild stimuli are perceived as highly noxious, and cortical 
abnormality which can cause the condiotn known as known as “asymbolia for pain” in 
which subjects lose the unpleasant quality of pain (Kandel et al., 2000; Squire et al., 
2013). 
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Figure 1 - Pain transmission through the spinal cord 
Figure 1 shows details of the incoming signal from a nociceptor in the skin entering the 
dorsal roots and the reflex motor pathway exiting via ventral roots (figure adapted from 
http://www.healingtherapies.info/SCIoverview.htm). 
The transmission from the periaqueductal grey-rostral ventromedial site particularly has 
the ability to suppress nociceptive inputs conducted through the nociceptors C-fibres 
and conserving sensory-discriminative information conducted by nociceptor Aδ-fibres 
(Heinricher et al., 2009). This process of descending signal from the brain in response 
to the painful stimulus involves mainly the neurotransmitters serotonin, noradrenaline 
and endogenous opioids (J.A.Stamford, 1995). 
The different nociceptors, fibre types and neurotransmitters have important functions in 
the pain pathway and will be explained in the following sections. 
1.3.3 Nociceptors 
Acute pain and chronic pain are initiated by activation of nociceptors, which are the 
sensory receptors, that are less sensitive compared to the so-called touch receptors. They 
are specialised for responding with electrical activity in the event of potential hurt or 
injury that can be provoked by damaging or penetrating the skin (Matthews, 2001). 
These sensory receptors are in the periphery of the body and have the function of 
responding to changes to pressure, temperature and chemicals, and are classified as 
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mechanoreceptors, thermoreceptors and chemoreceptors, respectively. In general, 
nociceptors are present in all tissues and have their cell bodies localised in the dorsal 
root or trigeminal ganglia. These neurones possess a single axon that morphologically 
bifurcates into a peripheral branch that innervates peripheral target tissue ending in a 
nociceptor, and a central axon that activates second order neurones that transmit the 
signal for pain sensation (Woolf and Ma, 2007). The fibres Aδ (myelinated) and C 
(unmyelinated) specially can be activated through pain stimuli caused by intense heat, 
mechanical stimuli and several chemicals (Caterina et al., 2005). These sensory fibres 
are located within the skin or in the tissues such as viscera, bone and muscle. Through 
these fibres the painful stimulus is conducted to the spinal cord; Aδ being faster to 
conduct this signal than the C fibre due to their myelination. Therefore, it is the Aδ fibre 
that provides the sensory stimulus that contributes to generate a withdrawal reflex 
(Matthews, 2001). After entering the spinal cord the majority of the Aδ and C fibres 
terminate superficially by synapsing with secondary neurones in the grey matter of the 
dorsal horn (Park et al., 2000a). Most of Aδ and C fibres synapse with intermediate 
neurones in the deeper layers of the dorsal horn; these fibres terminate within spinal 
cord laminae I-X. The nociceptive information provided by Aδ and C fibres are mainly 
received within laminae I, II, V and VI (Hunt and Bester, 2005). The Aδ nociceptors 
have been subdivided into two main classes named type I and II and classified as 
mechanical and heat-sensitive nociceptors. The type I fibre has a higher threshold for 
heat than type II, whereas type II has a higher threshold for mechanical stimuli. Type I 
can become sensitive to heat after prolonged stimulation, thus it has been suggested that 
the sensation during first exposure to heat is conducted through the type II (Treede et al., 
1998). Some of the transient receptor proteins present in thermal nociceptors and 
activated by heat or cold have been named as TRPM8, TRPA1, TRPV1, and TRPV2 
(Chen et al., 2006a). For the C fibres, they have been classified as polymodal for their 
ability to respond to thermal, chemical and mechanical stimuli, and these nociceptors 
are responsible for the slow and long lasting pain sensation after body injury (Taguchi 
et al., 2010). These slow conducting fibres represent the majority of sensory neurones in 
the peripheral nervous system (Goodman and Gilman, 2006). 
The Aδ and C fibres play an important role in the process of pain pathway, which can 
be explained through the “gate-control pain theory” first proposed by Melzack and Wall 
(1965). Being a psychologist, Melzack aimed to explain the differences in the level of 
pain sensation felt by individuals. The principal idea behind this theory is that the 
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signals received from the nociceptors in the spinal cord, specifically the second order 
neurones (spinothalamic cells), can be suppressed or enhanced by the inhibitory or 
excitatory mechanisms controlled by interneurones in the substantia gelatinosa. At this 
location several chemical events can affect the ascending messages to the brain wich are 
processed in the thalamus, therefore it is known as a “gate for pain transmission” 
(Melzack and Wall, 1996). This pain pathway is illustrated in Figure 2. This theory 
revolutionised the concept of pain sensation, and contributed much to explain symptoms 
such as phantom pain, a type of pain which is provoked by hyperactive second order 
neurones of the spinal cord caused by damaged or missing C or Aδ fibres nociceptors. 
In the case of phantom limb symptoms, N-methyl-D -aspartate receptors are constantly 
activated through the damaged C fibre nociceptor and through Aδ fibre at the spinal 
dorsal horn which transmit incessant pain signals through second order nociceptive 
neurones to the brain (Nikolajsen and Jensen, 2000). 
 
 
Figure 2 - Basic pain pathway. Figure taken from http://virtual.yosemite.cc.ca.us/ 
dward/physo101/f05_pages/s5_cns/sup_somatosensory_pain.htm. 
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In the basic pain pathway, shown in Figure 2, the thermal noxious stimuli is transduced 
in electrical signals that are conducted through nociceptors fibres to the dorsal horn in 
the spinal cord. This signal can induce withdrawal reflex by synapsing with 
interneurone to motor neurone. Synapses can also occur between the nociceptors and a 
second order neurone in the dorsal horn transmit the pain signals through pathways tract 
such as spinothalamic towards the thalamus and midbrain. In the thalamus  synapses will 
occur with third order neurone that will transmit the pain signals to the somatosensory 
cortex processing localisation and perception of the pain. The descending pathways 
transmit signals generated in the brain to the dorsal horn, these signals have the ability 
to supress or potentiate the passage of nociceptive messages to the brain. 
As described above, for an individual to feel pain sensation caused by an injury, this 
information is sent from the part of body affected through nociceptors, the information 
travels through the spinal cord where it can be decreased, increased or blocked before 
reaching the brain, this is the ascending pathway. Once in the brain, the signal is 
interpreted as a pain sensation therefore sending a response to withdraw reaction or 
protection of the area affected, descending pathway (Matthews, 2001). However, the 
mechanism involved in this process is not as simple as described. The nociceptors 
conduct this information through action potentials, this electrical signal starts from the 
location injured that suffered depolarisation caused by the noxious stimulus through 
chemical mediators such as prostanoids, bradykinin and 5-hydroxytryptamine 
(Dickenson and Suzuki, 2005). These signals are faster to reach the brain when the 
nociceptor is myelinated. The depolarisation is caused by changes of cell membrane 
permeability by special ion channels. For example the increase of sodium ions (Na+) 
into the axoplasm in a quantity that reaches above a threshold will trigger action 
potential (Brown, 2001). The action potential transmission will be propagated by 
opening and closure of sodium and potassium channels. Some neurones can also be 
activated through calcium channels. The action potential resulting from these channels 
are slower and have the ability to produce longer depolarisation (Grahame-Smith and 
Aronson, 2002). The voltage-gated sodium and calcium channels have been the focus of 
pain relief drug discovery especially for neuropathic pain, due to the fact that these 
channels exert an important role in the process of controlling cellular excitability. As a 
result they have the key for blocking or enhancing pain transmission through action 
potential. Some sodium blockers are already well known, but because these drugs are 
not specific they would compromise the body by blocking its normal function 
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propagation. Therefore, they are most used as local anaesthetic, an example of this type 
of drug is lidocaine (Zuliani et al., 2010). Consequently, the target of research is to find 
molecules that potentially can select certain Na+ channels subunits that are more 
specifically involved in pain transmission (Baker and Wood, 2001; Leo et al., 2010). 
1.3.4 Neurotransmitter receptors and Pain 
There are several neurotransmitters that play an important role transmitting or inhibiting 
pain, some of them are substance P and glutamate that are usually excitatory. Regarding 
the inhibitory neurotransmitter, the majority of this synapse is carried out through 
gamma amino butyric acid and glycine. There are some neurotransmitters that are more 
involved in the descending pathway transmission process, these neurotransmitters are 
serotonin, noradrenaline and opiates such as endorphin (Yin et al., 2011; Sacerdote and 
Levrini, 2012; Wozniak et al., 2012). 
Some of these neurotransmitters function at synapses through a diverse range of 
receptors; therefore some of them have been linked with pain treatment or have been 
used as the target for drug discoveries. Some of these receptors can be divided into two 
categories; ligand-gated or ionotropic receptors and G protein-coupled or metabotropic 
receptors (Iwama and Gojobori, 2002). 
The transmission through ligand-gated ion channels is made by opening ionic channels. 
This process takes place after binding of a neurotransmitter (Novère and Changeux, 
1999). Regarding metabotropic receptors, their involvement is far more complex and 
there are many factors of its mechanism that are still under investigation. However, it 
has been suggested that the process of depolarisation is carried out for second 
messengers, as an example phospholipase C (Lee et al., 2004). These receptors are 
known for being the most abundant and diverse family of cell surface receptors and 
proteins. These receptors have been reported for being involved in neurotransmission 
and pain modulation, for this reason they represent a primary target for pain treatment. 
(Pan et al., 2008). Also they have been suggested to be involved in the process of 
chronic pathological pain including hyperalgesia, allodynia and paroxysmal or 
spontaneous pain (Cahill et al., 2007). 
Examples of metabotropic receptors are the metabotropic glutamate, muscarinic 
acetylcholine, GABAB, norepinephrine, epinephrine, histamine, dopamine, 
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neuropeptides bradykinin B2, adenosine A1 and endocannabinoids. Examples of 
ionotropic receptors are 5-HT3, ATP, nicotinic, TRPV1 for capsaicin and related 
vanilloids (Lee et al., 2004). 
The following sections very briefly outline some of the major receptor classes which 
have been associated with pain and are, thus, potential targets for antinociceptive agents. 
1.3.5 Receptors with potential targets for pain relief 
1.3.5.1 Cannabinoid receptor 
The cannabinoid receptor also belongs to the G protein-coupled receptor superfamily. 
These receptors can be activated by the naturally body ligand endocannabinoids and by 
plant cannabinoids such as tetrahydrocannabinol (Ryberg et al., 2007). The cannabinoid 
receptors GPCRs, CB1, CB2 and GPR55 are peroxisome-proliferator-activated 
receptors. These cannabinoid receptors are present in the central and peripheral system 
and they are involved in the processing of pain signals (Greco et al., 2010). However, 
its antihyperalgesic and antinociceptive activities result from mediation of several 
mechanisms that are still under establishment (Akopian et al., 2009). 
1.3.5.2 Glutamate and GABA receptors 
As mentioned before, glutamate is an important transmitter involved in pain 
transmission, mainly because it functions at excitatory synapses both at brain and spinal 
cord levels, its postsynaptic effect operating through ionotropic and metabotropic 
receptor types. These receptors are classified as alpha-amino-3-hyfroxy 5-methyl-4-
isoxazeloproprionic acid (AMPA), N-methyl-D-aspartate (NMDA) and the G-protein-
linked metabotropic family of receptors (mGluR5). Research has been focused on these 
receptors as a target for chronic pain (Kew and Kemp, 2005; Bleakman et al., 2006). 
Metabotropic glutamate and metabotropic GABA receptors (specifically GABAB) are 
distributed at different levels of the central nervous system, one of their roles involves 
transmission of nociceptive signals (Goudet et al., 2009). GABAB receptors are known 
for controlling neuronal excitability and synaptic neurotransmission modulation. Both 
receptors have a vital role in many physiological functions and have been associated 
with several types of neurodegenerative and pathophysiological disorders including 
chronic pain (Cahill et al., 2007). 
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1.3.5.3 Lysophosphatidic acid (LPA) 
Six G protein-coupled receptors (LPA(1)/Edg2, LPA(2)/Edg4, LPA(3)/Edg7, 
LPA(4)/GPR23/P2Y9, LPA(5)/GPR92 and LPA(6)/P2Y5) have been identified, that are 
specific to lysophosphatidic acid (LPA), a phospholipid involved in neuropathic pain 
that has been identified (Hama and Aoki, 2010). LPA have been reported to activate 
demyelination of Schwann cells of the periphery and oligodendrocytes linked with the 
central nervous system. Since it has been suggested that demyelination of fibre is a key 
factor associated with neuropathic pain, these receptors might represent an important 
target for chronic pain treatment (Lin et al., 2010). 
1.3.5.4 Muscarinic acetylcholine receptors 
Muscarinic acetylcholine receptors are G protein-coupled receptors found in the plasma 
membranes of certain neurones. These receptors exert different roles, including acting 
as main and end-receptors in the parasympathetic nervous system contributing to the 
process of releasing acetylcholine (Eglen, 2006). Acetylcholine release in the spinal 
cord at substantia gelatinosa was observed to induce antinociception by decreasing 
excitatory transmission induced by glutamate (Jones and Dunlop, 2007). 
1.3.5.5 Opioid receptors 
The opioid receptors are G protein-coupled receptors, and neurotransmission through 
this receptor decreases the cyclic adenosine monophosphate involved, that consequently 
stop depolarisation induced by neurotransmitters such as substance P. There are three 
protein types that generate opioids peptide, these precursor proteins are 
proopiomelanocortin, prodynorphin and proenkephalin (Przewlocki and Przewlocka, 
2001). 
Also there are three types of opioid receptors that are linked with antinociception. These 
receptors are described as µ, δ and к types (Kosterlitz and Paterson, 1985). The µ 
receptor is most known as the morphine receptor type, perhaps one of the most 
important studies leading to its establishment was carried out by Martin (1979). Opioid 
receptors and its target for drugs will be discussed later in this chapter. 
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1.3.5.6 Serotonin receptors 
Most of the serotonergic receptors are G protein-coupled receptors, only the 5-HT3 is a 
ligand-gated ion channel (Hannon and Hoyer, 2008). The activation of presynaptic 5-
HT3 by 5-HT receptors on central terminals of spinal afferents, induces the increase of 
transmission in the spinal cord via the dorsal horn and provokes a pain increase and 
reflex responses. Inhibition of 5-HT3 receptors has been shown to prevent the 
development of chronic pain in rats (Suzuki et al., 2004). 
1.3.5.7 Somatostatin and galanin receptors 
The neuropeptide somatostatin, also known as somatotropin, has been reported for its 
involvement during painful stimuli as an inhibitory activator. It seems that this activity 
is mediated by five G protein-coupled receptors. Research has shown that when these 
receptors are activated it reduces pain sensation (von Banchet, 2008). Galanin known as 
GalR1, GalR2 and GalR3 are neuropeptide with G-protein-coupled receptors that assist 
with synapse function in the central, peripheral and in the endocrine system. These 
receptors have also been targeted for the treatment of pain (Mitsukawa et al., 2008). 
As described these receptors represent an important target for pain relief drugs thus 
giving perspective and hope for sufferers that in the near future many of their symptoms 
could be treated. However, pain receptors are far from being the only target of research 
nowadays, another line of research has been the focus to understand the difference of 
pain threshold between individuals based in their genes and gender, the idea behind 
these studies is that it might be more effective to treat pain based in each individual 
variability condition. The next section briefly describes some of these results. 
1.3.6 Gender and genetic differences involved in pain perception and modulation 
Studies have been discussing the implication of gender differences in pain perception. 
Although it is a controversial area it has shown some very interesting facts. The 
majority of studies hypothesising gender differences are carried out with individuals 
suffering from irritable bowel syndrome (IBS), due to the prevalence of this symptom in 
woman. Research has shown that women have a lower threshold to rectosigmoid 
distension than men (Chang et al., 2006). Also, reports have suggested that several areas 
of male and female brains can react differently when given the exactly same pain 
stimulus provoked by IBS. The female brain demonstrated to have higher activation in 
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the ventromedial prefrontal cortex, right anterior cingulate cortex, and left amygdala, 
which are involved as “emotion based centres”, however in the male brain this 
activation was reported to be predominant in the right dorsolateral prefrontal cortex, 
insula and dorsal pons/periaqueductal gray regions (Naliboff et al., 2003). Some of 
these variations could be the result of genetic differences related to the sex 
chromosomes where the hormones testosterone and estradiol influence sensitivity to 
pain as well as its modulation, therefore the difference of concentration of these 
hormones would influence pain perception according to the gender (Foulkes and Wood, 
2008). 
Although the pain physiological pathway and its molecular mechanism present 
similarity between species and individuals, there are established differences in pain 
modulation and perception caused and influenced by genetic variability and 
environment. These variations of mutation in the genes can increase the propensity to 
feel pain or lose it completely by having total insensitivity to painful stimuli. An 
example of pain insensitivity caused by mutation was reported by a study involving 
consanguineous families, where the mutation in the gene SCN9A encoding the alpha 
subunit of Na v1.7 voltage-gated sodium channel can cause complete inability to sense 
pain (Cox et al., 2006). Further studies involving gene influence in pain perception have 
shown that single nucleotide polymorphisms have a substantial impact on pain 
sensitivity. These nucleotide polymorphisms were observed in the genes for catechol-O-
methyltransferase that facilitates the inactivation of catecholamine neurotransmitters, 
for the melanocortin-1-receptor, also for the µ-opioid receptor OPRM1 (A80G, A118G), 
and for tetrahydrobiopterin (BH4) that is an important cofactor in nitric oxide, serotonin, 
and catecholamine production. These genes are all involved in pain sensitivity 
variations and also contribute to the mechanism of pain inhibition undertaken by 
endorphins, µ-opioids and κ-opioids (Foulkes and Wood, 2008). 
So far this chapter has described pain propagation and some of the mechanism involved, 
the aim of next section is to present some of the pain relief treatment and also its action 
mechanism. 
1.3.7 Pain management and mechanisms of pain relief 
The relief of pain has been a major target of pharmacotherapy and drug discovery for 
centuries. Several plants such as Papaver somniferum and Salix family have been used 
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to relieve pain for thousands of years. Their active agents have been the precursors of 
pain relief drugs and their compounds have elucidated and established the opiates and 
cyclooxygenase inhibition in the mechanism of pain moderation. These drugs have 
enabled medicine to have better control and manipulation of pain (Brune, 2002). 
However, these drugs are not without their side effects and several pain symptoms are 
still untreatable, therefore the pharmaceutical industries are in a competitive search for 
new or more efficient drugs, especially for symptoms like chronic pain, where many 
treatments have failed (Jensen and Finnerup, 2007). 
Drugs for the treatment and management of pain (analgesics), can be broadly placed 
into two categories: opioids and non-opioids (Park et al., 2000b). 
1.3.7.1 Opioids 
Opioid compounds, such as morphine from Papaver, have been used for thousands of 
years and historically represent one of the oldest treatments used for pain relief. The 
activities of opioids, such as heroin and morphine, occur as a result of “mimicking” the 
body’s naturally occurring substances. These substances are usually endogenous opioid 
peptides which occur as three families: endorphins, enkephalins and dynorphins. These 
peptides are present in the spinal cord, brain and peripheral nerves (Grahame-Smith and 
Aronson, 2002). The production of these opioid peptides by the body can be triggered 
by immune cells such as T and B-lymphocytes, monocytes and macrophages in 
response to injury, as well as in response to painful stimuli. The general mechanism of 
action induced by opioids is described acting as central rather than peripheral, despite 
opioid receptors also being located on the peripheral terminals (Kandel et al., 2000). 
The opioid activation reduces pain transmitter release by opening potassium or closing 
calcium channels (Shipton, 1999). The sites of action of opioids have been reported to 
be localised in the spinal cord (substantia gelatinosa), midbrain and thalamus (Chahl, 
1996; Kumamoto et al., 2011). 
As described in the receptor section, opiate receptors are classified as three subtypes, µ, 
δ and κ. The analgesic drugs that have their effects through opiate receptors act as 
partial or total agonists. Some agonists of subtype κ act by closing calcium channels and 
activation of these receptors has been shown to have an effect that is rather more 
dysphoric than analgesic. Therefore the theory is that δ-opioid receptors might have a 
much lower drug dependence than µ-opioid (Waldhoer et al., 2004). Most opioid drugs 
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act at the µ receptor and opiates acting at δ receptor are less effective for visceral pain. 
There is a high concentration of µ receptors in the periaqueductal gray matter which is 
substantially involved in supressing pain through the descending pathway regulation 
(Kandel et al., 2000). The µ and δ receptor operates by opening of potassium channels, 
the drug morphine acts at δ and κ receptor, therefore it is a drug that induces analgesia 
and dysphoria, also in some cases it causes dependence (Shipton, 1999; Carr and Mague, 
2008). Morphine is mainly used to treat severe pain and despite its high indices of 
addiction it remains the most efficient drug available to treat cancer pain (Bonica et al., 
2009). Some researchers have been involved in projects for morphine molecule 
modification and have delivered versions known as diamorphine or heroin and 
hydromorphine. However, in the course of time, heroin presented to be more highly 
addictive than morphine. Further investigations have found a possible less addictive 
opium molecule named as codeine. But it is more recommended as a mild pain reliever 
(Grahame-Smith and Aronson, 2002). 
Although morphine was one of the first opioids in the market, its mechanism of action 
still need clarifications. Morphine efficiently activates G protein signals but inefficiently 
induces endocytosis, this fact has been associated with the receptor desensitisation and 
drug tolerance (Dang and Christie, 2012). Due to several sides effects caused by 
morphine as well some inefficiency as an anesthetic, an alternative for this drug was 
investigated, and in 1960 a more powerful synthetic opioid named as fentanyl was 
announced (Stanley, 1992). Fentanyl is known for acting quickly for a short period. For 
example, intranasal fentanyl has a half-life of 6.5 minutes. Although, it is more 
powerful than morphine it is only more recommended for acute severe pain than chronic 
pain (Foster et al., 2008). 
As mentioned, δ-selective agonists are a promising target for drug development, 
particularly for chronic pain where morphine, despite its dependence problem, is still 
the recommended drug. Preclinical studies have presented positive results for δ-
selective agonists where they demonstrated to have antinociception in several chronic 
pain models including neuropathic and cancer pains. However so far, there are not δ 
opioid drugs available. The drug Snc-80 (GSK, NIH) is one of the leading δ opioids but 
it is still under development (Walwyn et al., 2010; Nagase and Fujii, 2011). 
© Newcastle University 2013 22 
1.3.7.2 Non-opioids 
Non-opioid analgesic drugs can be generally represented by aspirin, related salicylates 
and paracetamol. Aspirin and other salicylates belong to the group known as the non-
steroidal anti-inflammatory drugs or NSAIDs. The NSAIDs are usually available as 
over the counter drugs and are among the most used drugs worldwide (Ray et al., 2001; 
Grahame-Smith and Aronson, 2002). 
Regarding their mechanism of action, they block the production of certain prostanoids 
such as prostaglandin. This blockage is obtained through inhibition of the enzyme 
responsible for their production, the enzyme cyclo-oxygenase (COX). This enzyme 
synthetises prostaglandin from arachidonic acids (Shipton, 1999). 
In the process of pain, prostaglandin acts as a lowering pain threshold inducer, it 
facilitates the neurone to fire and deliver pain signals. The inhibition of prostaglandin 
by NSAIDs increases the body’s threshold for pain, making the neurones less sensitive 
to pain stimuli (Grahame-Smith and Aronson, 2002). When NSAIDs mechanism was 
first unveiled, it was suggested that their activities only involved a peripheral 
mechanism, however more recently studies have supported that they might also have 
central involvement in their actions (Samad et al., 2002). 
Further studies have found that there are isoforms of the COX enzyme, which are 
known as COX-1 and COX-2. The enzyme COX-1 appears to be more involved with 
normal physiological function occurring in the body. For example, it is involved in the 
gastrointestinal protection process. Therefore, analgesic inhibiting COX-1 such as 
aspirin have been causing gastrointestinal irritation and bleeding. The COX-2 enzyme is 
more involved in the process of inducing hypoxia, and inflammatory stimuli (Shipton, 
1999). Hence, it attracted the attention of the drug industry to search for selective COX-
2. These drugs came to the marked as celecoxb which is a sulfonamide-containing 1,5-
diarylpyrazole and some of them have the brand name celebrex. However, later on 
researchers found out that although it might be safer in terms of gastrointestinal 
bleeding it was increasing the risk of cardiovascular dysfunction. The reason for these 
events is due to the fact that COX-2 inhibitor only decreases prostacyclin and not 
thromboxane. The availability of this prostanoid in the system without its functional 
competitor results in an increase of blood vessel constriction and platelet-aggregation, 
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thus leading to thrombosis and heart failure (Kearney, 2006; Funk and FitzGerald, 
2007). 
On the other hand, drugs such as paracetamol or acetaminophen, despite the fact that 
their mechanism still needs deep clarification, are a weak COX inhibitor for which 
COX selection occurs in the brain. For this reason they have been used as an alternative 
analgesic by people with haemophilia and heart disease (Rang et al., 2007). 
1.4 The Genus Hyptis Jacq: Chemical and Biological Studies 
1.4.1 Hyptis genus distribution and the Hyptis crenata species 
Plants from Hyptis genus are fast growing and perennial. In general Hyptis species 
contain essential oil which generates interest about its volatiles properties (Noudjou et 
al., 2007b; Tonzibo et al., 2009; Zellner et al., 2009). There are over 300 species of 
Hyptis that are mainly found in the tropical Americas and African savannah areas 
(Harley, 1988; Ogunbinu et al., 2009). There are several of these species that have been 
reported in the Brazilian territory, specifically found in the Cerrado that is also a 
tropical savannah area (Zellner et al., 2009). The species Hyptis crenata Pohl ex Benth 
studied in this PhD project mainly grows in the central west of Brazil (Pott, 1997). A 
photo of H. crenata growing in Mato Grosso state is displayed in Figure 3. H. crenata is 
characterized by being a subshrub from 0.3 to 0.8 m height with a strong smell of mint. 
It has flowers and leaves almost all year round except for August-September when the 
aerial part dies. It is one of the preferable plants used by the honeybee, and due to the 
eugenol compounds usually present in the plant, the honey produced has a clove scented 
flavour (Pott, 1997). 
Figure 4 shows the distribution of where the Hyptis genus grows throughout the world. 
The Hyptis growing in Australia is an alien invasive from tropical America, this species 
is H. suaveolens and has been considered as a problematic weed for Australian 
agriculture (Cowie and Werner, 1993; Kissinger, 2003). 
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Figure 3 - Photograph of Hyptis crenata growing in Mato Grosso, Brazil 
 
 
Figure 4 - Hyptis genus world distribution.  
Source: http://www.discoverlife.org/hyptis; year: 2009 
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1.4.2 Traditional use of Hyptis species 
Species from the genus Hyptis Jacq have been used widely in traditional medicine 
mainly in South America and Africa for treatment of various illnesses, such as 
rhinopharyngitis, nasal congestion, skin diseases, gastric disorders, fever and pain. 
Some Hyptis species are used as anticancer and antifertility agents (Menezes et al., 
2007; Tonzibo et al., 2009). Some Hyptis species are especially used for fungal 
infections or other dermatitis (Celine et al., 2009). The tea from leaves have been 
reported to be used as a diaphoretic, tonic, stimulant to treat inflammation of eyes and 
throat, constipation and arthritis (Van de Berg, 1993). 
The only available traditional use survey regarding H. crenata as medicinal use was 
reported by De Jesus et al. (2009). This study was carried out in Distrito de Pirizal, 
Mato Grosso, Brazil. Thirty eight people were interviewed. Among the 49 species 
mentioned, H. crenata Pohl and H. suaveolens were the most indicated to antiulcer and 
anti-inflammatory effects. The study showed that they used Hyptis species leaves or the 
entire plant as a tea or bath. Hyptis leaves were also reported to be used as insect 
repellent when rubbed on the skin (Pott, 1997) and Hyptis flowers have been used as a 
source of nectar for production of honey and propolis, known to contain antibacterial 
compounds (Park et al., 2002; Santos et al., 2003). 
1.4.3 Biological studies reported for Hyptis genus 
Although the traditional use of H. crenata has been reported, as mentioned above, there 
have been no reports about pharmacological studies of this species. On the other hand, 
there are a number of reports of biological activities of other Hyptis species, as 
presented in Table 1. 
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Activities Species Authors 
Insecticidal  H. fruticosa,  
H. martiussi,  
H. pectinata,  
H. suaveolens,  
H. spicigera  
H. verticillata 
(Buchanan et al., 2000; Araujo et 
al., 2003; Boeke et al., 2004; 
Amusan et al., 2005; Facey et al., 
2005; Kouninki et al., 2005a; 
Kouninki et al., 2005b; Omolo et 
al., 2005; Jaenson et al., 2006; 
Sanon et al., 2006a; Sanon et al., 
2006b; Ngamo et al., 2007; 
Ngassoum et al., 2007; Njan 
Nlôga et al., 2007; Noudjou et al., 
2007b; Noudjou et al., 2007a; 
Oliva et al., 2007; Silva et al., 
2008; Bum et al., 2009; Ladan et 
al., 2009; Misra, 2009; Othira et 
al., 2009; Conti et al., 2010; 
Ilboudo et al., 2010; Ladan et al., 
2010; Conti et al., 2011) 
Acaricidal H. verticillata (Porter et al., 2009) 
Antibacterial and antifungal H. brevipes,  
H. crenata,  
H. fasciculata,  
H. martiusii,  
H. mutabilis,  
H. ovalifolia,  
H. pectinata,  
H. sidifolia,  
H. spicigera,  
H. suaveolens,  
H. verticillata 
(Goun et al., 2003; Souza et al., 
2003; Stadnik et al., 2003; 
Fragoso-Serrano et al., 2005; 
Krishnamurthy and Shashikala, 
2006; Mahida and Mohan, 2006; 
Oliva et al., 2006; Nascimento et 
al., 2008; Sharma and Tripathi, 
2008; Coutinho et al., 2009; 
Ladan et al., 2009; Bussmann et 
al., 2010; Coutinho et al., 2010; 
Mbatchou et al., 2010) 
Anti-HIV activities H. capitata,  
H. lantanifolia,  
H. atrorubens 
(Kashiwada et al., 1998; Antoun 
et al., 1999; Matsuse et al., 1999) 
Antiplasmodial,antitrypanocidal 
and leishmanicidal activities 
H. suaveolens,  
H. brevipes,  
H. stellulata,  
H. lacustris 
(Ziegler et al., 2002; Bourdy et 
al., 2004; Abe et al., 2005; 
Chukwujekwu et al., 2005; Celine 
et al., 2009) 
Antioxidant, dermatological and 
anti-aging activities 
H. fasciculate,  
H. martiusii,  
H. suaveolens,  
H. crenata,  
H. fasciculate,  
H. heterodon 
(Shirwaikar et al., 2003; Silva et 
al., 2005; Kolawole et al., 2009; 
Silva et al., 2009; Simionatto et 
al., 2010) 
Anti-cancer and proliferative 
activities 
H. brevipes,  
H. capitata,  
H. emoryi,  
H. fasciculate,  
H. martiusii,  
H. tomentosa,  
H. suaveolens  
H. verticillata 
(Sheth et al., 1972; Yamagishi et 
al., 1987; Lee et al., 1988a; Lee 
et al., 1988b; Yamagishi et al., 
1988a; Yamagishi et al., 1988b; 
Kashiwada et al., 1998) 
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Activities Species Authors 
Anti-cardiovascular H. fruticosa (Santos et al., 2007a) 
Anti-inflammatory H. brevipes,  
H. suaveolens, 
H. verticillata,  
H. martiusii 
(Kuhnt et al., 1994; Gonzalez et 
al., 1995; Shenoy and Shirwaikar, 
2002; Grassi et al., 2006; 
Raederstorff et al., 2008) 
Anti-depressive H. pectinata (Bueno et al., 2006) 
Antinociceptive H. fruticosa,,  
H. pectinata,  
H. suaveolens 
(Bispo et al., 2001; Lisboa et al., 
2006; Marcal et al., 2006; 
Menezes et al., 2007; Santos et 
al., 2007b; Arrigoni-Blank et al., 
2008; Raymundo et al., 2011) 
Anti-ulcer H. mutabilis,  
H. crenata,  
H. spicigera 
(Barbosa and Ramos, 1992; De 
Jesus et al., 2009; Takayama et 
al., 2011) 
Table 1 - Biological activities reported for species of the genus Hyptis 
 
The majority of Hyptis experimental studies involved testing the essential oil and these 
species were reported to have activities such as insecticidal, fungicidal, anti-HIV and 
antiplasmodial, although there are Hyptis species for which these effects were not 
confirmed by these experiments (Almtorp et al., 1991; Antoun et al., 1999; Bourdy et 
al., 2004). This factor could be due to genotype and the environmental condition that 
plays a very important role in the type and quantity of compounds found in the plant 
essential oil (Pino et al., 2002; Martins et al., 2006; Koba et al., 2007; Ngassoum et al., 
2007; Sales et al., 2007; Silva et al., 2007; Grassi et al., 2008). 
The anti-inflammatory effects of Hyptis also have been the subject of study of several 
researchers. The compound sideritoflavone from H. verticillata was suggested for being 
responsible for its anti-inflammatory effect by inhibiting prostaglandin release (Kuhnt et 
al., 1994). Also, suaveolol and methyl suaveolate, both diterpenes from H. suaveolens 
are mentioned with this effect. According to the research these compounds showed 
nearly the same dose-dependent topical anti-inflammatory activity, only two to three 
times lower than indomethacin (Grassi et al., 2006). In addition, H. brevipes ethanolic 
extract has been reported with a high capacity of xantine oxidase inhibition and also 
suggested as an alternative treatment for gout that is considered as an acute case of 
inflammation (Goun et al., 2003). Two patents of compound carnosic acid 12-methyl 
ether found in Hyptis have been registered for the treatment or prevention of 
inflammatory disorders involving joints (Raederstorff et al., 2008). 
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As mentioned in the previous section, Hyptis genus has always been linked with 
stomach discomfort relief in traditional use medicine. Possibly due to this association 
this species has been tested for antiulceration effects (Barbosa and Ramos, 1992; 
Takayama et al., 2011). This research showed that the essential oil of H. mutabilis was 
able to reduce ulcers induced by indomethacin, a non-steroidal anti-inflammatory drug 
that works by inhibiting the production of prostaglandins (Flower, 1974). The 
interesting fact from this result is that the methanolic extract of H. mutabilis has also 
been reported for anti-inflammatory properties (Melo, 2003). Although the mechanism 
of this effect is not described, it might be different from the anti-inflammatory effect of 
H. verticillata whose compounds decrease prostaglandin levels (Kuhnt et al., 1994) 
because prostaglandin inhibitors drugs are known for causing gastric damage (Takeuchi 
et al., 2005), this is not the case of H. mutabilis, that has the ability to inhibit the ulcer 
formation induced by indomethacin. Therefore, from these studies it could be suggested 
that although some different species of Hyptis can have the same activities, it is possible 
that this effect can be obtained through different mechanisms induced by different 
compounds. Alternatively it could be that the H. mutabilis treatment tested in the anti-
inflammatory experiment had compounds such as sideritoflavone, and that this type of 
compound was not present in the anti-ulcer treatment due to the extraction methods 
and/or environmental condition where the plant was growing. 
The antidepressive effect of H. pectinata leaves was tested in mice and rats by Bueno et 
al. (2006). The authors reported that a significant effect of the aqueous extract was 
observed in the open field, forced swimming and apomorphine-induced hypothermia, 
but no effects on elevated plus maze and sleep test. Although according to this article H. 
pectinata compounds might be involved in the anxiolytic linked anti-depressant effects, 
several publications, as will be described later in this section, also reported 
antinociceptive activity of H. pectinata. This antinociception effect can be playing a role 
in enhancing the threshold of hypothermia and swimming since pain can be involved in 
both procedures (Mahesh et al., 2010), therefore it could be a false positive result for 
antidepressant effect. 
There are four studies that reported the antinociceptive activity of H. pectinata, these 
studies evaluated this property using several extraction methods; aqueous, hexane, 
chloroform, ethyl acetate and essential oil. In the hexane, chloroform and ethyl acetate 
extracts the researchers suggested an opioid-like effect and supraspinal site of action 
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(Bispo et al., 2001; Lisboa et al., 2006; Arrigoni-Blank et al., 2008; Raymundo et al., 
2011), while aqueous extraction was indicated as acting in the cyclooxygenase and 
lipoxygenase pathways (Bispo et al., 2001). Different genotypes of H. pectinata were 
evaluated by Arrigoni-Blank et al. (2008). They described that the essential oil from 
these genotypes showed both peripheral and central effects and suggested that these 
effects were due to the interaction of all constituents present in the essential oil samples, 
not only the majority compounds, in this case indicated as β-caryophyllene and 
pectinone. The species H. suaveolens and H. fruticosa were also tested for 
antinociception using aqueous extract, ethyl acetate extract and the essential oil (Marcal 
et al., 2006; Menezes et al., 2007; Santos et al., 2007b). For the H. suaveolens study 
involvement of the opioid system in a central site of action was suggested, while the 
latter study suggested peripheral activity. The authors have suggested that 
sesquiterpenes and monoterpenes could be playing an important role in these 
antinociceptive effects. The majority of these antinociceptive studies have indicated that 
the non-polar compounds of Hyptis tested are likely to be acting as opioid effect 
whereas the more polar compounds have their activities through cyclooxygenase and 
lipoxygenase mechanism. However it is still not clear which specific compound(s) is 
(are) responsible for these effects. 
The doses applied in these studies were mainly 100, 200 and 400 mg/kg, without 
justification for the amounts used or explanation if they were based in traditional use 
research. The majority of these studies reported that the Hyptis treatments were not 
dose-dependent (Bispo et al., 2001; Lisboa et al., 2006; Marcal et al., 2006; Menezes et 
al., 2007; Santos et al., 2007b; Arrigoni-Blank et al., 2008; Raymundo et al., 2011). 
Perhaps this lack of dose dependence response is due to the doses given to the animals. 
Because the range of these doses was from 100 to 400 mg/kg, therefore they might be 
too high in relation to the receptor occupancy that reached the maximum response 
(Adler and Geller, 1984; Lutz et al., 2006). 
1.4.4 Overview of chemical compounds reported from the genus Hyptis 
The chemistry information of H. crenata species have been reported in three studies 
however all of them are describing only volatile compounds. These compounds were 
terpinolene, β-caryophyllene, 1, 8-cineole, borneol, β-caryophyllene, α-pinene, 
limonene, β-pinene, camphor (Scramin et al., 2000; Pino et al., 2002; Rebelo et al., 
2009). The compounds α-pinene, 1,8-cineole, β-pinene, camphor, limonene and γ-
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terpinene were part of the composition of an H. crenata preparation that was effective 
as an antioxidant (Rebelo et al., 2009). 
For the genus Hyptis in general, the diterpenes were compounds frequently associated 
with reports of insecticidal, anti-inflammatory, antiplasmodial and cytotoxic effects. 
Also, sesquiterpenes and monoterpenes are reported as antinociceptive and anti-
inflammatory. 
Some of the chemical compounds described for Hyptis genus are listed in Appendix A. 
The table includes the compound name, molecular formula, molecular weight, the 
Hyptis species that contained the compound and pharmacological effect(s) ascribed to 
this compound in the literature. 
In the literature the 5 compounds described in the highest number of papers reporting 
chemical constituents of Hyptis plants were: β-carophyllene (in 29 papers), Trans-α-
bergamotene (15), Eucalyptol (1,8 cineole) (14), Sabinene (14) and Germacrene D (9). 
In addition, the topic about compounds from the Hyptis genus will be further explored 
in the chemical analyses of Hyptis crenata decoction and its fractions, in Chapter 7. 
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1.5 Aims 
The overall objective of this project is to evaluate the antinociceptive properties of 
Hyptis crenata Pohl. The specific aims are: 
1. To determine the traditional methods for preparing H.crenata and its uses; 
2. Investigate the antinociceptive effects of H. crenata Pohl using the extraction 
mentioned in the traditional use in animal models; 
3. Investigate the H. crenata chemical compounds and mechanisms involved in the 
antinociceptive activity. 
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1.6 Overall Plan for the Study 
1.6.1 Time-line diagram 
 
 
 
1 – Traditional Use 
Survey 
 
(Chapter 2) 
2 – Preparation of Extracts 
(Chapter 2) and 
Fractionation of Decoction 
Extract  (Chapter 3) 
3B – COX Inhibition 
Assay 
 
(Chapter 6) 
3A – Animal 
Experiments 
 
Hargreaves Test 
(Chapter 3) 
 
Acetic Acid Test 
(Chapter 4) 
3C –Chemical 
Analysis of Hyptis 
Extracts 
 
(Chapter 7) 
4 – C-fos Analysis 
after Acetic Acid Test 
 
(Chapter 5) 
Overall the goal of this thesis was to investigate the antinociceptive activity of H. crenata 
(reported in the traditional use survey) and its mechanism. Therefore, H. crenata decoction 
extract and its fractions were tested through animal trials, brain analysis was performed for the 
animals treated with the decoction extract to measure Fos protein expression and also the 
decoction extract and its fractions were evaluated for their potential as COX inhibitors. In 
addition, chemical analysis of these treatments was performed in order to identify which 
compound(s) might be playing an important role in this effect. 
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2.1 Overall Procedures 
2.1.1 Flowchart 
 
Traditional Use Survey 
Interview 
Preparation of Extracts 
Mentioned in Survey 
Salicylic Acid Analysis Analysis of Volatile 
and Phenolic 
Compounds 
Preparation of 
Decoction Extract for 
Animal Experiment 
Fractionation of 
Decoction Extract for 
Animal Experiment 
Chapter 3 
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2.2 Traditional Use and Method of Preparation of Hyptis crenata Pohl 
As described in the Hyptis genus studies (Section 1.4), Hyptis crenata species have been 
mainly referred to in papers on traditional medicine for treatment of gastric disorders 
and pain related symptoms. However, there were no available details of its preparations 
or its specific use. Therefore, the objective of this survey was to investigate and describe 
the traditional methods of preparation and utilisation of Hyptis crenata Pohl, as 
background information for an evaluation of the described effects and the plant 
preparation through pre-clinical trials. 
2.2.1 Material and methods 
2.2.1.1 Recruitment of interviewees 
The first step was to interview users of H. crenata to find out what H. crenata was used 
for, and its methods of preparation.The aim was to investigate at least 20 users located 
in the Vila Bela and Porto Esperidiao regions. The procedure to approach the users was; 
showing the plant at strategic places such as supermarkets or direct visiting homes, 
enquiring if they knew the plant and if they use it. Figure 5 shows an example of this 
approach with one of the people interviewed.The criterion for participation was that a 
person had used H. crenata and knew how it had been prepared. 
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Figure 5 - Hyptis crenata being shown as a method of approach to check if a person 
knew and used it 
 
2.2.1.2 Method of collecting data  
The interviews were conducted using questionnaires conducted with 20 people, with 
open and closed questions. With the permission of the interviewee the conversation was 
recorded, later the recorded interview was listened to and any missing information in the 
written questionnaire was added. 
The questionnaire is presented in Appendix B of this thesis. The main questions were: 
What was H. crenata used for, how was it prepared and how much was consumed? 
The reason for asking these and other questions written in the questionnaire was to be 
able to reproduce a H. crenata treatment to be tested in the pre-clinical trial that would 
be similar to what people have been using. This should include for example the type and 
concentration of plant material in the preparation, volume of intake, administration 
route, etc. In addition, these results would contribute to the choice of animal model and 
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other test to be used. Similar questionnaires have been applied in ethnobotanical studies, 
although these questions were usually less specific about the details of method of plant 
preparation (Rodrigues and Carlini, 2006; Souza, 2007). 
The amount of plant material (e.g. number of leaves, branch etc.) mentioned for making 
the preparation was weighed in order to calculate the amount in grams. 
2.2.2 Results 
The interviews were carried out with 10 females and 10 males, with a median age of 48 
years. None of the individuals were from the same household, so the same data were not 
repeated. 
The survey results showed that H. crenata has been used mainly for pain related 
purposes; it was used to relieve forms of mild pain, headache, stomach discomfort, 
menstrual pain and inflammation as shown in Table 2. It was also mentioned by two of 
the interviewees that they knew of H. crenata being used by others to treat prostate 
cancer, although they had not used it themselves for this purpose. 
When the plant was used to treat headache and stomach discomfort the administration 
route was orally through drinking the preparation. For treating flu, fever and infections 
they used H. crenata medication as a bath. 
When using the tea to treat worms, the people described drinking the plant preparation 
once per day for 2 to 3 days. Interviewees reported using the treatment for just 1 day to 
treat headaches and fever, 2 to 3 days to treat uterus and bladder infection and 6 days for 
using H. crenata for “blood cleasing”. 
The interviewees answered that they were aware that it is not used to cure illness, it is 
only used to relieve the symptoms. They also reported that it was not taken as a regular 
drink, only as a medication (15/20). Some of the people had been using the plant since 
childhood (8/20). The knowledge of using the plant had usually been taught by a parent, 
grandparent or parent-in-law (14/20). The majority of interviewees indicated that this 
medication can be taken any time of the day (19/20), also the plant material can be 
collected at any time of the day (16/20) and the year (19/20).  
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None of the interviewees reported taking H. crenata together with other medication. 
Regarding side effects, one participant reported that the plant cannot be taken every day 
because it might cause some toxicity. 
The average volume of a preparation ingested for each time that the treatment was 
administrated was 200 ml. 
Symptoms Type of utilization Frequency of 
citation* 
Pain Stomach pain 
Headache 
Menstrual pain 
12 
6 
1 
Infections Uterus/bladder infections 
 
1 
Flu Coughs 
Fever 
Treatment of flu 
 
1 
4 
3 
Others Diuretic and anxiolytic 
Worms 
“Blood cleansing” 
Sinusitis 
Use in babies nappies to 
help calm the baby 
1 
3 
1 
1 
1 
How they feel after taking H. crenata as medication  
Relieved of symptoms 
Calmer and less anxious 
17 
3 
Administration route  
Oral  
Bath 
15 
5 
*More than one category can be mentioned by each interviewee 
Table 2 - Description of utilisation of H. crenata Pohl. Obtained from the 
combination of the questionnaire results applied in the traditional use survey. 
 
Regarding the preparation method used, seven different methods were reported as 
described in Table 3, however decoction was the most common. The differences 
between these methods consisted in variations of temperatures, and the type and 
concentration of solvents. 
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Considering the part of plant used, the majority used both leaves and stems and some 
reported using the leaves and stems together with the roots (3/20). The plant could be 
prepared using dry (8/20) or fresh (18/20) material. For drying the plant material, it was 
distributed on a table outdoors, and the place was sheltered from direct sunlight. The 
material is dry when it is easily broken by hand. After drying it can be stored in brown 
paper bags or boxes in a cool, dry place shielded from light (5/20). The material can be 
stored for up to one year. 
When enquired how far they travel to collect the plant, 13/20 said that it was not so far, 
a maximum of 2km walking from their houses. 
 
Methods of preparation Average of amount 
of material (g) used 
for 1l of solvent 
Frequency of 
citation 
Decoction – Decoction method consists of 
placing the plant material in water and 
heating it for up to 30 minutes 
50 11 
Infusion – The infusion consists of adding 
water at approximately 80C° onto the H. 
crenata leaves and covering it. 
23 5 
Cold water extraction – H. crenata leaves 
and stems are slightly crushed and left for 2 
hours. 
20 2 
Cold 15% alcohol extraction – the plant 
materials are placed in a container with 
wine and left for 8 days. 
7 2 
Cold 40% alcohol extraction – the plants 
are placed in a container with pinga, a 
Brazilian spirit, and left for 1 day. 
7 1 
Milk decoction – the plant is placed in a pan 
with milk and boiled for 5 minutes. 
60 2 
Syrup – after decoction, it is filtered, sugar 
is added and it is heated until the sugar has 
melted. 
100 1 
Table 3 - Description of method of preparation of H. crenata Pohl. Obtained from 
the combination of the questionnaire results applied in the traditional use survey 
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2.2.3 Discussion 
The primary aim of the traditional use survey presented was to describe how people are 
using H. crenata and for what, to ensure that design of the animal experiment 
corresponded to the traditional use of this plant. It was found that it has been used 
mainly to relieve pain and the main preparation used is decoction. 
Although not specifically described, the pain relief property of H. crenata can also be 
found in the ethnobotanical study carried out by De Jesus et al. (2009). This property 
was not considered because this research group was focused on anti-ulcer and anti-
inflammatory symptoms. Therefore, when the interviewee indicated that the plant was 
used for stomach pain, it was interpreted as anti-ulcer relief. Their results showed that 
from 38 people interviewed, this plant was one of the most used against ulcer and 
inflammation. 
Between the pain indications mentioned, menstrual and stomach pain raised the 
question of whether the plant was able to affect the visceral nociceptive mechanism, and 
also whether it would have an effect in the central or peripheral nervous system, since it 
was also indicated for headache and inflammatory pain. For this reason it was decided 
to perform tests using animal models that would answer these questions. Another 
hypothesis for this plant activity would be that its extract could be inhibiting COX, 
since it was mentioned to be effective against fever and some cases of inflammation. 
The size of the survey was not large enough to have a confident statistical analysis that 
would correlate method of preparation and type of use. However, this survey was 
enough to indicate that the decoction extract was the most recommended to treat pain. 
This plant is also used to treat worms and coughs using a modified version of the 
decoction extract, where for treatment of worms milk is used as solvent instead of water 
and to treat coughs sugar is added after the decoction process. Different methods of 
preparation for the same species are reported in Brazil and worldwide, as well as the use 
of milk for decoction and syrup (Ghedini et al., 2002; Bhattarai et al., 2010). 
Traditionally, the motive for adding milk and sugar to remedies is to disguise the smell 
or the bitter taste of the plant preparation (Iamoni, 1997; Newton, 2012). For this reason, 
these two methods of preparation were not reproduced in the laboratory. 
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The anti-worms and anti-cough properties of H. crenata are not reported in the survey 
published by De Jesus et al. (2009). As mentioned in the Hyptis studies chapter, this is 
the only ethnopharmacological study reporting H. crenata use. However, the utilisation 
of Hyptis to treat these symptoms is reported for other species of this genus (de 
Albuquerque et al., 2007; Hossan et al., 2009). 
The infestation of worms in the human body, especially in children, induces intense 
abdominal pain (Wardhan et al., 1993; Memon et al., 2009). Considering that the main 
use of H. crenata is for stomach pain, maybe the treatment used is only relieving the 
pain symptoms caused by the worms and the person would assume that the infection 
was cured. Or perhaps, the person feeling an abdominal pain could associate it with 
worms and presume its infestation. These possibilities make the anti-worms indication 
doubtful and for this reason it is not explored in this study. 
Cough symptoms are widely treated with drugs such as codeine which is also used as 
pain relief medication (Persson et al., 1995; Eccles, 1996). Like in the pain mechanism 
process, the symptom of cough also involves the activation of Aδ and C fibres 
nociceptors (Kollarik et al., 2007; Lee and Undem, 2008). Therefore, these facts could 
suggest that the use of H. crenata for the cough symptoms may be also connected with 
pain relief properties. 
The results of the survey show that H. crenata was given by parents to their children 
when they had stomach aches, fever and worms. Also the majority of people described 
that the knowledge about using and preparing the plant was passed down from their 
parents or grandparents. This implies that the plant could be a possible low toxicity 
medicine, since this remedy has been “tested” for efficacy and adverse effects through 
generations. 
The fact that most people use leaves and stems instead of roots, gives a positive aspect 
for this species in relation to the possibility of it being cultivated. Since leaves and 
stems can be harvested repeatedly from the same plants.The plant can be collected 
almost any time, only it is not possible when the leaves fall in the dry season. Also the 
majority of people described that it can be collected any time during the day, which 
suggests that the active compounds are relatively stable, since studies have shown that 
in some plant species variation occurs during the day in the quantity and quality of 
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compounds in the leaves due to the different amount of sun light exposure (Gobbo-Neto 
and Lopes, 2007). 
The majority of people use the material when it is fresh, however it is possible that this 
could be due to the availability of H. crenata, because for the majority of users the plant 
grows nearby their homes.Due to the availability of H. crenata and that it is a weed that 
grows fast, for most users there is little need to dry and store the plant, even though 
some of them are aware that this is feasible as described by one of the interviewed who 
stores it for a period of one year. However, she emphasised that it is important to store it 
protected from the light, an indication which could suggest that some of Hyptis 
compounds might disintegrate with exposure to sunlight after the plant is harvested. 
Although this plant is known in Brazil as “Hortelazinha” meaning “little mint”, the 
plant is not usually taken as the common mint tea, it is only consumed as a medication. 
From the interviews it does not seem to have any addictive properties, since the users do 
not feel the need to have it as a regular drink. 
Some users described burning the H. crenata material and hanging babies cotton 
nappies above it to absorb the smoke, claiming that it would make the baby calmer, 
while others poured the tea preparation in the bath when they had fever or menstrual 
pain. These uses may indicate that some of the plant compounds could have a role as an 
anxiolytic agent or a muscle relaxant. There is a possibility that this effect might be 
caused by the volatile compounds from the essential oils inhaled or absorbed by the skin 
during the bath or from the baby nappies. The occurrences of essential oils in H. crenata 
have been reported (Pino et al., 2002; Zoghbi et al., 2002; Rebelo et al., 2009) as well 
as the ability of some H. crenata compounds such as 1,8-cineole to exhibit anxiolytic 
effects and muscle relaxation (Coelho-De-Souza et al., 2005; Satou et al., 2010). 
It is possible that the relief of the symptoms experienced by the users might not be due 
to the H. crenata treatment but could be influenced by the placebo effect. Placebo 
factors are reported to have influence in the physiology of a person taking a preparation 
with no therapeutic component (Price et al., 2008). Therefore, the results of this 
traditional use survey study need to be interpreted cautiously, it still cannot be used to 
indicate the effectiveness of the use of H. crenata species as a medication. For this it 
would be necessary to carry out a pharmacological study evaluating the effect indicated. 
In addition, the fact that interviewees have not reported toxic effect using the plant does 
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not mean that there is no toxicity. In order to clearly demonstrate that H. crenata 
treatments would be safe and effective to use, it would be necessary to carry out a 
detailed test of the toxicicity of the preparation to be used and clinical trials. 
2.2.4 Conclusions 
The survey carried out with H. crenata users shows that this plant is mainly used for 
pain relief and the parts used are the leaves and stems. The plant is only used as a 
medication and is prepared using seven different methods. The variation of methods of 
preparation consists of changes in temperature and in the type and concentration of 
solvents. The decoction extract method is the most used. 
The type of pain treated with H. crenata is headache, stomach and menstrual pain. 
Therefore, it might indicate that the compounds present in the plant induce central and 
visceral antinociception. 
The indication of anti-inflammatory and anti-fever effects raises the possibility of the 
plant compounds having effects on chemicals messengers such as prostaglandin. The 
plant compounds might induce cyclooxygenase inhibition, lowering fever and 
inflammation symptoms. 
2.3 Chemical Analyses of Compounds from H. crenata and Preparation of 
Extracts  
Since the survey indicated that the main use of H. crenata is for pain relief, the next step 
of this project was to carry out an investigation that would test the antinociceptive 
activities of the plant. 
Before deciding which type of preparation to use it was important to assess if the quality 
and quantity of volatile and phenolic compounds from H. crenata would vary according 
to the different temperatures, types and concentrations of solvents used. Therefore, apart 
from the milk extraction that was indicated for worms and syrup for cough, all other 
extraction methods mentioned in the survey were reproduced in the laboratory and 
analysed by GC-MS and HPLC. 
In addition a preliminary HPLC analysis was carried out to investigate if salicylic acid 
would be present in the H. crenata sample. Salicylic acid is a phenolic acid and is 
present in plants due to environmental stress conditions (Borsani et al., 2001). 
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Pharmacologically, salicylic acid is widely known for its ability to reduce fever, 
inflammation and pain. This effect is obtained through inhibition of cyclooxygenase 
that consequently reduces prostaglandin production (Ekinci et al., 2011). 
2.3.1 Material and methods 
2.3.1.1 Taxonomic identity 
The taxonomic identity of the plant species was verified by Professor Heleno Dias 
Ferreira, with voucher Nº29738, and deposited in the University of Goias herbarium. A 
sample of the plant was also identified and stored in the herbarium of Universidade 
Federal de Mato Grosso – UFMT, with registration Nº 37605. 
2.3.1.2 Plant collection and preparation 
The plant material tested in this study was collected in May 2008 under IBAMA 
personal license nº 24273-1 during the morning at Morrinho’s farm, Porto Esperidiao, 
Mato Grosso, Brazil, which is in the cerrado area. The cerrado is classified as savanna 
vegetation and it covers 23% of Brazilian territory (Ratter et al., 1997). 
Only well-developed plants were selected and the entire plant from the ground upwards 
was collected (the roots were left in the ground). The plants were not flowering at the 
time. The material was transported in boxes and left to dry for 3 days in a room exposed 
to wind circulation; this room was similar to a shed that protected the material against 
direct exposure to sunlight. The material was spread on tables, the room temperature 
was approximately 30° C. The indication that the plant was dried was when the leaves 
and stems could be crushed by hand. After drying, the material was packed into a 
cardboard box and posted to Newcastle University by Professor Evandro Luiz Dall’ 
Oglio from University Federal de Mato Grosso (UFMT) under agreement between 
UFMT, SISBIO and Graciela Silva Rocha (Newcastle University), SISBIO registration 
nº 1995110. 
After arrival at Newcastle University, the dried H. crenata leaves and stems were 
reduced to powder in a mill (Cyclotec 1093/ mesh 0.5mm) and stored in a freezer at -24 
ºC. 
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2.3.1.3 Methods of extraction reproduced in the laboratory 
From the traditional use survey, five different methods of extraction were identified 
which are used to prepare the plant to treat pain related symptoms. These methods were 
reproduced in the laboratory as described below (see Figure 6) and the amount of plant 
material used for each preparation followed the traditional use indication as shown in 
the results section. The temperature during the process of making infusion and 
decoction and the extract cooling process were monitored and noted in order to have 
more precise values in relation to the heat fluctuation. 
 
 
Figure 6 - Different extraction methods reproduced in the laboratory 
 
2.3.1.3.1 Decoction 
H. crenata decoction extract was prepared by gradually adding 1 litre of distilled water 
(25ºC) to 50 g of powdered material (dried leaves and stems) in a glass beaker, mixing 
with a spoon for 5 min in cold water, heating it until it boiled and boiling for 5 min. The 
decoction was then left for 15 min to cool without covering it. Next, the decoction was 
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filtered (Filter paper 125 mm 540, hardened ashless, circles, 125mm 
diameters/Whatman®) and was ready to be chemically analysed. 
2.3.1.3.2 Infusion 
H. crenata infusion extract was prepared by gradually adding 1 litre of distilled water 
(80 ºC) to 20 g of powdered material (dried leaves and stems) in a glass beaker, 
covering and leaving for 30 min while monitoring the temperature, filtering and ready 
to be chemically analysed. 
The details of temperature during the process of making decoction and infusion, as well 
as the cooling processes of decoction are shown in Figure 7. 
 
 
Figure 7 – Details of temperature during the process of making infusion and 
decoction extract 
 
2.3.1.3.3 Cold extraction (CEwater) 
The extract was prepared by gradually adding 1 litre of water (25ºC) to 23 g of 
powdered material (dried leaves and stems) in a glass beaker and mixing with a spoon 
for 5 min. The solution container was closed, protected from light using household 
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aluminium foil and left at a temperature of 25ºC for 24h (1 day). Then it was filtered 
and ready to be chemically analysed. 
2.3.1.3.4 Cold extraction with water and ethanol (CE15%) 
This extraction was to reproduce the traditional preparation with white wine that varies 
between 10 to 15% of alcohol concentration. This extract was prepared by gradually 
adding 1 litre of hydroalcoholic solution (15% at 25ºC) to 7g of powdered material 
(dried leaves and stems) in a glass beaker and mixing with a spoon for 5 min. The 
container was closed, protected from light using household aluminium foil and left at a 
temperature of 25ºC for 144h (6 days). Then it was filtered and ready to be chemically 
analysed. 
2.3.1.3.5 Cold extraction with water and ethanol (CE40%) 
This extraction was to reproduce the traditional preparation with “Pinga”, Brazilian 
sugar cane rum, which has an alcoholic concentration of around 40%. Therefore, in the 
laboratory the extract was prepared by gradually adding 1 litre of hydroalcoholic 
solution (40% at 25ºC) to 7g of powdered material (dried leaves and stems) in a glass 
beaker and mixing with a spoon for 5 min. The container was closed, protected from 
light using household aluminium foil and left at a temperature of 25ºC for 24h (1 day). 
Then it was filtered and ready to be chemically analysed. 
2.3.1.4 Analyses of quantity of plant material ingested by the people according to 
different extractions 
In order to verify the amount of plant material that has been ingested by people, each 
extract was freeze dried to quantify the amount of dried weight. 20 ml of each extract 
were allocated in pre-weighed containers (small bowls made of aluminium foil) and 
covered with perforated aluminium foil. The containers were freeze dried and the 
container weight subtracted from the total weight. 
2.3.1.5 Analyses of volatile and phenolic compounds by gas chromatography mass 
spectrometry GC-MS and high-performance liquid chromatography, HPLC. 
After preparation, all the five extracts were analysed by GC-MS and HPLC to assess the 
contents of volatile and phenolic compounds. The analyses were carried out according 
to the following methods. 
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2.3.1.5.1 GC-MS conditions 
The GC-MS analysis was performed by Paul Donohoe, a technician in the School of 
Engineering and Geosciences at Newcastle University. GC-MS analysis of the aliphatic 
or aromatic compounds from the decoction extract was performed on a Hewlett-Packard 
7890A GC split/split less injector (280°C) linked to a Agilent 5975C MSD (electron 
voltage 70eV, source temperature 230°C, quad temperature 150°C multiplier voltage 
1800V, interface temperature 310°C). The acquisition was controlled by a HP Compaq 
computer using Chemstation software, initially in full scan mode (50-600 amu/s) or in 
selected ion mode (30 ions 0.7 cps 35 ms dwell) for greater sensitivity. 
The sample (1μl) in DCM was injected by an HP7683B auto sampler and the split 
opened after 1 minute. After the solvent peak had passed, the GC temperature 
programme and data acquisition commenced. Separation was performed on an Agilent 
fused silica capillary column (30 m x 0.25 mm i.d.) coated with 0.25 μm dimethyl 
polysiloxane (HP-5MS) phase. The GC was temperature programmed from 50-300°C at 
5°C min and held at final temperature for 10 min with Helium as the carrier gas (flow 
rate of 1 ml/min, initial pressure of 50kPa, split at 30 ml/min). Peaks were identified 
and labelled after comparison of their mass spectra with those of the NIST05 library if 
>90% fit or from their elution order from the literature. 
2.3.1.5.2 HPLC conditions 
The different extractions were analysed on a Shimadzu High Performance Liquid 
Chromatography (LC-20AD, Diode Array detector SPD-M20A, noise level of 0.6×10-5 
AU, wavelength range 190-800 nm), Auto sampler Sil-20 AC, Thermo Scientific ODS 
Hypersil column 250 mm x 4.6 mm, particle size 5 μm. The column (reverse phase) was 
eluted by using a linear gradient of water (solvent A) and methanol (solvent B), starting 
with 0% B/100% A (0 min) and increasing to 10% B (10 min), 30% B (20 min), 75% B 
(35 min), 90% B (45 min), decreasing to 0% B (50 min) and stopping at 65 min. 
Solvent flow rate was 0.8 ml/min. 
2.3.1.5.3 HPLC conditions (salicylic acid analyses) 
The decoction extract and a salicylic acid solution (69 µg/2 ml) were analysed in a 
Shimadzu High Performance Liquid Chromatography (LC-20AD, Diode Array detector 
SPD-M20A), Auto sampler Sil-20, Column AC Thermo Scientific ODS Hypersil Dim 
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250 mm x 4.6 mm particle size 5 μm. The column was eluted by using a linear gradient 
of water + 2% acetic acid (solvent A) and acetonitrile (solvent B), starting with 0% B (0 
min) and increasing to 15% B (30 min), 50% B (50 min), 100% B (55-60 min), 
decreasing to 0% B (60-70 min) with a solvent flow rate of 0.8 ml/min (Kim et al., 
2006). 
2.3.2 Results 
Through GC-MS analysis it was observed that the different extractions have a variation 
in the type of compounds contained in the samples and also in their concentrations. 
The major constituents present in these five extractions were camphor and 1.8-cineole 
eucalyptol, as shown in Table 4. Also, some other not identified compounds (ONI) were 
observed. The CE40% extraction was the sample that had the highest ONI, however the 
maximum concentration reached for any of these compounds was 3.2% and in total 
these compounds represented up to 19% of the sample. In relation to other extractions, 
it was observed that the ONI were less than 2% and in total comprised no more than 
6.5% of volatile amounts in the samples. 
These analyses also showed that the decoction extract has more variety of volatile 
compounds than the others. The CE40% showed an additional compound, the other 
extracts only contained camphor and 1.8-cineole in their volatile composition. These 
two compounds were present in all extracts. Camphor was the major compound in all 
samples. In relation to the comparison of variation in concentration of camphor and 1.8-
cineole; despite the concentration of plant material for preparing the extractions being 
different (see material and methods) the percentage of total composition of each 
extraction sample showed that the amount of these volatile compounds was influenced 
by the temperature and concentration of alcohol. Increased temperature drastically 
decreased the amount of 1.8-cineole in the decoction (4% of total) compared to cold 
extraction (24% of total) and infusion (21% of total) that was prepared with low heat. 
On the other hand, for camphor the % of total component in the sample was higher 
(84%) in the decoction than for other samples. Another observation was that although 
the amount of plant material used to prepare the alcoholic extractions were exactly the 
same, the concentration of each volatile compound increased when the alcohol 
concentration increased, when comparing CE15% with CE40% as shown in Table 4 and 
Figure 8. 
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Extraction Compounds % of 
total 
Peak 
area 
Area / mg 
dry matter 
(1 ml of 
extraction)* 
Infusion 1.8-cineole (eucalyptol) 
Camphor 
ONI 
Total 
21 
76 
3 
100 
7770136 
27982728 
1204517 
36957381 
3700065 
13325109 
573580 
17598753 
Decoction 1.8-cineole (eucalyptol) 
Camphor 
Borneol 
Thymol 
Trimethyltricyclododecane-2,9-diol  
ONI 
Total 
4 
84 
2.4 
2.3 
1.2 
6.1 
100 
428366 
9059655 
266221 
250647 
135818 
705344 
10846051 
93123 
1969490 
57874 
54488 
29526 
153336 
2357837 
CEwater 1.8-cineole (eucalyptol) 
Camphor 
ONI 
Total 
24 
75 
1 
100 
4587181 
13973705 
185397 
18746283 
2698342 
8219826 
109057 
11027225 
CE15% 1.8-cineole (eucalyptol) 
Camphor 
ONI 
Total 
20 
74 
6 
100 
2969450 
10954430 
1418649 
15342529 
1562868 
5765489 
746657 
8075015 
CE40% 1.8-cineole (eucalyptol) 
Camphor 
2- (4 - Methoxyphenyl)-2-(3-methyl-
4 methoxiphenyl) propane  
ONI 
Total 
15 
53 
13 
 
19 
100 
4088946 
14219520 
3439737 
 
5221844 
26970047 
4088946 
14219520 
3439737 
 
5221844 
26970047 
ONI=other not identified 
* The dry matter values for each preparation is shown in the Table 5 
Table 4 - Type and concentration of volatile compounds of decoction, infusion and 
cold extractions reproduced in the laboratory 
 
The HPLC analyses showed phenolic compounds present in the different analyses at 
absorption of 280nm. It was observed that the decoction and infusion extractions were 
similar when comparing the types of phenolic compounds, while the cold extracts were 
remarkably different (Table 4 and Figure 8). The CEwater and CE15% extractions 
showed two peaks of compound(s) between 17 and 26 minutes retention time (RT), that 
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are only present in these extractions. Also CE40% was the only one to contain 
compounds between 34-43 min RT. This indicates that this extraction selected 
compounds that have a more non-polar behaviour compared to others, since they are 
appearing later in this reversed-phase chromatography. 
 
Figure 8 - Comparison of phenolic chemical compounds peaks in the different 
extractions, according to retention time. High performance liquid chromatography 
analyses 
 
Regarding the amount of intake of dried extract according to each extract preparation 
method, the results show that the decoction extract dose is 15 mg/kg body weight (b.w.) 
being the most concentrated as shown in Table 5. 
© Newcastle University 2013 52 
Extraction Amount of 
plant 
material 
used  
Dried material 
obtained from 
20 ml of 
sample 
Concentration 
in 200 ml 
(people 
treatment) 
Concentration 
in 60 kg 
(people 
weight*) 
Decoction 50 g/l 91 mg 910 mg 15.2 mg/kg 
Infusion 20 g/l 42.1 mg 421 mg 7.0 mg/kg 
Cold extract water 23 g/l 34.8 mg 348 mg 5.8 mg/kg 
Cold extract 15% 7 g/l 39.6 mg 396 mg 6.6 mg/kg 
Cold extract 40% 7 g/l 20.3 mg 203 mg 3.4 mg/kg 
*People’s weights were estimated as 60 kg (Monteiro et al., 2009), since this was not 
measured. 
Table 5 - Amount of extract dry matter ingested by the people when using the 
different extractions as treatments. 
 
2.3.2.1 Results of the investigation of salicylic acid in the decoction extract 
When comparing the retention time and spectra, the HPLC analyses showed that 
salicylic acid was not detectable in the H. crenata decoction extract (Figure 9). Figure 
9A displays the HPLC chromatogram of decoction extract and SA trace. The 
chromatogram shows that at 38.25 min an overlap occurred between SA and HC 
decoction, in order to check the similarity between these peaks the absorption spectra 
was verified. The analyses of these spectra showed that they were different as presented 
in Figure 9B and Figure 9C. 
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Figure 9 – Comparison of spectra from HC compounds and salicylic acid. (A) 
HPLC chromatogram of Hyptis crenata decoction (HC; solid line) and salicylic acid 
(SA; dotted line) peaks. The chromatogram shows the absorption at 256 nm and 
indicate that the peak absorption occurs at slightly different retention times (RT).  (B,C) 
Absorption spectra at 250-400 nm for the HC decoction peak at RT 38.15 min (B) and 
for the salicylic acid peak at RT 38.20 (C). Although the peaks of HC and SA are very 
close in retention time (A), their spectra are different (B,C), indicating that they are 
different compounds. 
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2.3.3 Discussion 
The main aim of the experiments presented in this section was to reproduce in the 
laboratory the extractions that have been described in the traditional use survey and to 
perform chemical analyses of them. As reported, these extractions were decoction, 
infusion and three types of cold extractions that used water or its mixture with alcohol at 
15% and 40% concentration. The analyses of dried material for each extract preparation 
showed that the decoction extract, when compared to the others, contains the highest 
content of dry matter, but it has the lowest amount of volatiles. 
As was presented in the results, H. crenata extractions showed that temperature and 
solvent have a significant impact on the quality and quantity of phenolic and volatile 
compounds present in each preparation. This fact confirms the importance of 
establishing standard procedures to prepare the plant for consuming as a medication. 
Otherwise, if the person is not aware of how long the plant should be boiled and, for 
example, leaves it on the heat longer than recommended, the preparation might suffer 
changes in the type and concentration of compounds that might have a negative 
influence in the therapeutic activity, possibly even having adverse effects. The 
appearance of different compounds influenced by the heat is clearly demonstrated when 
comparing volatile compounds in the H. crenata infusion extract, prepared at 80°C, 
with a decoction extract that was boiled for 5 minutes. Although in a relatively low 
concentration the compounds borneol and thymol were found in the decoction but not in 
the infusion. Few studies are available about the effects of temperature on volatile 
compound extraction; these are usually not focused on the method for preparing extracts 
of medicinal plants, but often on using temperature to optimize a method to obtain a 
certain compound. Examples of this are the work of Xue and Yin (2009) and Yang et al. 
(2009) where the amount of the compound beta-cyclodextrin and zingiberene from the 
species Ledum palustre and Zingiber officinale were, respectively, increased or 
decreased according to temperature variation during the process of sample preparation. 
On the other hand, temperature influence on extraction of phenolic compounds is 
frequently reported. Thus, confirming the results observed for H. crenata where the 
phenolic compounds varied their type according to temperature and concentration of 
alcohol as a solvent. An example is the results presented by Bucić-Kojić et al. (2009) 
where it was reported that the types and concentration of polyphenols of Vitis vinifera L 
were “highly dependent” on solvent and temperature. 
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In general, the influence of different types and concentrations of solvents are usually 
part of the methods used for medicinal plant investigations involving volatiles and 
phenolic compounds. However, it seems that there is a lack of awareness regarding the 
influence of temperature when preparing medicinal plant extract at home, and even in 
the scientific community. Also there are not substantial data that indicate if the general 
public have this knowledge. This is alarming, in particular when so many people make 
use of this type of medication, as was described in the introduction to this thesis. 
Among the pharmacological activities reported in the literature on the volatile 
compounds in H. crenata are that the compound 1.8-cineole (eucalyptol) has significant 
sedating and antipyretic activities, and is associated with inhibition of cytokine 
production and arachidonic acid in anti-inflammatory effects (Ortiz de Urbina et al., 
1989; Juergens et al., 1998). The volatile camphor has been described as an agonist of 
transient receptor potential ion channel vanilloid subtypes 1 and 3, known as TRPV1 
and TRPV3. These receptors are present in the skin, dorsal root ganglion neurons and in 
the brain. They are Ca2+ selective channels, camphor has been described to have the 
ability to “sensitize” TRPV3 and “desensitize” TRPV1, these receptors being 
responsible for reproducing pain sensation caused by heat and chemicals (Xu et al., 
2005; Vennekens et al., 2008; Bang et al., 2012). The compounds thymol and borneol, 
only found in the decoction extract, were also described for activating TRPV3 receptors, 
thymol being a more potent agonist than borneol (Vogt-Eisele et al., 2007). In addition, 
these compounds are indicated to modulate γ-aminobutyric acid, GABA - A receptors, 
inducing anxiolytic and sedative effects (Vogt-Eisele et al., 2007). 
This is the first time that the compound thymol is reported in H. crenata species. 
Volatile compounds of H. crenata have been reported by five research groups (Scramin 
et al., 2000; Pino et al., 2002; Zoghbi et al., 2002; Rebelo et al., 2009; McNeil et al., 
2011). The results of these investigations showed that the type and concentration of 
volatile compounds varied according to the environment where the plant was collected. 
For example, Zoghbi et al. (2002) examined the essential oils of H. crenata in different 
areas of Brazil. The main compounds observed in the essential oil in the area localised 
in the state of Tocantins in central Brazil were terpinolene (37.8%) and beta-
caryophyllene (9.9%), whereas in the state of Para, in northern brazil the main 
components were 1.8-cineole (eucalyptol) (23.9%), borneol (21.8%) and beta-
caryophyllene (18.8%). Camphor was the main volatile in the aqueous extracts in this H. 
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crenata study, and it was reported for H. crenata species growing in Pará and Pantanal, 
with concentrations of 11% by Scramin et al. (2000) and 17.3% by Rebelo et al. (2009), 
respectively. 
One conclusion from this literature is that the volatile compounds of H. crenata can be 
different if collected in a different place and time. This PhD project used H. crenata 
material that was collected once, in May, and in one location. The disadvantage of this 
procedure is that the chemical profile, mainly the volatile compounds of H. crenata 
described in this project, might not represent with accuracy the composition of the plant 
produced during the year or in other areas, due to the possibility of influence of 
environmental factors such as drought, soil and sunlight. However, the decision of 
testing the material with this single collection was based on the results from the 
traditional use survey, where the majority of users mentioned that the material can be 
collected any time during the year, therefore suggesting that the compounds that have 
variation according to environmental changes, such as volatiles, might not play an 
important role in the medical effects. Also it would not be advantageous to do 
pharmacological tests using material tests representing different seasons in the year, 
when the plant studied is a wild species rather than cultivated. Since the compounds 
found in a native species might suffer changes when this species will be cultivated, as 
has been verified in studies that showed this variation in volatile and phenolic 
compounds (Bhatt et al., 2012). Considering if H. crenata shows interesting results that 
might make it worthwhile to produce a phytomedication, the ideal is that the plant 
would be cultivated, to meet the demand of its use and avoiding the decline of the native 
species available. 
The traditional use survey also indicated that symptoms such as fever and inflammation 
might be relieved by the plant extract, suggesting that H. crenata compounds might 
have an effect on reducing prostaglandin production, thus decreasing activity of pain 
mediators such as bradykinin and histamine (Santos et al., 1998). If H. crenata 
compounds are able to inhibit cyclooxygenase, lowering the amount of prostaglandin, 
this effect could potentially be caused by salicylic acid because this compound is well 
known as one of the COX inhibitors. However the results of this chapter showed that 
salicylic acid is not present in the decoction sample, therefore it may be another 
compound inducing this effect (Xu et al., 1999). 
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2.3.4 Conclusions 
As described, the main indication of H. crenata reported in the traditional use survey 
was for pain relief, and the extracts used for this indication were reproduced according 
to the traditional use method in the laboratory. 
The chemical analyses showed that the amount and type of volatile and phenolic 
compounds in the extracts were influenced by the temperature used during their 
preparation and also for the type and concentration of solvent, in this case alcohol and 
water. 
The decoction was the extract that showed the greatest variety of volatile compounds, 
some of them, such as thymol and borneol, were only found in this type of extraction. 
The compounds camphor and 1.8-cineole (eucalyptol) were present in all extractions, 
and camphor was the major volatile in all the samples. 
Finally, H. crenata decoction extraction compounds are not identical with salicylic acid. 
2.3.5 Implications for the next stage of the project 
The next stage of this project was to evaluate the antinociceptive activities of H. crenata, 
since pain relief was reported as the main indication. The decoction extraction that has 
been used at the dose of 15 mg/kg
 
body weight, was the method chosen to prepare the 
pharmacological treatments to be tested. This was the most common method used in the 
traditional use survey. Furthermore, this extraction method exhibited a more diverse 
composition, which showed a range of different types and concentrations of phenolic 
and volatile compounds when compared to other methods. However, for the 
pharmacological study the volatile compounds were not tested because the decoction 
extract, the most used method by the H. crenata users, gave the lowest concentration of 
volatile compounds per mg extract dry material compared to other methods used, 
indicating that the volatiles were not important for the effect. Additionally, these types 
of compounds are difficult to evaluate due to their variability that occurs under 
environmental conditions where the plant grows. Therefore the H. crenata treatments 
tested in this study did not contain the volatile compounds mentioned earlier in the 
decoction results presented. As the treatments tested in this study were lyophilised, this 
process removed those volatile compounds.In the results of the traditional use survey 
there are indications that the plant is used for stomach pain, menstrual pain, headache, 
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fever and uterus or bladder inflammation. Therefore, we could propose that the 
decoction extract might have an effect on physiological pain, inflammatory pain and/or 
visceral pain. To answer if H. crenata would be effective against pain caused by 
chemical stimuli like in the indigestion cases, the acetic acid test inducing writhing was 
used. In this test an animal model was used which is described to mimic the visceral 
pain suffered by humans. In addition, we also investigated whether H.crenata was an 
inhibitor of the peripheral nociceptive system. In order to test this hypothesis, the 
Hargreaves test was used. By using this test we could verify whether the extract was 
affecting the activation or transmission of the thermal nociceptive system. 
The use survey also indicated that symptoms such as fever and inflammation might be 
relieved by the plant extract, suggesting that H. crenata compounds might have an 
effect on reducing prostaglandin production, thus decreasing activities of pain mediators 
such as bradykinin and histamine (Santos et al., 1998). If H. crenata compounds are 
able to inhibit cyclooxygenase and consequently lower the amount of prostaglandin, this 
effect cannot be caused by salicylic acid, which is well known as one of the COX 
inhibitors (Xu et al., 1999), because salicylic acid was not detected in the decoction 
sample. 
Furthermore, the fact that this plant was mentioned as anti-inflammatory could indicate 
that it has a COX inhibition effect. In order to answer these questions the COX 
inhibition assay was used to predict the levels of prostaglandin and chemical analysis of 
decoction compounds was carried out and is presented later in this thesis. 
 
© Newcastle University 2013 59 
 
 
 
 
 
 
 
 
 
Chapter 3. Evaluation of Antinociceptive Effects of Hyptis crenata 
Decoction Extract and Fractions Using Hargreaves Test – Acute 
Thermal Test 
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3.1 Overall procedures 
3.1.1 Flowchart 
 
 
 
Evaluation of 
decoction extract at 
doses 0, 15 and 150 
mg/kg 
Evaluation of 
decoction extract at 
doses 0, 1, 5 and 45 
mg/kg 
Evaluation of 
decoction fractions 
hexane, DCM, 
methanol and water 
Chapter 4 
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3.2 Introduction 
The results obtained from the survey of traditional use of H. crenata (Chapter 2) as well 
as previous antinociceptive studies on other species of Hyptis have suggested that H. 
crenata may possess antinociceptive properties, this was investigated both in respect of 
acute noxious pain and abdominal pain (Bispo et al., 2001; Lisboa et al., 2006; Marcal 
et al., 2006; Menezes et al., 2007; Santos et al., 2007b; Arrigoni-Blank et al., 2008; 
Franco et al., 2011; Raymundo et al., 2011). The Hargreaves test was the method 
chosen to examine whether H. crenata decoction would be able to inhibit pain caused 
by a noxious stimulus, applied at the surface of the body. This is an acute animal model 
test which uses the heat of infrared light as the noxious stimulus. It has been widely 
used for evaluating analgesic drugs and for estimating their activities in humans 
(Hargreaves et al., 1988). The main advantage of Hargreaves compared to other tests, 
such as hot plate, is that the animal is unrestrained while applying the pain stimulus, 
heat, on the paw. Therefore, using this test the animal might be less stressed, 
contributing to a more accurate measure of antinociception (Kocevski and Tvrdeic, 
2008). The challenge for this experiment, or for any experiment using animals as the 
subject, is the fact that animals are not able to communicate verbally if they are feeling 
pain or to communicate the intensity or location of pain. Therefore, behaviour is one of 
the methods that can be used for interpreting and evaluating pain. In the case of 
Hargreaves test it is the paw withdrawal, measuring how long they can stand with 
infrared light application (Kesim et al., 2002). 
The Hargreaves test can be comparable with other thermal tests such as tail flick and hot 
plate. The difference between Hargreaves and these tests is that “Hargreaves heats a 
specific point in the animal paw whereas these other tests heat both paws at the same 
time” (Galbraith et al., 1993). 
3.2.1 Hargreaves test to evaluate activity of medicinal plants and drugs 
There are few articles that reported antinociceptive studies of medicinal plants using the 
Hargreaves test (Feltenstein et al., 2003; Amendoeira et al., 2005; Acosta-Madrid et al., 
2009; Kang et al., 2010). However, when a search is made looking for “hot plate” used 
for evaluation, a larger number of articles appear in the databases Web of Knowledge, 
Scopus and Medline. It is apparent from the number of antinociceptive studies using hot 
plate compared to Hargreaves that researchers studying medicinal plant antinociception 
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have a preference for the hot plate method, or it could be that it is the most accessible 
compared to Hargreaves test, since any laboratory could possess a hot plate but not 
specialised test equipment for antinociception plantar evaluation. 
On the other hand, if the search is made for “analgesic drugs” using the “Hargreaves 
test”, this method is more widely used for evaluating new drugs or checking the effects 
of standard drugs. Some of the drugs evaluated are mirtazapine, acemetacin, codeine, 
nalbuphineracemic AM1241, huperzine A, amotrigine, clonidine and dexmedetomidine 
(Ortiz et al., 2007; Roh et al., 2008; Yanarates et al., 2010; Aggarwal et al., 2011). 
Certainly, as with other animal model methods, this test has its disadvantages, such as 
the interference of the animal skin temperature with the results outcome. To overcome 
this issue the research needs to minimize factors that would induce changes in the 
animal’s temperature while being measured (Le Bars et al., 2001). 
3.3 Aim of this experiment 
The aim of this experiment was to evaluate the antinociceptive effects of different doses 
of H. crenata decoction extract and its fractions by assessing their effects at different 
times after treatment through the Hargreaves test. 
3.4 Material and methods 
3.4.1 Preparation of treatments 
3.4.1.1 Decoction extract 
The method of preparing the H. crenata decoction extract studies was the same as 
described in Chapter 2. The difference was that after the process of making and filtering 
the decoction extract, it was lyophilised using a freeze dryer machine (condenser 
temperature = -54C and the chamber temperature = -25C). After lyophilisation it was 
kept in a small sealed container in a freezer (-24ºC). When it was needed for the animal 
experiment, the container was collected from the freezer and left for 60 minutes at room 
temperature to warm up before opening to prevent condensation on the dry material. It 
was then measured according to doses and reconstituted in the first experiment with 10 
ml water for injection, when evaluating HC 15 mg/kg and HC 150 mg/kg, and for the 
second experiment was reconstituted with 10 ml of water for injection (98%) + 
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Polysorbate 80 (Tween) (2%), when evaluating HC 1 mg/kg, HC 5 mg/kg and HC 45 
mg/kg. 
3.4.1.2 Fractionation of decoction extract 
For the study of different fractions, the lyophilised decoction extract was fractionated by 
hexane, dichloromethane, methanol and water. These solvents were chosen due to their 
polarity index range being 0, 3.1, 5.1 and 9 respectively (Byers, 2003). The procedure 
of fractionation was as follows: Firstly, the lyophilised decoction extract was weighed 
(45 mg) in a plastic centrifuge tube (50 ml). Then, 10 ml of the solvent hexane (HPLC 
grade CH3 (CH2) 4 CH3) was added to this material, magnetically stirred for 10 min 
(motor velocity 2, Ikamag® RH), then centrifuged for 10 min at 4000 rpm to remove 
any particulate matter, and the solvent phase was transferred to a glass tube and was 
then dried (see below). The above procedure was repeated with the solvents 
dichloromethane DCM; (Fisher Chemicals – CH2Cl2), methanol (HPLC grade 
CH3OH) and water (double purified and deionised by Nanopure Diamon-Barnstead) 
respectively. 
The method for drying the fractions was as follows: The prepared fractions of solvents 
hexane, DCM and methanol were placed in a sample evaporator (40ºC, using nitrogen 
to dry). Dichloromethane was evaporated in 30 min (4 mg dried yield 8.9% of the 
original 45 mg), hexane after 50 min (2.1 mg dried yield 4.7%) and methanol at 70 min 
(14.8 mg dried yield 32.9%). The water fraction was lyophilised in an aluminium foil 
container (23 mg dried yield 51.1%). In total 43.9 mg of the original 45 mg was 
recovered. After drying, the glass tubes containing the material for the hexane, DCM 
and methanol fractions were sealed and stored in a freezer (-24 ºC). For the water 
fraction, after drying, the foil container was sealed by wrapping in Parafilm®, covered 
with aluminium foil and then stored in the freezer. In order to reconstitute the fractions 
to be used as treatments for the animals, a tube with 10 ml of water for injection (98%) 
+ Polysorbate 80 (Tween) (2%) was added to each fraction. Firstly, 0.2 ml of 
Polysorbate solution was added to the fraction tube and stirred with a spatula to dissolve 
the fraction dried material, and then 9.8 ml of water for injection was added and stirred 
again and mixed using a vortex mixer. 
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3.4.1.3 Positive drug control 
The positive control used was indomethacin sodium trihydrate (Indocid ® PDA, 
Ovation), supplied in a vial with 1 mg of powder. The reconstitution of indomethacin 
was made following its guidelines, which involved adding 1 ml of water for injection to 
achieve a concentration of 0.1 mg/0.1 ml. Indomethacin was selected as this has been 
successfully used in numerous studies of the acetic acid and hot-plate tests. 
Indomethacin belongs to the group of medicines known as the non-steroidal anti-
inflammatory drugs or NSAIDs (Ray et al., 2001; Grahame-Smith and Aronson, 2002). 
This type of drug inhibits pain by blocking the production of certain prostanoids such as 
prostaglandin. This blockage is obtained through inhibition of the enzyme responsible 
for its production, the enzyme cyclo-oxygenase (COX), which synthetises prostaglandin 
from arachidonic acids (Shipton, 1999). 
3.4.1.4 Vehicle control 
In the first experiment when H. crenata 15 mg/kg, 150 mg/kg and indomethacin were 
evaluated, water for injection (Hameln Pharmaceuticals Ltd., Gloucester) was used as 
vehicle. For the second experiment Polysorbate 80 (Tween) in a concentration of 2% 
was added to the water for injection. The reason for adding polysorbate to the vehicle 
was that it was used as control for evaluation of the fractions. As mentioned in the 
fractionation section, the fractions required this non-ionic surfactant in order to be 
successfully dissolved. 
3.4.1.5 Treatment doses and the order of experimentation 
The first part of the experiment was to evaluate the antinociceptive effect using the 
same dose indicated in the traditional use survey (15 mg/kg) and a 10 times higher dose 
(150 mg/kg) in order to be certain whether there were any effects. The dose of 15 mg/kg 
was not translated using scaling between species (Green et al., 2009a). The traditional 
use survey results showed that the average amount of plant material used to prepare a 
decoction extraction was 50 g per litre of water, and that they consumed an average of 
200 ml of this for medication. Therefore, the amount of lyophilised extract was 
calculated according to the traditional use, with a dose of 15 mg per kg of body weight 
in the range that would be taken by people (approximately similar mg plant material 
weight / kg body weight). Humans take approximately 200 ml of an extract containing 
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910 mg dry matter, which approximates to 15 mg/kg (p.o.). For a 25 g mouse the dose 
administered was 0.38 mg reconstituted in 250 µl (10 ml/kg b.w.) for the low dose and 
for the high dose 3.8 mg in 250 µl. 
After the doses of 15 mg/kg (p.o.) and 150 mg/kg (p.o.) complete extract were shown to 
have effects the next step of the project was to evaluate lower and higher doses 
compared with 15 mg/kg (p.o.) in order to determine dose dependency and effective 
threshold dose. These doses were 1, 5 and 45 mg/kg (p.o.). The final stage of this study 
was to evaluate the decoction fractions. The H. crenata decoction fractions administered 
to the animals had the same concentration of dried material obtained after the 
fractionation process since it was reconstituted with 10 ml of solution equivalent to 10 
ml/kg ingested by the animals. Therefore the fractions doses were: 2.1 mg/kg (p.o.) 
(hexane fraction), 4 mg/kg (p.o.) (DCM fraction), 14.8 mg/kg (p.o.) (methanol fraction) 
and 23 mg/kg (p.o.) (water fraction). In other words, each animal will have received the 
same amount of active ingredient as the 45 mg/kg of crude extract, only separated into 
the four fractions. As in the fractions treatments the HC 1 mg/kg (p.o.), HC 5 mg/kg 
(p.o.) and HC 45 mg/kg (p.o.) also had 2% of polysorbate 80 (Tween) when the extract 
was reconstituted. The practice of adding polysorbate 80 to dissolve extracts has been 
reported in several studies, and appears to have no effect on the animals (Navarro et al., 
2006; Wang and Song, 2006). 
The positive control indomethacin (ID) was administered at a dose of 10 mg/kg (p.o.) 
and for the vehicle the same volume of water for injection was given (10 ml/kg). 
There were eight mice in each of the active treatment groups, while the vehicle group 
was evaluated in two batches totalling 16 mice. Cages were used with eight mice in 
each cage in order to avoid any group effect or transfer of behaviour between batches of 
animals. The different treatments were each given to two mice in each cage. Each cage 
was a separate batch for the purpose of performing the test, with the activities of 
subsequent batches staggered relative to each other. 
All the treatments were given orally by gavage using a mouse-compatible tube. 
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Figure 10 – Diagram illustrating how the mice were housed and the distribution of 
treatments within a cage. 
3.4.2 The Hargreaves test procedure 
For the Hargreaves test the thermal nociceptive threshold testing procedure was based 
on the original protocol published by Hargreaves et al. (1988) with some modifications 
regarding the measurements time point. The reason for this change will be explained in 
the next section. Foot withdrawal response to thermal stimulation was measured using 
the Hargreaves apparatus (Ugo Basiles R.L. model 7371), as shown in Figure 11. 
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Figure 11 - Plantar test instrument (Ugo Basiles), Hargreaves method (Plantar test, 
2012) 
Each mouse was measured for its baseline nociceptive threshold 24 h before treatment 
(-24 h baseline). There was no information of when or how long the proposed 
antinociception for H. crenata treatments would occur. For this reason several 
measurements were taken after the mouse was treated. These measures were taken at 1, 
3, 6 and 24 h after treatment. 
For the purpose of randomisation, each batch of animals measured in the Hargreaves 
machine contained a mouse representing a different treatment group. The measurements 
were taken blinded regarding which treatment the mouse received. The treatments were 
administered by a technician who performed no further role in the experiment. 
The following Hargreaves test procedure was adapted by Professor Paul Flecknell, Dr 
Matthew Leach and Dr Johnny Roughan from the Comparative Biology Centre of 
Newcastle University. 
Mice were individually confined in Plexiglas chambers (20 cm x 20 cm x 14 cm) on a 
glass platform. The cut-off time for the equipment was set at 30 s (i.e. the maximum 
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period of exposure to a heat stimulus). The mobile radiant heat source was placed under 
the mid-plantar region of the hind paw at an intensity of 50% of maximum heating 
capacity (190 mW/cm
2
). The responses (duration until paw withdrawal) for each time 
point evaluated consisted of taking three measurements from each animal. These 
measurements were taken from the right and left hind paws, two from the left and one 
from the right or two from the right and one from the left. Each animal was tested once 
before moving to the next animal. Measurements alternated between each foot to ensure 
one foot was not measured more than once within a 5 min period. This interval was 
allowed to reduce the likelihood of inadvertent alteration in skin nociceptor sensitivity 
by repetitive testing. Attempts were made to only test mice when stationary and not 
exhibiting other behaviours (e.g. sleeping and grooming) as this is thought to confound 
the test, since sleeping animals show attenuated behaviour and grooming mice show 
relative hypoalgesia (Callahan et al., 2008). The equipment and Plexiglas chambers 
were cleaned with 10% alcohol solution following each trial to remove urine to ensure 
that heating remained as consistent as possible and also to avoid the possibility that the 
urine would induce stress to the next animal to be measured. 
The sequence of the measurements at different times performed in the Hargreaves test is 
displayed in Figure 12. 
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Figure 12 - Treatment and measurement sequence for the Hargreaves test 
 
3.4.2.1 Animals used 
The experiment was performed on C57/BL6 mice, from Charles River Laboratories 
(Margate, UK). This strain was selected for their sensitivity to pain tests and has been 
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used in the development of several pain models (Anuforo et al.; Brierley et al.; 
Harrington et al.; Rowley et al.; Silva et al.; Mirza et al., 2001). 
The mice, which were all female and approximately 6-8 weeks old at the time of arrival, 
were kept for one week to acclimatise before starting the study (room temperature 20
o
C). 
They were housed in groups of 8 in plexiglass cages (size: 16" x 11" x 5") and supplied 
with wood chipping bedding and water and rodent chow ad libidum. The mice ranged in 
weight from 14-25 g. The room temperature was approximately 24º C in the first 
experiment when testing vehicle, Indomethacin, HC 15 mg/kg and HC 150 mg/kg and 
20º C when testing vehicle, HC 1 mg/kg, 5 mg/kg, 45 mg/kg and HC decoction 
fractions in the second experiment. 
The study was carried out under project (PPL Nº60/3793) and personal licences (PIL 
60/11886) approved by the Secretary of State for the Home Office, under the United 
Kingdom’s 1986 Animals (Scientific Procedures) Act. The premises were also approved 
and complied with the Code of Practice for the Housing and Care of Animals used in 
Scientific Procedures, Home Office, 2005. The work was also approved by the local 
ethical review committee at Newcastle University. 
3.4.2.2 Statistical analysis 
The mean of the three responses on the hind paws were calculated for each mouse to 
give a representative nociceptive threshold at each data time point, which were: 24h 
before treatment (-24 h) and 1 h, 3 h, 6 h and 24 h after the treatment. 
In order to remove the individual variation in response from the treatment effect, the 
average of reaction measurements of baselines were subtracted from the reaction data. 
Because no effect was observed after 24 h of treatments, the average of 24 h before and 
24 h after treatment was used as the baseline, and the average of the baseline measures 
were subtracted from the 1 h, 3 h and 6 h time points. This provides a value of change in 
response time. Another reason for choosing 24 h after treatment as baseline is that it 
would be a more reliable measurement, since the mice would be more familiar with the 
test environment considering that they could learn from the first measurement that they 
would receive a thermal noxious stimulus when inside the boxes. 
The data were transformed using Log10 for normality fitting; Mean ± S.E.M. were 
calculated for all results. The results were analysed using SigmaPlot 11.0. The tests 
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performed were two way repeated measures ANOVA (time-point x treatment) and one 
way ANOVA (treatment). A value of P<0.05 was considered significant. 
3.5 Results 
All animals tolerated the acute administration of the treatments well and no immediate 
adverse response was observed (although see below for later response to indomethacin). 
However, the analyses of effect after time of treatment for the experiments, showed that 
in all 3 sets of tests most of the withdrawal reaction measurements dropped at 3 h after 
treatment and increased at 6 h after treatment, as shown in Figure 13, Figure 14 and 
Figure 15, showing unusual pharmacokinetics for time-effect response. Also,  the two 
way repeated measures ANOVA showed that there was not interaction between time 
and treatment (F=0.615, DF=20, SS=0.442, P=0.898). Therefore, it was decided to 
analyse the average of the values obtained at 1 h, 3 h and 6 h. In addition, 24 h after 
treatment the withdrawal response had a similar value as the baseline measurements of 
24 h before treatment. Therefore it was decided to use the average of 24 h before and 
after treatment as baseline. 
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Figure 13 – Withdrawal response delay in the Hargreaves test, evaluation of time-
varying response of indomethacin and HC doses. Mean + S.E.M. of data of paw 
withdrawal response delay plotted against time relative to the treatment with vehicle 
(p.o.), indomethacin 10 mg/kg (p.o.), H. crenata (HC) decoction extract 15 mg/kg (p.o.) 
and 150 mg/kg (p.o.). All data points are n=8. 
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Figure 14 - Withdrawal response delay in the Hargreaves test, evaluation of time-
varying response of HC doses. Mean + S.E.M. of data of paw withdrawal response 
delay plotted against time relative to the treatment with vehicle (p.o.), H. crenata (HC) 
decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.) and 150 mg/kg (p.o.). 
All data points are n=8. 
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Figure 15 - Withdrawal response delay in the Hargreaves test, evaluation of time-
varying response of HC decoction extract fractions. Mean + S.E.M. of data of paw 
withdrawal response delay plotted against time relative to the treatment with vehicle 
(p.o.), H. crenata (HC) decoction extract fractions (hexane fraction 2.1 mg/kg (p.o.), 
DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and water fraction 23 
mg/kg (p.o.)). All data points are n=8.  
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3.5.1 Effect of H. crenata decoction extract and its dose-response relationship 
The results of the one way ANOVA of groups treated with H. crenata decoction 
showed that the dose of 15 mg/kg (p.o.) and the 10 times higher dose at 150 mg/kg 
(p.o.) significantly increased withdrawal response delay compared to vehicle. However, 
indomethacin (10 mg/kg (p.o.)) failed to reach significance level when compared to 
vehicle (Figure 16, Table 6 and Table 7). The next step of this study was to evaluate 
dose-response of H. crenata doses by testing lower and higher doses compared with 15 
mg/kg (p.o.), these doses were 1, 5 and 45 mg/kg (p.o.). The result for this experiment 
showed significant increase of withdrawal response delay for dose 45 mg/kg (p.o.) 
when compared to vehicle, but not for the lower doses 1 mg and 5 mg/kg (Figure 17, 
Table 8 and Table 9). In order to analyse the dose-dependency response for HC 
decoction doses, the data was plotted and analysed using linear regression calculation. 
The results of this analysis showed that dose-dependence response occurred from 0 mg 
to 15 mg/kg, but the response plateaued between 15 mg/kg and 45 mg/kg (Figure 18). 
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Figure 16 - Withdrawal response delay in the Hargreaves test, evaluation of 
indomethacin and HC doses response (15 mg/kg and 150 mg/kg). Mean + S.E.M. of 
sum of paw withdrawal response delay data collected at 1 h, 3 h and 6 h, minus average 
of 24 h before and 24 h after treatments, animals treated with vehicle (p.o.), 
indomethacin 10 mg/kg (p.o.), H. crenata (HC) decoction extract 15 mg/kg (p.o.) and 
150 mg/kg (p.o.). All data points are n=8. * One way analysis of variance multiple 
comparisons versus control group (vehicle). Holm-Sidak method: Overall significance 
level < 0.05. (Back-transformed averages of Log10-transformed data, plotted in 
logarithm scale). 
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Comparison Diff of Means t Unadjusted P Critical Level 
Vehicle vs. HC 15 mg/kg 0.267 3.080 0.005 0.017 
Vehicle vs. HC 150 mg/kg 0.262 3.023 0.005 0.025 
Vehicle vs. indomethacin 0.167 1.922 0.065 0.05 
Table 6 – Comparison between HC treated groups, indomethacin and vehicle. 
Multiple comparisons statistic one way analysis of variance for paw withdrawal 
response delay data, animals treated with indomethacin 10 mg/kg (p.o.), H. crenata 
(HC) decoction extract 15 mg/kg (p.o.) and 150 mg/kg (p.o.) versus control group 
vehicle (p.o.). All data points are n=8. Holm-Sidak method: Overall significance level < 
0.05. Log10 transformed data. 
 
Source of Variation  DF   SS   MS   F   P  Power 
Treatment 3 0.375 0.125 4.147 0.015 0.666 
Residual 28 0.843 0.0301    
Total 31 1.218     
Table 7 - Output of one way analysis of variance for paw withdrawal response 
delay data. Animals treated with H. crenata (HC) decoction extract 15 mg/kg (p.o.), 
150 mg/kg (p.o.) and indomethacin 10 mg/kg (p.o.) compared with vehicle (p.o.). 
Holm-Sidak method: Overall significance level < 0.05. All data points are n=8. (Log10 
transformed data). 
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Figure 17 - Withdrawal response delay in the Hargreaves test, evaluation of HC 
doses response (1 mg/kg, 5 mg/kg and 45 mg/kg). Mean + S.E.M. of sum of paw 
withdrawal response delay data collected at 1h, 3h and 6h, minus average of 24h before 
and 24h after treatments, animals treated with vehicle (p.o.), H. crenata (HC) decoction 
extract 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.). All data points are n=8. * 
One way analysis of variance multiple comparisons versus control group (vehicle). 
Holm-Sidak method: Overall significance level < 0.05. (Back-transformed averages of 
Log10-transformed data, plotted in logarithm scale). 
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Treatment comparison Diff of Means t Unadjusted P Critical Level 
Vehicle vs. HC 1 mg/kg 0.105 1.592 0.123 0.025 
Vehicle vs. HC 5 mg/kg 0.101 1.518 0.140 0.050 
Vehicle vs. HC 45 mg/kg 0.244 3.680 <0.001 0.017 
Table 8 - Multiple comparisons statistic of one way analysis of variance for paw 
withdrawal response delay data. Analyses of animals treated with H. crenata (HC) 
decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.) versus control 
group vehicle (p.o.). Holm- Sidak method: Overall significance level < 0.05. All data 
points are n=8. (Log10 transformed data). 
 
Source of Variation  DF   SS   MS   F   P  Power 
Treatment 3 0.241 0.0803 4.569 0.010 0.729 
 
Residual 28 0.492 0.0176    
Total 31 0.733     
Table 9 – Output of one way analysis of variance for paw withdrawal response 
delay duration data. Analyses of animals treated with H. crenata (HC) decoction 
extract HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.) and HC 45 mg/kg (p.o.) compared with 
vehicle (p.o.). Holm-Sidak method: Overall significance level < 0.05. All data points are 
n=8. (Log10 transformed data). 
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Figure 18 – Dose response of HC treatments during Hargreaves test. Data of paw 
withdrawal response delay for each animal during Hargreaves test, showing dose 
response for animals treated with vehicle (p.o.), H. crenata (HC) decoction extract 1 
mg/kg (p.o.), 5 mg/kg (p.o.) and 15 mg/kg (p.o.) and saturation from the doses 15 
mg/kg (p.o.), 45 mg/kg and 150 mg/kg (p.o.). All data points are n=8 except vehicle 
(n=16). The values show the correlation statistics R2 and significance values for the two 
phases of the dose-response relationship. 
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3.5.2 Effect of H. crenata decoction fractions and comparison between all treatments 
tested 
This study also evaluated the antinociceptive effect of the HC decoction fractions 
(hexane fraction, DCM fraction and water fraction). When comparing the effect of the 
fractions against the vehicle group (n=8), the one way ANOVA results showed that 
none of the fractions reached significance level (Figure 19 and Table 10), however this 
results was due to the statistical low power (0.442), because when the analysis was 
carried out with all HC doses and fractions compared to vehicle (n=16), the results 
showed there was a significant effect of hexane and water fractions and also it 
confirmed the significant effect previously observed for HC 15 mg/kg (p.o.), HC 45 
mg/kg (p.o.) and HC 150 mg/kg (p.o.) (Table 11 and Table 12). 
In order to analyse if there were differences between the effect of the fraction and the 
HC decoction doses tested, all the data from both experiments were plotted and from the 
HC doses linear regression the effect between the treatments were compared. The line 
showed that the hexane fraction was more efficient than indomethacin and that the 
Hyptis decoction extract had the same effect as indomethacin (Figure 20). Although the 
effects of each of the fractions and the whole extract HC 45 mg/kg (p.o.) are not 
significantly different from each other regarding increase of withdrawal response delay 
as shown in the multiple comparison using HC 45mg/kg (p.o.) as a control group (Table 
13 and Table 14), the hexane fraction appears to have stronger antinociceptive effect per 
mg compared with the decoction un-fractionated extract, while this was not the case for 
any of the other fractions or for indomethacin. 
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Figure 19 - Withdrawal response delay in the Hargreaves test, evaluation of HC 
decoction fractions. Mean + S.E.M. of sum of paw withdrawal response delay data 
collected at 1h, 3h and 6h, minus average of 24h before and 24h after treatments, 
animals treated with vehicle (p.o.), H. crenata (HC) decoction extract fractions (hexane 
fraction 2.1 mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg 
(p.o.) and water fraction 23 mg/kg (p.o.)). All data points are n=8. * One way analysis 
of variance multiple comparisons versus control group (vehicle). Holm-Sidak method: 
Overall significance level < 0.05. (Back-transformed averages of Log10-transformed 
data, plotted in logarithm scale). 
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Source of Variation  DF   SS   MS   F   P  Power 
Treatment 4 0.389 0.0971 2.629 0.051 0.442 
 
Residual 35 1.293 0.0369    
Totalv 39 1.682     
Table 10 - Output of one way analysis of variance for paw withdrawal response 
delay data. Analyses of animal groups treated with H. crenata (HC) decoction extract 
fractions (hexane fraction 2.1 mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol 
fraction 14.8 mg/kg (p.o.) and water fraction 23 mg/kg (p.o.)) versus control group 
vehicle (p.o.). Holm-Sidak method: Overall significance level < 0.05. All data points are 
n=8. Log10 transformed data. 
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Figure 20 - Withdrawal response delay in the Hargreaves test, dose response of HC 
doses and decoction extract fractions. Mean + S.E.M. of sum of paw withdrawal 
response delay data collected at 1h, 3h and 6h after treatment, minus average of 24h 
before and 24h after treatments, animal groups treated with vehicle (p.o.), H. crenata 
(HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 mg/kg (p.o.) 
and 150 mg/kg (p.o.), its fractions (hexane fraction 2.1 mg/kg (p.o.), DCM fraction 4 
mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.), water fraction 23 mg/kg (p.o.)) and 
indomethacin 10 mg/kg (p.o.) compared with vehicle (p.o.). This graph uses the dose 
response curve previously presented in Figure 18 and indomethacin was plotted as an 
additional data point in the same coordinates for comparison with H. crenata full extract. 
* One way analysis of variance multiple comparisons versus control group (vehicle). 
Holm-Sidak method: Overall significance level < 0.05. All data points are n=8 except 
indomethacin (n=5) and vehicle (n=16) (Back-transformed averages of Log10-
transformed data, plotted in logarithm scale). 
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Treatment comparison Diff of Means t Unadjusted P Critical Level 
Vehicle vs. HC 1 mg/kg 0.125 1.653 0.102 0.017 
Vehicle vs. HC 5 mg/kg 0.12 1.588 0.116 0.025 
Vehicle vs. HC 15 mg/kg 0.248 3.270 0.002 0.006 
Vehicle vs. HC 45 mg/kg 0.264 3.481 <0.001 0.006 
Vehicle vs. HC 150 mg/kg 0.243 3.205 0.002 0.007 
Vehicle vs. indomethacin 0.147 1.943 0.055 0.013 
Vehicle vs. hexane fraction 0.282 3.724 <0.001 0.005 
Vehicle vs. DCM fraction 0.0769 1.016 0.313 0.05 
Vehicle vs. methanol fraction 0.181 2.390 0.019 0.01 
Vehicle vs. water fraction 0.242 3.190 0.002 0.009 
Table 11 - Multiple comparisons statistic of one way analysis of variance for paw 
withdrawal response delay data. Analyses of animals treated with vehicle (p.o.), H. 
crenata (HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 
mg/kg (p.o.) and 150 mg/kg (p.o.), its fractions (hexane fraction 2.1 mg/kg (p.o.), DCM 
fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.), water fraction 23 mg/kg 
(p.o.)) and indomethacin 10 mg/kg (p.o.) compared with vehicle (p.o.). All data points 
are n=8 except indomethacin (n=5) and vehicle (n=16). Log10 transformed data. 
 
Source of Variation  DF   SS   MS   F   P  Power 
Treatment 10 0.866 0.0866 2.832 0.004 0.810 
Residual 85 2.599 0.0306    
Total 95 3.465     
Table 12 - Output of one way analysis of variance for paw withdrawal response 
delay data. Analyses of animals treated with H. crenata (HC) decoction extract 1 
mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 mg/kg (p.o.) and 150 mg/kg (p.o.), its 
fractions (hexane fraction 2.1 mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol 
fraction 14.8 mg/kg (p.o.), water fraction 23 mg/kg (p.o.)) and indomethacin 10 mg/kg 
(p.o.) compared with vehicle (p.o.). All data points are n=8 except indomethacin (n=5) 
and vehicle (n=16). Log10 transformed data. 
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Treatment comparison Diff of 
Means 
t Unadjusted 
P 
Critical 
Level 
HC 45 mg/kg vs. hexane fraction 0.0094
5 
0.128 0.898 0.05 
HC 45 mg/kg vs. DCM fraction 0.196 2.655 0.009 0.013 
HC 45 mg/kg vs. methanol fraction 0.0915 1.242 0.217 0.017 
HC 45 mg/kg vs. water fraction 0.0310 0.421 0.675 0.025 
Table 13 - Multiple comparisons statistic one way analysis of variance for paw 
withdrawal response delay data. Analyses of animals treated with H. crenata (HC) 
decoction extract 45 mg/kg (p.o.) and its fractions (hexane fraction 2.1 mg/kg (p.o.), 
DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and water fraction 23 
mg/kg (p.o.)) versus control decoction extract 45 mg/kg (p.o.). Holm-Sidak method: 
Overall significance level < 0.05. All data points are n=8. Log10 transformed data. 
 
Source of Variation  DF   SS   MS   F   P  Power 
Treatment 4 0.679 0.170 2.726 0.033 0.050: 0.507 
 
Residual 113 7.040 0.0623    
Total 119 7.720     
Table 14 - Output of one way analysis of variance for comparison of paw 
withdrawal response delay. Analyses of animals treated with H. crenata (HC) 
decoction extract 45 mg/kg and its fractions (hexane fraction 2.1 mg/kg (p.o.), DCM 
fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and water fraction 23 
mg/kg (p.o.)). All data points are n=8. (Log10 transformed data) 
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After the Hargreaves test an unexpected fatality occurred in animals treated with 
indomethacin: 2 mice from the indomethacin group died and 1 was euthanized because 
it appeared to be unwell. Post-mortem examination of the two mice that were found 
dead showed that one died from gastric obstruction and another due to liver damage. 
The mouse that was unwell and was euthanized showed no internal abnormality. The 
mouse with gastric obstruction died 4 days after being treated, the one that had liver 
damage died 2 days after treatment and the sickness behaviour of the euthanized mouse 
was also observed 2 days after indomethacin treatment. No unusual behaviour or 
adverse events occurred during the Hargreaves test on these animals. 
These fatalities only occurred for the animals treated with indomethacin. Under advice 
of Dr. Robert S Shiel, lecturer of data analyses at AFRD Newcastle University, a 
Poisson analyses was carried out to predict whether the incidence rate for death events 
is more than expected by chance. However, due to the small number of occurrences it 
was not possible to obtain accurate results that would suggest any association of 
indomethacin as the cause of these deaths Table 15. 
Table 15 - Poisson analyses for incidence of mouse death.  
Test and Confidence Interval (CI) for Two-Sample Poisson Rates: death, treatment 
Total Rate of death Occurrences  N  Occurrence Vehicle 0/8 0.000 Indomethacin 3 /8 
0.375 
Difference = Rate (vehicle) – rate (indomethacin) Estimate for difference: 0.375 95% 
CI for difference: (-0.799345, 0.0493447) Test for difference >= 0 (vs not = 0): Z = -
1.73 P-Value = 0.083,Exact Test: P-Value = 0.250* NOTE * The normal 
approximation may be inaccurate for small total number of occurrences. Analyses 
carried out with Minitab 16 
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3.6 Discussion 
The aim of this experiment was to verify the ability of H. crenata decoction and its 
fractions to inhibit nociception caused by thermal stimuli. These study results supported 
thermal antinociception induced by H. crenata compound(s) present in the decoction 
extract and its fractions; hexane and water fractions, although hexane and water 
fractions only presented significant effect when analysed with a larger number of 
treatment groups. 
This was the first study to report the antinociceptive effect of H. crenata. However, this 
species is not the only one in the genus to be reported with this property. There are 
reports on three other species (H. fruticosa, H. pectinata and H. suaveolens). Like H. 
crenata these species are described in literature as having traditional use indication 
against pain and inflammation. These species have also been tested for their 
antinociceptive properties through pre-clinical trials, the animal models most used in 
these evaluations were the hot plate test and acetic acid test (Bispo et al., 2001; Lisboa 
et al., 2006; Marcal et al., 2006; Menezes et al., 2007; Santos et al., 2007b; Arrigoni-
Blank et al., 2008; Franco et al., 2011; Raymundo et al., 2011). 
Among these antinociceptive studies on Hyptis species, H. pectinata was reported in 
five articles, being the most studied in relation to antinociceptive properties. The first 
study with H. pectinata was carried out by Bispo et al. (2001) which evaluated an 
aqueous extract at doses of 100, 200 and 400 mg/kg (p.o.). According to their results the 
200 mg dose presented a percentage inhibition of 47.0% and, surprisingly, the 400 mg 
dose had a lower inhibition, 37.6% compared to vehicle. The lack of dose-dependence 
observed in this study could indicate that the dose used was very high causing saturation 
in the effect. A similar lack of dose-dependence is shown in two studies of H. pectinata 
when the doses of 200 mg/kg and 400 mg/kg were evaluated (Lisboa et al., 2006; 
Arrigoni-Blank et al., 2008). Similar saturation in the effect was seen in the present 
study with H. crenata, but in a lower dose range between 15 mg/kg and 45 mg/kg and 
with a dose-dependent effect observed at lower doses. 
As described in the treatment preparation, the dose of 15 mg/kg that was effective was 
based on the results from the traditional use survey, following information about the 
concentration of extract that people take for effective treatment. However, this 
calculation is without using dose translation from humans to animals. Dose translation 
© Newcastle University 2013 89 
based on body surface area has been suggested by some research in order to establish a 
dose to be used in a clinical trial when a drug has been tested in animals (Winneke and 
Lilienthal, 1992; Reagan-Shaw et al., 2008; de la Torre et al., 2009; Green et al., 2009b; 
Casteleyn et al., 2010). However, in the H. crenata study it would be the opposite, 
because it is the translation from humans to the animal. If using this suggested animal 
scale conversion the traditional use dose 15 mg/kg would be translated to 187 mg/kg for 
testing in the animals. The fact that a significant effect was obtained in a much lower 
dose without using this proposed dose translation means that the result obtained with 
this experiment would be better than expected by the dose translation proponents. 
Although this result also indicates that, if it were used, the 187 mg/kg dose would 
probably have shown the same effect demonstrated by the 150 mg/kg since it appears 
that the antinociception effect reached a maximum response at this concentration. 
There was no interaction between time and the effect measured after treatment. The 
main reason for this is due to the fact that all treated groups decreased the delay in 
withdrawal reflex response at 3 h and unexplainably increased the response delay again 
6 h after treatment. This drop in response delay was observed not only in one 
experiment but when it was repeated. Also it was not only observed for treatments of 
Hyptis decoction extract or its fractions, but a similar reaction pattern was observed for 
the positive and negative control, indomethacin and vehicle. Therefore, it is possible 
that this change in reaction threshold was a function of the measurement condition at 3 
h, perhaps due to the relatively short time (2 h) between the two test times. Thus, the 
literature was examined to determine if this same event was reported by other 
researchers. The Hargreaves results reported had a different pattern of time points, 
which might not be accurate to make a direct comparison. However, the fact that one of 
these reported results presented measurements with a 2 h interval and did not show a 
decrease and subsequent increase in response time (Freynhagen et al., 2006), has placed 
doubt in the supposition that the event observed in the H. crenata experiments might be 
caused by the test and particular time points. Therefore, a reasonable explanation for 
this event was not obtained. 
In general, conclusive details of the pharmacokinetics and pharmacodynamics of Hyptis 
compounds are still unknown. This is an issue which does not just apply for these 
species but for medicinal plants in general, because most medicinal plant studies are 
carried out with complex mixtures of compounds. In the case of H. crenata this 
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complexity can be seen in the chemistry analysis section (Chapter 7), where 88 
compounds were detected for the H. crenata decoction extract. For this reason it is very 
complicated to decipher and control the metabolism and the action of these compounds 
in the body. In fact, these diverse compounds in Hyptis could perform different 
functional responses on their targets, for example some of them could be receptor 
agonists or antagonists. Thus, they could intensify or moderate the antinociceptive 
effect according to each compound concentration (Rowland and Tozer, 2011). It is 
possible that increasing the dose of plant extract would increase the exposure of a 
compound that would inhibit the effect of other active antinociceptive compounds. This 
could be the case when evaluating H. crenata in a higher dose and also this could 
explain the results observed by Bispo et al. (2001) that reported a greater effect of H. 
pectinata treatment at a dose of 200 mg/kg than at 400 mg/kg. Nevertheless, from the 
present study it is proposed that the maximum response Emax for H. crenata decoction 
extract is obtained between 15 mg/kg and 45 mg/kg, since at 45 mg/kg concentration it 
appears to reach a steady state regarding its metabolism and possibly its elimination 
(Mazoit et al., 1993). 
There are some suggestions from other reports about a possible antinociceptive 
mechanism induced by Hyptis when evaluated by a thermal test. Although these are not 
detailed descriptions, it has been reported that opioid receptors are involved in the 
effects of H. pectinata essential oils (Arrigoni-Blank et al., 2008). This assumption is 
confirmed and described in more detail by Raymundo et al. (2011) who evaluated H. 
pectinata essential oils treatments using the hot plate test, and suggested that this plant 
not only has opioid activities but also affects the cholinergic system. This conclusion 
was revealed by using naloxone and atropine as antagonists before treating with H. 
pectinata extract, observing that the effect of the plant essential oil was attenuated by 
these antagonists. Interestingly their results showed antinociceptive activities of Hyptis 
essential oil at lower doses (10 mg/kg), as observed for the H. crenata extract shown 
here, although the present study tested an aqueous extract instead of essential oil. 
Aqueous extracts of Hyptis species have also been described by other authors but in 
much higher doses (200 and 400 mg/kg) and have been described as inducing 
antinociception through an opioid mechanism, after testing with naloxone as opioid 
antagonist (Bispo et al., 2001; Santos et al., 2007b). 
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It is uncertain if the effect of H. crenata aqueous extract and its fractions could be 
involved in the same antinociceptive pathway as described by these earlier Hyptis 
studies. However, it is possible to suggest that the phenolic terpenes found in these 
other Hyptis species, and also mainly observed in the most active H. crenata treatment, 
which was hexane fraction (as shown in the chemistry section, Chapter 7), could be 
playing an important role in the thermal antinociception effect. However, there is a limit 
to how comparable it is to analyse results from different plant species, because even if 
the plant belongs to the same species, the compounds can be variable due to several 
factors occurring in the environment. When comparing results between different species, 
it is even more likely that differences will arise from genetic factors. Furthermore, the 
method of extraction used to prepare the plant treatment will have an enormous 
influence on the effect obtained due to the selectivity of the type and concentration of 
compounds. These contrasting effects can be seen in the study by Menezes et al. (2007) 
which evaluated Hyptis essential oil of the species H. fruticosa using the hot plate test. 
In contrast with H. pectinata, this species was unable to inhibit nociception. Conversely, 
an earlier study Marcal et al. (2006) had shown that H. fruticosa can induce thermal 
antinociception, but when extracted using the solvent ethyl acetate. The explanation for 
these results could be that ethyl acetate, with a polarity index of 4.4, might be capturing 
different compounds not present in the essential oil, therefore it would be able to 
possess antinociceptive effects which were not observed by Menezes et al. (2007). 
When reviewing these Hyptis studies it is notable that none of the groups that have 
studied Hyptis used indomethacin as a control for the thermal test; all of them used 
morphine as positive control. However, there is uncertainty whether either of these 
drugs is ideal to be used as the positive control for the thermal test, because a thermal 
noxious stimulus mainly recruits Aδ fibre (McCormack et al., 1998). There are several 
studies examining whether these drugs would be efficient to reduce pain under an acute 
thermal experiment condition and the main conclusion is that when these drugs have 
been shown to be effective it is due to the occurrence of pain conducted by the C fibres 
that are possibly sensitised by inflammatory agents (Le Bars et al., 2001). For this 
reason, it is possible that the antinociceptive activity reported for these Hyptis studies 
might also involve anti-inflammatory effects. However, in the present study, if 
considering the amount of HC dry material injested by the animals, HC hexane fraction 
was more efficient than indomethacin in inhibiting pain, this effect became prominent 
when comparing the hexane fraction and other treatments in the linear regression graph. 
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Overall, the hexane fraction was the most potent inhibitor of pain, because it was 
administered at a lower dose (2.1 mg/kg (p.o.)). Furthermore, the fact that the  ANOVA 
showed that indomethacin had an effect, but was not significantly different from the 
vehicle, could indicate that this experiment was mainly evaluating nociceptive effects 
transmitted through Aδ fibres. Therefore, treatments like the hexane fraction and the 
effective HC doses might be more likely to be Aδ fibre inhibitors (Yeomans et al., 
1996). 
Another puzzling fact involving indomethacin is that in this experiment three animals 
died and they were all from the indomethacin group. There is no obvious explanation 
for this event, mainly because the statistical analysis was not able to reveal that the fact 
that these animals died from only one treatment group would be greater than expected 
by chance, which would suggest that indomethacin could be associated with these 
deaths. However, these deaths occurred more than 48 h after the indomethacin intake. 
Considering that Indocid has a relatively short half-life of 4.5 h (Drug Bank, 2012), 
theoretically when these mice died they should not be exposed to the administered drug, 
but it is possible that they suffered side effects caused by an indomethacin metabolite 
(Rowland et al., 1972). One of these effects could be the gastric blockage observed in 
the mouse that died four days after treatment. Moreover, another aspect that would 
increase the correlation of indomethacin treatment with this death is the fact that gastric 
side effects have been substantially reported for this non-steroidal anti-inflammatory 
drug (Tomisato and Mizushima, 2003). 
Many questions still remain regarding how the antinociceptive effects of the decoction 
extract or its fractions occur. The Hargreaves results show that some of these ingested 
compounds are clearly affecting the pain pathway, since the mice treated were able to 
withstand heating from the infrared light for longer, but it is not possible to predict how 
and where in the pain pathway the H. crenata compounds are acting. These compounds 
could have their action from the beginning of the thermal pain pathway, impeding 
depolarisation of nociceptive neurons, or could be affecting the ascending pathway via 
spinal cord projections to the brain or even blocking the discriminatory pain feeling 
processed in the cortex or simply intercepting the pain through the descending control 
(Paxinos, 2004). There are numerous possibilities for the mechanism of action and these 
increase further when you bear in mind the test treatment contains 16 to 88 compounds 
in the sample (Chapter 7). An additional factor in relation to these large numbers of 
© Newcastle University 2013 93 
compounds is that they have different concentrations in the sample, making the 
interpretation of mechanisms even more challenging, because each of these compounds 
could be performing completely different things, since some of them have a very 
distinct structure. Also, multiple compounds could be acting on similar functions, 
thereby having a synergistic effect. Thus, if this synergy was happening, the effect 
would be that these compounds together would result in a greater antinociceptive action 
than when fractionated (Wagner, 2011). However, when comparing the decoction 
extract with the effective fractions it seems that the hexane fraction possessed a greater 
inhibition of pain than the crude extract. Also it is interesting that the DCM and 
methanol fractions were not effective. This indicates that the compounds present in 
these fractions might not be important in the antinociceptive process. Therefore, it is 
possible to rule out a synergy effect for all decoction compounds together, and propose 
that there are selective compounds that might be the key protagonist in this 
antinociceptive event. On the other hand, is not possible to discard that the effect 
observed from the hexane fraction is achieved through all compounds acting together. 
In order to verify this possibility it would be necessary to assess the effect using further 
fractionation and isolation of compounds. Although this would be interesting to 
evaluate, exploring this possibility was not a priority for the present study. 
The measurement of antinociception obtained through the Hargreaves test is only based 
on the withdrawal reaction of the mouse’s paws. For this reason, it is possible that this 
type of animal model can present false positive results when the animals are subject to 
muscle relaxant effects and, despite feeling the pain, they might be slower to move their 
paw from the noxious stimulus (Le Bars et al., 2001). Such effects are observed through 
anti-cholinergic drugs, such as the curare derivate compounds (Sterz et al., 1986). 
Because Hyptis has been reported to have some effects as a cholinergic agonist, this 
would make the muscle relaxant effect less likely (Raymundo et al., 2011). Methods for 
verifying muscle relaxant effect can be through the rota rod method or through 
locomotor and hanging behaviour analyses (Budden et al., 1979; Zhang et al., 2011; 
Klein et al., 2012). In the present study, in order to investigate this muscle relaxant 
influence, behavioural analyses of mice was carried out before and after administration 
of treatments. This investigation took place as part of the acetic acid test that will be 
presented in the next chapter. 
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3.7 Conclusions 
The study presented in this chapter provides evidence of thermal antinociception 
induced by Hyptis crenata compounds from the decoction extract when administered at 
doses of 15, 45 and 150 mg/kg (p.o.) and for its 45 mg/kg fractions using hexane and 
water as solvent. No antinociceptive effect was detected for the decoction fractions 
extracted with DCM and methanol. There was no interaction between time and the 
effect measured after treatment. However, the antinociceptive effect terminates within 
24 h of treatment. Overall, the hexane fraction possessed the most potent 
antinociceptive effect, especially when considering that it has the lowest concentration 
when compared to other H. crenata treatments. 
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4.1 Overall procedures 
4.1.1 Flowchart 
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4.2 Introduction 
Considering that the result of the traditional use survey (Chapter 2) showed that many 
individuals reported using H. crenata for the treatment of stomach pain, it was proposed 
that this treatment might have an effect on visceral pain. In order to test this possibility, 
an animal model for visceral pain was chosen, which was the acetic acid inducing 
writhing test (Collier et al., 1968). 
In the viscera the nociceptor endings have been described to innervate the organ walls, 
the parenchyma, the vessels and the serosal membranes outside the organs. The 
nociceptor cell bodies are localized in the dorsal root ganglia and nodose ganglia 
(Gebhart, 2000). Models of visceral pain have been extensively used to evaluate 
analgesic drugs (Bradesi et al., 2008), these models can involve activation of 
mechanoreceptors or chemoreceptors that innervate the viscera. Chemical noxious 
stimuli are specially transmitted by vagal afferents whose cell bodies are localized in the 
nodose ganglia (Kollarik et al., 2010). An example of mechanoreceptor activation is 
using physical interventions such as rectal distension with an inflatable balloon to 
provide an acute stimulus, and chemoreceptor activation can be achieved through acetic 
acid injection in the animal’s peritoneum. The disadvantage of physical intervention 
with an inflatable balloon is that it requires surgery and does not always permit 
measurement of free behaviour (Stam et al., 2004). The chemical stimulant model using 
acetic acid is a more common evaluation method, due to the fact that it only requires the 
intraperitoneal injection of acetic acid (Martinez et al., 1999). For this reason, and for 
the fact that this is one of the most widely used tests to mimic visceral pain suffered by 
humans (Le Bars et al., 2001), it was chosen for evaluation of the visceral 
antinociceptive properties of H. crenata extracts. 
The acetic acid model was developed by Koster (1959) for the screening of analgesic 
drugs and can be used to assess peripherally and centrally acting agents (Tjolsen et al., 
1992; Le Bars et al., 2001). Once this chemical noxious agent is injected, it causes 
tissue irritation when in contact with the peritoneal regions, and this induces the release 
of pain mediators, such as prostaglandin. Prostaglandin levels have been reported to 
increase greatly in the peritoneal fluid, particularly after the acetic acid injection, and it 
has been reported that the levels of prostaglandin 2 (PGE2) were higher than 
prostaglandin 1 (PGE1) (Collier et al., 1968). The chemosensitivity to acetic acid also 
involves the proton-sensitive transient receptor potential vanilloid 1 (Sándor et al., 
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2010). This receptor is considered as a molecular integrator for various noxious stimuli 
(Bölcskei et al., 2005). This pain mediator depresses C fibre transmitting the visceral 
pain signals (Calvino et al., 1984; Cervero and Laird, 2004). It has also been reported 
that acetic acid-induced pain signals are dependent on spinal activation of ERK, JNK, 
p38 and PI3K, and microglia (Pavao-de-Souza et al., 2012). Consequently, this cascade 
of activation events induces a characteristic abdominal stretching behaviour, or writhing, 
that was described to be “a pseudo affective reflex response that involves stretches of 
the torso accompanied by hyperextension of the hindlimbs and concave arching of the 
back” (Laird et al., 2001). It is this behaviour that is used as an index of pain in the test. 
The acetic acid test has been widely used to evaluate the analgesic effects of standard 
drugs and it has also been extensively used when evaluating medicinal plants, including 
some species of the genus Hyptis which has seven studies reported using this method 
(Bispo et al., 2001; Lisboa et al., 2006; Menezes et al., 2007; Santos et al., 2007b; 
Arrigoni-Blank et al., 2008; Franco et al., 2011; Raymundo et al., 2011). In addition, 
the acetic acid test has been used in studies evaluating analgesic drugs, including 
common drugs such as paracetamol, gabapentin, diclofenac and nabumetone (Bjorkman, 
1995; Seguin et al., 1995; Wetzel and Connelly, 1997; Barden et al., 2004; Hedner et al., 
2004). 
4.3 Aim of this experiment 
The aim of this experiment was to evaluate the antinociceptive effects of different doses 
of H. crenata decoction extract and its fractions by assessing their effects through a 
visceral model of pain. Before administering the acetic acid test this study also analysed 
changes of exploratory and motor behaviour of mice after treating with H. crenata and 
its fractions (baseline data). 
4.4 Material and methods 
The acetic acid test and behaviour analyses (baseline data) were carried out one week 
after the Hargreaves test using the same mice and also administered the same treatment. 
The preparation of the decoction extract and its fractions were the same as described in 
Chapter 2 and Chapter 3. 
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4.4.1 Treatments and order of experimentation 
As in the Hargreaves test described in Chapter 3, the first part of the experiment was to 
evaluate the dose of H. crenata (HC) 15 mg/kg (p.o.), that was indicated in the 
traditional use survey, and a 10 times higher dose 150 mg/kg (p.o.), together with 
vehicle and a positive control, indomethacin (10 mg/kg (p.o.)). The next step of this 
study was to determine the dose-dependency and the baseline behaviour response of H. 
crenata using vehicle (p.o.), 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.). In 
addition, the four fractions of the decoction extract were examined; hexane fraction (2.1 
mg/kg (p.o.), n=8), DCM fraction (4 mg/kg (p.o.), n=8), methanol fraction (14.8 mg/kg 
(p.o.) n=8) and water fraction (23 mg/kg (p.o.), n=8). 
As described in Chapter 3, in order to reconstitute the decoction fractions water for 
injection was added containing 2% Polysorbate 80, because the fractions required this 
nonionic surfactant and emulsifier in order to be successfully dissolved. For this reason 
one of the vehicle groups was treated with water for injection containing 2% 
Polysorbate 80, as well as the group HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.) and HC 45 
mg/kg (p.o.) that were evaluated in the same batch. In order to check if the polysorbate 
gave a different effect to the group without polysorbate, a comparison between the two 
vehicle groups was carried out of the behaviour during the acetic acid test (with and 
without polysorbate). The results of this analyses showed that there was no difference in 
the number of writhing occurrences between the two vehicle groups (difference of 
means (logarithm): 0.197, t: 1.213, unadjusted P: 0.229 and critical level: 0.002). 
All the treatments were given orally by gavage using a mouse-compatible tube. 
The animals used in this experiment were the same animals used in the Hargreaves test 
and under the same project license. 
In total, this experiment carried out evaluation on 93 mice, and with the exception of the 
indomethacin (n = 5) and vehicle (n = 16) groups, all other treatments contained 8 
animals. The acetic acid test was performed with only 5 mice as positive control, 
because 3 mice in the indomethacin group died after the Hargreaves test, as was 
described in Chapter 3. 
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4.4.2 Recording and analysing behaviour 
One week after the Hargreaves test the same mouse used was tested again for evaluation 
of exploratory and motor behaviours before and after treatments, and after the acetic 
acid injection. All these mice received the same treatment that was given in the 
Hargreaves test. 
The analysis of exploratory and locomotor behaviour was undertaken to investigate 
whether H. crenata was affecting behaviours that might indicate sedation and/or a 
muscle relaxation effect. These behaviours were analysed before and after treatments of 
H. crenata doses 0, 1, 5 and 45 mg/kg and decoction fractions (hexane fraction, DCM 
fraction, methanol fraction and water fraction). The animals were filmed for a 30 min 
period before the treatment and, after a 30 min wait after the treatment, filmed for 
another 30 min period. One hour after the treatment was given, the animals received an 
injection of acetic acid and were filmed for a 45 min period. 
The animals were set up in individual clear cages (29.5cm length x 18.8cm width x 
13cm height), randomised according to treatments. Each cage had a video camera for 
recording the mouse behaviour located horizontally in order that all parts of the cage 
could be seen. The animal cage is shown in Figure 21. The cameras used were Sony 
Handycam DCR-HC 52, the data were recorded directly onto tape and later converted to 
an electronic video file to be watched in the Windows Media Player. A randomised 
code, displayed briefly when the filming of the mouse started, was assigned to identify 
each mouse to ensure that the measurement was blind to the treatment. 
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Figure 21 - Cage used for animal behaviour analysis 
 
4.4.2.1 Behaviour data collection periods 
For analyses of exploratory and motor behaviour before and after treatments, 10 
minutes of footage was analysed immediately before the treatment (from -10 min until 0 
min in the timeline recording Figure 22), after treatment during 10 minutes (from 50 
until 60 min) and after injection of acetic acid during 20 minutes (from 66 min until 86 
min) for 64 mice treated with HC 0 mg/kg, 1 mg/kg, 5 mg/kg,45 mg/kg and the 
fractions (n = 8). 
After the first experiment it was decided to perform analyses of behaviour before and 
after treatments, before the acetic acid injection. This analysis was not performed for the 
groups HC 15 mg/kg, HC 150 mg/kg and indomethacin 10 mg/kg, which were 
evaluated in the first experiment. 
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Figure 22 - Timeline of filming and behaviour analysis periods 
Each video file was observed and the occurrence of specific behaviour was recorded by 
using a letter as a code and pressing the letter key on a computer keyboard every time 
the behaviour occurred. For some behaviour, such as hanging, the duration in seconds 
was recorded using the recording time showed by Windows Media Player. These codes 
were typed in an Excel sheet and transferred to SPSS 17 program to be quantified. 
For the two periods before and after treatment with HC extracts 10 different behaviours 
were recorded. These were: 
Drinking (number of events): was counted when the animal licked the tip of the water 
bottle. 
Eating (number of events): was counted when the animal ate the food available at the 
top of the cage, 
Sniffing (number of events): was counted when the animal sniffed the cage bedding. 
Digging (number of events): was counted every time the animal was observed digging 
holes in the cage bedding. 
Grooming (number of events): was counted when the animal licked or scratched itself 
(grooming body) or scratched its nose (grooming nose). 
Climbing (number of events): was counted when the animal’s front paws contacted 
the cage wall above floor level. 
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Hanging (duration in seconds): its duration was measured every time the animal 
climbed to the top of cage and stayed hanging holding the wires with its four paws. 
Rearing-up (number of events): was counted when the animal rose on its hind legs. 
Walking (number of events): was counted when the animal moved from one location 
to another in the cage. 
Total time stationary (duration in seconds): was counted in seconds, measuring how 
long the animal stayed stationary; if the animal moved its head or groomed itself it was 
still considered in a stationary situation. 
During the acetic acid test the same behaviours were recorded, but with the addition of 
writhing and twitching. 
Writhing (number of events): was counted when the animal showed a movement of 
constriction and elongation passing along the abdominal wall, sometimes accompanied 
by twisting of the body and followed by extension of the hind limbs. 
Twitching (number of events): was counted when the mouse had muscle contractions 
displayed as a tremor. 
The total time stationary during the acetic acid test was abreviated as TSAC, to 
differentiate it from the total time stationary observed before the acetic acid injection. 
However as before the acetic acid injection, the total time stationary during the acetic 
acid test, was also counted in seconds, measuring how long the animal stayed 
stationary; if the animal moved its head or groomed itself it was still considered in a 
stationary situation. 
4.4.3 Categorisation of behaviour, analyses of data and statistical procedures 
Previous studies have characterised different behaviours in respect of the action of drugs 
and this categorisation has been used in the interpretation of the effects of the H. 
crenata extracts. 
The sum of sniffing, grooming and rearing were categorised as (parameter BIS), since 
the reduction of these behaviours indicate sedation (Rodgers et al., 2000; Aragão et al., 
2006; Gomes et al., 2008; Lopes Campêlo et al., 2011). The sum of digging, climbing 
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and walking were categorised as indicators of locomotor activities and neuroleptic 
effect (parameter BLY) (Faulkes, 2006; Semler et al., 2011). Total time stationary and 
hanging were analysed as indicators of motor impairment and muscle relaxant effect. 
The hanging observed in this study is related to the behaviour observed during the 
hanging wire test which is used to evaluate muscle relaxant effect (Zhang et al., 2011; 
Klein et al., 2012), the main difference is that the animals were not forced to hang in the 
cage wire, they did it freely. 
For the acetic acid test evaluation, the behaviours that would indicate exploratory and 
locomotor activities (parameter ELA) were defined. These behaviours were the sum of 
sniffing, rearing, climbing, eating, drinking and walking (Baumans et al., 1994; 
Hawkins, 2002). The behaviours of writhing, total time stationary (TSAC) and 
twitching were counted separately. 
The behaviours BIS, BLY, hanging and total time stationary observed before treatment 
with H. crenata decoction and its fractions were subtracted from those observed after 
the treatment. Before this difference was calculated a normality test was performed and 
some of them were transformed using Log10 for normality fitting. The mean ± S.E.M. 
of the difference were obtained using SigmaPlot 11.0 and the tests performed were one 
way ANOVA with multiple comparisons of treatment versus control. A value of P<0.05 
was considered significant. 
The behaviours observed during the acetic acid test were also analysed with one way 
ANOVA and the post-hoc test (Holm-Sidak method). 
4.4.4 The Acetic Acid Test procedure 
In this study the acetic acid test was based on the original protocol by Collier et al. 
(1968) with modifications made by the Newcastle pain research group (Flecknell and 
Roughan, 2004). Sixty min after receiving the treatments, each mouse received an 
intraperitoneal injection of acetic acid (0.6%, 20 ml/kg b.w.). After the injection the 
mouse was placed in the cage and filming was started for behavioural analysis, as 
described in Section 4.4.2. 
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4.5 Results 
4.5.1 Effect of H. crenata decoction extract and its dose-response relationship 
The first step of this study was to evaluate the antinociceptive activities of HC 
decoction extract at the dose of 15 mg/kg (p.o.) and a 10 times higher dose of 150 
mg/kg (p.o.) against vehicle and indomethacin as positive control. The analysis of 
writhing during the acetic acid test showed that the HC extracts and indomethacin 
significantly decreased writhing compared to vehicle (p<0.05) (Figure 23, Table 16 and 
Table 17). The multiple comparison analyses showed that HC 15 mg/kg (p.o.) and HC 
150 mg/kg (p.o.) treatments were as effective as indomethacin in reducing writhing 
behaviour (Table 18). The fact that indomethacin had shown an effect gave confidence 
that the experiment procedure was succeeding. 
The next step of this study was to evaluate the dose-dependent response of lower and 
higher doses of HC compared with 15 mg/kg (p.o.), these doses were 1, 5 and 45 mg/kg 
(p.o.). The result of this evaluation showed that HC 5 and 45 mg/kg (p.o.) significantly 
reduced writhing when compared with vehicle (Figure 24, Table 19 and Table 20), but 
no effect on writhing was observed for HC 1 mg/kg (p.o.). The dose response 
relationship for H. crenata decoction extract on reduction of writhing was determined 
and the correlation analysis showed that there was dose response from 0 mg/kg, 1 
mg/kg, 5 mg/kg and 15 mg/kg (p<0.0001, t= 0.469, df= 22), but that the response 
plateaued at higher doses of 15 mg/kg, 45 mg/kg and 150 mg/kg (p<0.3, t= 5,087, df= 
38) (Figure 25). 
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Figure 23 - Number of writhing occurrences in the acetic acid test, evaluation of 
HC doses and indomethacin. Mean + S.E.M. data for number of writhing occurrences 
during 20 min in the acetic acid test, for animals treated with vehicle (p.o.), 
indomethacin 10 mg/kg (p.o.), H. crenata (HC) decoction extract 15 mg/kg (p.o.) and 
150 mg/kg (p.o.). *Multiple comparisons versus control group (Holm-Sidak method): 
Overall significance level < 0.05. All data points are n=8 except indomethacin (n=5). 
(Back-transformed averages of Log10-transformed data, plotted in logarithm scale) 
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Treatment comparison Diff of 
Means 
t Unadjusted 
P 
Critical 
Level 
Vehicle vs. HC 150 mg/kg 0.536 3.802 <0.001 0.017 
Vehicle vs. HC 15 mg/kg 0.52 3.686 0.001 0.025 
Vehicle vs. Indomethacin 0.359 2.231 0.035 0.05 
Table 16 - Multiple comparisons statistic of one way ANOVA for writhing 
occurrences. Analyses of writhing observed during 20 min in the acetic acid test for 
animals treated with H. crenata (HC) decoction extract 15 mg/kg (p.o.), 150 mg/kg 
(p.o.) and indomethacin 10 mg/kg (p.o.) versus control group, vehicle (p.o.). One way 
ANOVA (Holm-Sidak method), overall significance level <0.05. All data points are 
n=8 except indomethacin (n=5). Log10 transformed data. 
 
Behaviour Source of 
Variation 
DF SS MS F P Power 
 
Writhing 
Between Groups 3 1.488 0.496 6.235 0.003 0.89 
Residual 25 1.989 0.0795    
Total 28 3.477     
Table 17 - Output of one way ANOVA for writhing occurrences. Analyses of 
writhing observed during 20 min in the acetic acid test for animals treated with H. 
crenata (HC) decoction extract 15 mg/kg (p.o.), HC 150 mg/kg (p.o.) and indomethacin 
10 mg/kg (p.o.) compared with vehicle (p.o.). All data points are n=8 except 
indomethacin (n=5). (Log10 transformed data) 
 
Treatment comparison Diff of 
Means 
t Unadjusted 
P 
Critical 
Level 
Indomethacin vs. HC 150 mg/kg 0.177 1.104 0.28 0.017 
Indomethacin vs. HC 15 mg/kg 0.161 1.002 0.326 0.025 
Table 18 - Pairwise multiple comparisons statistic of one way ANOVA for writhing 
occurrences. Analyses of writhing observed during 20 min in the acetic acid test for 
animal groups treated with H. crenata (HC) decoction extract 15 mg/kg (p.o.), 150 
mg/kg (p.o.) and indomethacin 10 mg/kg (p.o.) (Holm-Sidak method). Overall 
significance level = 0.05. All data points are n=8 except indomethacin (n=5). (Log10 
transformed data) 
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Figure 24 - Number of writhing occurrences in the acetic acid test, evaluation of 
HC doses response. Mean + S.E.M. data for number of writhing occurrences during 20 
min in the acetic acid test, for animals treated with vehicle (p.o.), H. crenata (HC) 
decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.). *Multiple 
comparisons versus control group (Holm-Sidak method): Overall significance level < 
0.05. All data points are n=8. (Back-transformed averages of Log10-transformed data, 
plotted in logarithm scale). 
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Treatment comparison Diff of 
Means 
t Unadjusted 
P 
Critical 
Level 
Vehicle vs. HC 1 mg/kg 0.238 1.359 0.185 0.05 
Vehicle vs. HC 5 mg/kg 0.604 3.442 0.002 0.017 
Vehicle vs. HC 45 mg/kg 0.45 2.568 0.016 0.025 
Table 19 - Multiple comparisons statistic of one way ANOVA for writhing 
occurrences. Analyses of writhing observed during 20 min in the acetic acid test for 
animals treated with H. crenata (HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 
45 mg/kg (p.o.) versus control group vehicle (p.o.). One way ANOVA (Holm-Sidak 
method), overall significance level = 0.05. All data points are n=8. (Log10 transformed 
data) 
 
Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
 
Writhing 
Between Groups 3 1.651 0.55 4.475 0.011 0.716 
Residual 28 3.444 0.123    
Total 31 5.095     
Table 20 - Output of one way ANOVA for writhing occurrences. Analyses of 
writhing observed during 20 min in the acetic acid test for animals treated with H. 
crenata (HC) decoction extract 1 mg/kg (p.o.), HC 5 mg/kg (p.o.) and HC 45 mg/kg 
(p.o.) compared with vehicle (p.o.). All data points are n=8 except vehicle (n=16). 
(Log10 transformed data). 
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Figure 25 – Dose response of HC doses in the acetic acid test. Data of number of 
writhing occurrences for each animal during 20 min in the acetic acid test, showing dose 
response for animals treated with vehicle (p.o.), H. crenata (HC) decoction extract 1 
mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.) and saturation from the doses 15 mg/kg 
(p.o.), 45 mg/kg and150 mg/kg (p.o.). All data points are n=8 except vehicle (n=16). 
The values show the correlation statistics R2 and significance values for the two phases 
of the dose-response relationship. 
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4.5.2 Effect of Hyptis crenata decoction fractions and comparison between all 
treatments tested.  
This study also evaluated the antinociceptive effect of fractions from HC decoction 
extract (45 mg). These treatments were HC hexane fraction 2.1 mg/kg (p.o.), HC DCM 
fraction 4 mg/kg (p.o.), HC methanol fraction 14.8 mg/kg (p.o.) and HC water fraction 
23 mg/kg (p.o.). Statistical analysis from the results of these evaluations showed that 
only the hexane fraction was able to reduce writhing during the acetic acid test (Figure 
26, Table 21 and Table 22). In order to analyse if there was a difference between the 
effect of the different fractions and the HC decoction, all the data from both 
experiments were plotted, and the HC doses linear regression line was used to compare 
the effect between the treatments. The regression line showed that the hexane fraction 
was more efficient than indomethacin, and that the effect of HC decoction extract was 
the same as that of indomethacin (Table 25). However, pairwise comparisons (Table 23) 
showed that the effect of the fractions and its whole extract (HC 45 mg/kg (p.o.)) were 
not different from each other regarding the reduction in writhing. But considering that 
hexane was less concentrated it had a greater antinociceptive effect per mg comparing 
with the unfractionated extract, while this was not the case for any of the other fractions 
nor for indomethacin. In addition, a one way ANOVA was carried out with all HC 
doses and fractions compared to vehicle confirming the significant effect for the hexane 
fraction, HC 5 mg/kg (p.o.), HC 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.), but HC 45 
mg/kg (p.o.) was not significantly different from the control in this analysis (Table 24 
and Table 25). 
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Figure 26 - Number of writhing occurrences in the acetic acid test, evaluation of 
HC decoction extract fractions. Mean + S.E.M. data for number of writhing 
occurrences during 20 min in the acetic acid test, for animals treated with (p.o.), H. 
crenata (HC) decoction extract fractions (hexane 2.1 mg/kg (p.o.), DCM 4 mg/kg (p.o.), 
methanol 14.8 mg/kg (p.o.) and water 23 mg/kg (p.o.)). *Multiple comparisons versus 
control group (Holm-Sidak method): Overall significance level < 0.05. All data points 
are n=8. (Back-transformed averages of Log10-transformed data, plotted in logarithm 
scale). 
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Treatment comparison Diff of 
Means 
t Unadjusted 
P 
Critical 
Level 
Vehicle vs. hexane fraction 0.724 3.454 0.001 0.013 
Vehicle vs. water fraction 0.481 2.298 0.028 0.017 
Vehicle vs. methanol fraction 0.422 2.012 0.052 0.025 
Vehicle vs. DCM fraction 0.412 1.968 0.057 0.05 
Table 21 - Multiple comparisons statistic of one way ANOVA for writhing 
occurrences. Analyses of writhing observed during 20 min in the acetic acid test for 
animals treated with H. crenata (HC) decoction extract fractions (hexane 2.1 mg/kg 
(p.o.), DCM 4 mg/kg (p.o.), methanol 14.8 mg (p.o.) and water 23 mg/kg (p.o.)) 
compared with vehicle (p.o.), (Log10 data). All data points are n=8. 
 
Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
 
Writhing 
Between Groups 4 2.174 0.544 3.095 0.028 0.557 
Residual 35 6.147 0.176    
Total 39 8.322     
Table 22 - Output of one way ANOVA for writhing occurrences. Analyses of 
writhing observed during 20 minutes in the acetic acid test for animals treated with H. 
crenata (HC) decoction extract fractions (hexane 2.1 mg/kg (p.o.), DCM 4 mg/kg (p.o.), 
methanol 14.8 mg (p.o.) and water 23 mg/kg (p.o.)). All data points are n=8. (Log10 
transformed data) 
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Figure 27 – Dose response of HC doses and decoction fractions. Mean + S.E.M. data 
with linear regression for the number of writhing occurrences observed during 20 
minutes in the acetic acid test for animals treated with H. crenata (HC) decoction 
extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 mg/kg (p.o.) and 150 mg/kg 
(p.o.) and its fractions (hexane fraction 2.1 mg/kg, (p.o.), DCM fraction 4 mg/kg (p.o.), 
methanol fraction 14.8 mg/kg (p.o.), water fraction 23 mg/kg (p.o.)), indomethacin 10 
mg/kg (p.o.) and vehicle (p.o.). This graph uses the dose response curve previously 
presented in Figure 25 and the indomethacin was plotted as an additional data point in 
the same coordinates for comparison with H. crenata full extract. *Multiple 
comparisons versus vehicle group (Holm-Sidak method): Overall significance level < 
0.05. All data points are n=8 except indomethacin (n=5) and vehicle (n=16). (Back-
transformed averages of Log10-transformed data, plotted in logarithm scale). 
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Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
Writhing Between Groups 4 0.318 0.0796 0.539 0.708 0.05 
 Residual 35 5.173 0.148    
 Total 39 5.492     
Table 23 - Output of one way ANOVA for comparison of writhing occurrences. 
Analyses of writhing observed during 20 min in the acetic acid test for animals treated 
with H. crenata (HC) decoction extract 45 mg/kg and its fractions (hexane fraction 2.1 
mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and 
water fraction 23 mg/kg (p.o.)). All data points are n=8. (Log10 transformed data) 
 
Treatment comparisons Diff of Means T Unadjusted P Critical Level 
Vehicle vs. Indomethacin 0.408 2.448 0.017 0.01 
Vehicle vs. HC 1 mg/kg 0.14 0.995 0.322 0.05 
Vehicle vs. HC 5 mg/kg 0.505 3.59 <0.001 0.006 
Vehicle vs. HC 15 mg/kg 0.524 3.727 <0.001 0.006 
Vehicle vs. HC 45 mg/kg 0.352 2.501 0.014 0.009 
Vehicle vs. HC 150 mg/kg 0.533 3.786 <0.001 0.005 
Vehicle vs. hexane fraction 0.501 3.563 <0.001 0.007 
Vehicle vs. DCM fraction 0.254 1.804 0.075 0.025 
Vehicle vs. methanol fraction 0.272 1.932 0.057 0.017 
Vehicle vs. water fraction 0.299 2.126 0.036 0.013 
Table 24 - Multiple comparisons statistic of one way ANOVA for writhing 
occurrences. Analyses of writhing observed during 20 min in the acetic acid test for 
animals treated with H. crenata (HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 
15 mg/kg (p.o.), 45 mg/kg (p.o.) and 150 mg/kg (p.o.) its fractions (hexane fraction 2.1 
mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and 
water fraction 23 mg/kg (p.o.)) and indomethacin 10 mg/kg (p.o.) compared with 
vehicle (p.o.). All data points are n=8 except indomethacin (n=5) and vehicle (n=16). 
(Log10 transformed data). 
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Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
 
Writhing 
Between Groups 10 3.231 0.323 3.058 0.002 0.862 
Residual 82 8.662 0.106    
Total 92 11.892     
Table 25 - Output of one way ANOVA for writhing occurrences. Analyses of 
writhing observed during 20 min in the acetic acid test for animals treated with H. 
crenata (HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 
mg/kg (p.o.) and 150 mg/kg (p.o.) its fractions (hexane fraction 2.1 mg/kg (p.o.), DCM 
fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.), water fraction 23 mg/kg 
(p.o.)) and indomethacin 10 mg/kg (p.o.) compared with vehicle. All data points are n=8 
except indomethacin (n=5) and vehicle (n=16). (Log10 transformed data) 
 
4.5.3 Effect of Hyptis crenata and its fractions on other behaviour during acetic acid 
test 
During the acetic acid test, in addition to writhing, total time stationary (TSAC), 
twitching, exploratory and locomotor activities (ELA) were analysed. The one way 
ANOVA for these behaviours showed no significant effects on TSAC (Table 26 and 
Table 27) or ELA (Table 28 and Table 29) when compared to vehicle for H. crenata 
extracts doses 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 mg/kg (p.o.), 150 
mg/kg (p.o.), HC fractions (hexane fraction, DCM fraction, methanol fraction and water 
fraction) and indomethacin 10 mg/kg (p.o.) during the acetic acid test. Also no 
significant effect of these treatments was observed for twitching when compared to the 
vehicle (Figure 28). But there was a statistically significant difference observed between 
the groups (Table 30 and Table 31), it was due to the higher number of twitching 
occurrences from HC 45 mg/kg and DCM fraction groups. However the fact that 
twitching was not normally distributed even after log transformation makes this 
difference between treatments doubtful. 
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Behaviour Treatments N  Mean S.E.M. 
TSAC 
(seconds) 
Vehicle 16 322.8 31.9 
Indomethacin 5 266.2 83.7 
HC 1 mg/kg 8 367.6 44.6 
HC 5 mg/kg 8 395.6 33.4 
HC 15 mg/kg 8 217.8 54.8 
HC 45 mg/kg 8 439.1 45.8 
HC 150 mg/kg 8 298.8 55.0 
Hexane fraction 8 297.2 61.9 
DCM fraction 8 337.1 62.6 
Methanol fraction 8 394.1 44.1 
Water fraction 8 341.4 26.3 
Table 26 - Measurement of total time stationary during the acetic acid test (TSAC). 
Mean and S.E.M. data for TSAC for animals treated with vehicle (p.o.), indomethacin 
10 mg/kg (p.o.), HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.), HC 15 mg/kg (p.o.), HC 45 
mg/kg (p.o.), HC 150 mg/kg (p.o.) and HC fractions: hexane fraction (p.o.), DCM 
fraction (p.o.), methanol fraction (p.o.) and water fraction (p.o.). All data points are n=8 
except indomethacin (n=5) and vehicle (n=16). (Back-transformed averages of the 
differences between Log10 transformed values before and after treatment) 
 
Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
 
TSAC 
Between Groups 10 1.163 0.116 1.559 0.134 0.266 
Residual 82 6.118 0.0746    
Total 92 7.281     
Table 27 - Output of one way ANOVA for total time stationary during the acetic 
acid test. Effect of animals treated with vehicle (p.o.), indomethacin 10 mg/kg (p.o.), 
HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.), HC 15 mg/kg (p.o.), HC 45 mg/kg (p.o.), HC 
150 mg/kg (p.o.) and HC hexane fraction (p.o.), DCM fraction (p.o.), methanol fraction 
(p.o.) and water fraction (p.o.) on TSAC (total time stationary during acetic acid test). 
All data points are n=8 except indomethacin (n=5) and vehicle (n=16). (Differences 
between Log10 transformed values before and after treatment). 
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Behaviour Treatments N  Mean S.E.M. 
Total ELA 
Vehicle 8 46.0 9.1 
Indomethacin 8 73.3 16.3 
HC 1 mg/kg 8 54.1 6.3 
HC 5 mg/kg 8 37.8 7.3 
HC 15 mg/kg 8 58.1 9.2 
HC 45 mg/kg 8 44.9 10.1 
HC 150 mg/kg 8 61.7 10.0 
Hexane fraction 8 46.7 17.6 
DCM fraction 8 48.9 5.6 
Methanol fraction 8 48.5 9.3 
Water fraction 8 50.0 6.3 
Table 28 - Total number of occurrences for exploratory and locomotor activities 
(ELA). Mean and S.E.M. data for (ELA) for animals treated with vehicle (p.o.), 
indomethacin 10 mg/kg (p.o.), HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.), HC 15 mg/kg 
(p.o.), HC 45 mg/kg (p.o.), HC 150 mg/kg (p.o.) and HC hexane fraction (p.o.), DCM 
fraction (p.o.), methanol fraction (p.o.) and water fraction (p.o.) during the acetic acid 
test. All data points are n=8 except indomethacin (n=5) and vehicle (n=16). (Back-
transformed averages of the differences between Log10 transformed values before and 
after treatment). 
 
Behaviour Source of 
Variation 
 DF   SS   MS   F   P  Power 
 
ELA 
Between Groups 10 0.413 0.0413 0.727 0.697 Power 
Residual 82 4.662 0.0569   0.05 
Total 92 5.076     
Table 29 - Output of one way ANOVA for total number of occurrences for 
exploratory and locomotor activities (ELA). Effect on animals treated with vehicle 
(p.o.) indomethacin 10 mg/kg (p.o.), HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.), HC 15 
mg/kg (p.o.), HC 45 mg/kg (p.o.), HC 150 mg/kg (p.o.) and HC hexane fraction (p.o.), 
DCM fraction (p.o.), methanol fraction (p.o.) and water fraction (p.o.) on total 
exploratory and locomotor activities (ELA). All data points are n=8 except 
indomethacin (n=5) and vehicle (n=16). (Differences between Log10 transformed 
values before and after treatment). 
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Figure 28 – Number of twitching occurrences in the acetic acid test, evaluation of 
indomethacin, HC doses and fractions. Mean + S.E.M. data for number of twitching 
occurrences during 20 min in the acetic acid test, for animals treated with vehicle (p.o.), 
indomethacin 10 mg/kg (p.o.), HC 1 mg/kg (p.o.), HC 5 mg/kg (p.o.), HC 15 mg/kg 
(p.o.), HC 45 mg/kg (p.o.), HC 150 mg/kg (p.o.), HC hexane fraction (p.o.), DCM 
fraction (p.o.), methanol fraction (p.o.) and water fraction (p.o.). All data points are n=8 
except indomethacin (n=5) and vehicle (n=16). (Back-transformed averages of the 
differences between Log10 transformed values before and after treatment, plotted in 
logarithm scale). 
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Treatment comparison  Diff of 
Means 
t Unadjusted P Critical 
Level 
Vehicle vs. HC 1 mg/kg 0.091 0.593 0.555 0.01 
Vehicle vs. HC 5 mg/kg 0.012 0.0782 0.938 0.025 
Vehicle vs. HC 15 mg/kg 0.397 2.587 0.011 0.005 
Vehicle vs. HC 45 mg/kg 0.159 1.038 0.302 0.007 
Vehicle vs. HC 150 mg/kg 0.169 1.102 0.274 0.006 
Vehicle vs. Hexane 0.0109 0.0713 0.943 0.05 
Vehicle vs. DCM 0.14 0.914 0.363 0.009 
Vehicle vs. Methanol 0.0903 0.588 0.558 0.013 
Vehicle vs. Water 0.0719 0.468 0.641 0.017 
Vehicle vs. Indomethacin 0.354 1.949 0.055 0.006 
Table 30 - Multiple comparisons statistic of one way ANOVA for twitching 
occurrences. Analysis of twitching observed during 20 min in the acetic acid test for 
animals treated with H. crenata (HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), 
15 mg/kg (p.o.), 45 mg/kg (p.o.) and 150 mg/kg (p.o.) its fractions (hexane fraction 2.1 
mg/kg (p.o.), DCM fraction 4 mg/kg (p.o.), methanol fraction 14.8 mg/kg (p.o.) and 
water fraction 23 mg/kg (p.o.)) and indomethacin 10 mg/kg (p.o.) compared with 
vehicle (p.o.). All data points are n=8 except indomethacin (n=5) and vehicle (n=16). 
(Log10 transformed data). 
 
Source of Variation  DF   SS   MS   F   P  Power 
Between Groups 10 2.624 0.262 2.086 0.035 0.526 
Residual 82 10.314 0.126    
Total 92 12.938     
Table 31 - Output of one way ANOVA for twitching. Analysis of effect on animals 
treated with vehicle (p.o.), indomethacin 10 mg/kg (p.o.), HC 1 mg/kg (p.o.), HC 5 
mg/kg (p.o.), HC 15 mg/kg (p.o.), HC 45 mg/kg (p.o.), HC 150 mg/kg (p.o.) and HC 
hexane fraction (p.o.), DCM fraction (p.o.), methanol fraction (p.o.) and water fraction 
(p.o.) on twitching. All data points are n=8 except indomethacin (n=5) and vehicle 
(n=16). (Differences between Log10 transformed values before and after treatment) 
 
4.5.4 Effect of Hyptis crenata extract on basal behaviour 
The next stage of this study was to investigate whether H. crenata decoction and its 
fractions were having effects on exploratory and locomotor behaviour of mice. In order 
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to examine this possibility, analyses of behaviour were carried out before and after the 
administration of HC doses 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.) and the 
fractions. These behaviours were also analysed during the acetic acid test. 
It was observed that the mice displayed the same type of behaviour before and after 
treatment with HC doses and fractions, these behaviours were: drinking, eating, sniffing, 
digging, grooming, climbing, hanging, rearing-up, walking and time stationary, the 
description of these behaviours are presented in the methodology section. From these 
analyses it was also possible to confirm that the animals did not display writhing and 
twitching as was observed during the acetic acid test. In addition, from these analyses it 
was observed that the stationary time was substantially increased due to the effect of 
acetic acid injection, the average of total stationary behaviour before the treatments and 
the acetic acid test was 13 seconds whereas during the acetic acid test it was 369 
seconds. The paired t-test comparing all groups before the treatments and after the 
acetic acid injection is shown in Table 32. 
In order to analyse the effect of HC decoction doses and its fraction on ethological 
behaviours observed, they were categorised according to their potential indicators of 
effect. These effects were sedation (BIS), locomotor impairment and neuroleptic effect 
(BLY) and total time stationary and hanging as indicators of locomotor activity and 
muscle relaxation. 
The one way ANOVA analyses of differences in behaviours before and after treatments 
showed that the H. crenata 1 mg/kg (p.o.), 5 mg/kg (p.o.), 15 mg/kg (p.o.), 45 mg/kg 
(p.o.) and 150 mg/kg (p.o.) and its fractions did not induce a significant change for any 
of the behaviour categories analysed (BIS, BLY, total time stationary and hanging), as 
shown in Table 33, Table 34, Table 35 and Table 36. 
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Stationary time N  Mean (seconds) Std Dev SEM P t DF Power 
Before 
treatments 
64 13.176 8.628 1.078  <0.001 22.408 63 1 
After injection 64 369.512 128.694 16.087     
Difference 64 356.337 127.217 15.902     
Table 32 – Output of paired-t-test of the change in stationary time that occurred 
between baseline and after acetic acid injection. The analysis was performed with all 
groups in which behaviour analyses before and after acetic acid injection was performed.  
 
Behaviour Treatment N Mean S.E.M. 
BIS 
(Log10 back - transformed data) 
Vehicle 8 1.00 0.27 
HC 1 mg/kg 8 2.20 1.14 
HC 5 mg/kg 8 1.18 0.83 
HC 45 mg/kg 8 1.18 0.19 
 
BLY 
not log transformed 
Vehicle 8 -12.00 9.75 
HC 1 mg/kg 8 -2.88 17.10 
HC 5 mg/kg 8 -40.75 11.89 
HC 45 mg/kg 8 -26.63 11.19 
 
Stationary latency (seconds) 
(Log10 back - transformed data) 
Vehicle 8 3.10 1.02 
HC 1 mg/kg 8 2.36 1.46 
HC 5 mg/kg 8 1.51 1.26 
HC 45 mg/kg 8 2.49 2.08 
 
Hanging (seconds) 
(Log10 back - transformed data) 
Vehicle 8 2.90 1.71 
HC 1 mg/kg 8 4.37 3.88 
HC 5 mg/kg 8 1.42 1.82 
HC 45 mg/kg 8 1.38 1.05 
Table 33 – Effect of HC treatments on different baseline behaviours. Mean and 
standard error of mean (S.E.M.) of differences between values before and after 
treatment for categorized behaviours BIS (sum of sniffing, grooming and rearing), BLY 
(sum of digging, climbing and walking), behaviours hanging latency and total time 
stationary, for animal groups treated with vehicle (p.o.), H. crenata (HC) decoction 
extract 1 mg/kg (p.o.), 5 mg/kg (p.o.), and 45 mg/kg (p.o.). Some data are back-
transformed averages of the differences between Log10 transformed values before and 
after treatment). 
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Behaviours Source of 
Variation 
DF SS MS F P Power 
BIS Between Groups 3 0.549 0.183 0.904 0.451 0.049 
Residual 28 5.663 0.202    
Total 31 6.212     
 
BLY Between Groups 3 6643.625 2214.542 1.693 0.191 0.173 
Residual 28 36616.25 1307.723    
Total 31 43259.88     
 
Stationary 
(latency 
seconds) 
Between Groups 3 0.413 0.138 0.347 0.791 0.049 
Residual 28 11.102 0.397    
Total 31 11.515     
 
Hanging Between Groups 3 1.438 0.479 0.784 0.513 0.049 
Residual 28 17.12 0.611    
Total 31 18.559     
Table 34 - Output of one way ANOVA for effect of HC treatments on different 
baseline behaviours. Effect of animal groups treated with vehicle (p.o.) H. crenata 
(HC) decoction extract 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.) on the 
categorized behaviours; BIS (sum of sniffing, grooming and rearing), BLY (sum of 
digging, climbing and walking), hanging latency and total time stationary. All data 
points are n=8. (Some data are differences between log10 transformed values before and 
after treatment). 
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Behaviour Treatment N Mean S.E.M. 
BIS 
(Log 10 
transformed) 
Vehicle 8 1.00 4.21 
Hexane fraction 8 9.00 2.82 
DCM fraction 8 7.75 5.52 
Methanol fraction 8 0.75 5.86 
Water fraction 8 4.00 8.17 
 
BLY 
(not log 
transformed) 
Vehicle 8 -12.00 9.75 
Hexane fraction 8 -5.75 15.55 
DCM fraction 8 12.00 13.92 
Methanol fraction 8 -1.38 10.65 
Water fraction 8 -9.63 15.31 
 
Stationary latency 
(seconds) 
(Log 10 
transformed) 
Vehicle 8 3.10 1.02 
Hexane fraction 8 2.19 1.18 
DCM fraction 8 1.41 1.62 
Methanol fraction 8 1.15 0.37 
Water fraction 8 2.66 0.68 
 
Hanging (seconds) 
(Log 10 
transformed) 
Vehicle 8 2.90 1.71 
Hexane fraction 8 1.38 1.30 
DCM fraction 8 1.38 1.55 
Methanol fraction 8 1.29 1.06 
Water fraction 8 1.87 2.29 
Table 35 - Effect of HC decoction fractions treatments on different baseline 
behaviours. Mean and standard error of mean (S.E.M.) for categorized behaviours; BIS 
(sum of sniffing, grooming and rearing), BLY (sum of digging, climbing and walking), 
hanging latency and total time stationary, for animal groups treated with vehicle (p.o.), 
HC hexane fraction 2.1 mg/kg (p.o.), HC DCM fraction 4 mg/kg (p.o.), HC methanol 
fraction 14.8 mg/kg (p.o.). All data points are n=8. (Back-transformed averages of the 
differences between Log10 transformed values before and after treatment). 
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Behaviours Source of 
Variation 
 
DF  
 SS   MS   F   P  Power 
BIS 
(Log 10 
transformed) 
Between Groups 4 459 114.75 0.457 0.767 0.049 
Residual 35 8795 251.286    
Total 39 9254     
 
BLY 
(not log 
transformed) 
Between Groups 4 2875.85 718.962 0.512 0.728 0.05 
Residual 35 49179.25 1405.121    
Total 39 52055.1     
 
Stationary  
(latency 
seconds) 
(Log 10 
transformed) 
Between Groups 4 1.07 0.268 0.903 0.473 0.473 
Residual 35 10.369 0.296    
Total 39 11.439     
 
Hanging 
(seconds) 
(Log 10 
transformed) 
Between Groups 4 0.686 0.172 0.256 0.904 0.904 
Residual 35 23.438 0.67    
Total 39 24.124     
Table 36 - Effect of HC decoction fractions treatments on different baseline 
behaviours. Output of one way ANOVA for effect of animal groups treated with 
vehicle (p.o.), HC hexane fraction 2.1 mg/kg (p.o.), HC DCM fraction 4 mg/kg (p.o.), 
HC methanol fraction 14.8 mg/kg (p.o.) and HC water fraction 23 mg/kg (p.o.) on the 
categorised behaviours; BIS (sum of sniffing, grooming and rearing), BLY (sum of 
digging, climbing and walking), hanging latency and total time stationary. All data 
points are n=8. (Differences between Log10 transformed values before and after 
treatment). 
 
4.6 Discussion 
The main aim of the experiments described in this chapter was to evaluate the effect of 
H. crenata decoction and its fraction on reducing writhing in an animal model of 
visceral pain. The results of these experiments showed that H. crenata decoction extract 
at a dose of 15 mg/kg (p.o.) and 150 mg/kg (p.o.) significantly decreased the number of 
writhings, suggesting a possible effect of H. crenata compounds on the visceral 
nociceptive system. As expected, this effect was also observed for the treatment with 
indomethacin 10 mg/kg (p.o.), this drug is known for its ability to decrease 
prostaglandin levels and researchers have reported that this pain mediator increases its 
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amount in the peritoneal fluid after injection of acetic acid (Collier et al., 1968). This 
fact correspondingly could indicate that H. crenata decoction compounds could be also 
decreasing prostaglandin levels. 
Although the acetic acid test has the benefit of being very sensitive to detect even weak 
analgesic effects, it has the disadvantage of having a low specificity, which means that 
substances that are adrenergic blockers, antihistamines, muscle relaxants, monoamine 
oxidase inhibitors and neuroleptics could have a positive effect in the test (Le Bars et al., 
2001). It is possible that any of these mechanisms could be responsible for the 
antinociceptive effect observed in the acetic acid test and also in the thermal nociception 
test (Hargreaves test). Adrenergic blockers, antihistamines and monoamine oxidase 
inhibitors have also been reported to induce or enhance analgesia in the hot plate test. 
(Bianchi et al., 1992; Rojas-Corrales et al., 2000; Galeotti et al., 2002; Gürel et al., 
2009). In addition, a muscle relaxant effect has been reported to be a false positive for 
this test. Considering that H. crenata treatments could be acting in any of these potential 
mechanisms, it was decided that the next step of the experiment was to do a preliminary 
evaluation of the animal behaviour that would indicate a correlation with these effects. 
Because the next stage of this study would be to evaluate the dose-dependent response 
of lower and higher doses than HC 15 mg/kg and the antinociceptive effect of HC 
decoction fractions, the behaviour analyses was carried out for these treatment groups. 
Therefore, if H. crenata doses or its fractions were having an effect via the 
antihistaminic pathway, it is very likely that a decrease would be observed in the 
number of sniffing, grooming and rearing events categorised as an indicator of sedation, 
since it is well known that antihistaminic agents provoke sedation as an adverse effect 
(Hindmarch and Shamsi, 1999; Shamsi and Hindmarch, 2000; Bender et al., 2003). 
However, if H. crenata would have neuroleptic-like action similar to apomorphine that 
is a dopamine receptor agonist, it is likely that the extract would affect the occurrence of 
digging, climbing and walking behaviour categorised as indicators of neuroleptic effects 
(Puech et al., 1978; Lassen, 1979; Kendler et al., 1982). But if the antinociceptive 
effects observed were due to the fact that HC groups had a muscle relaxant effect, these 
animals would decrease hanging latency and increase total time stationary due to motor 
impairment. Because none of these behaviours were specifically affected by H. crenata 
decoction and its fractions, it could be suggested that the antinociceptive effect observed 
in H. crenata treatments might not be due to antihistaminic, muscle relaxant, or 
dopamine agonist action. In addition, the fact that none of the decoction fractions 
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altered the behaviours analysed reinforces this hypothesis, considering that any potential 
change of these behaviours analysed would theoretically be more evident since the 
process of fractionation selectively purifies the compound in the sample, and any effect 
induced by this compound might be noticed or amplified. Another possibility is that 
there was involvement of these mechanisms, however due to low statistical power the 
analyses failed to detect the change on the animal behaviour. 
A further objective of this experiment was to investigate the dose response curve of H. 
crenata extract. The analyses showed that 5, 15, 45 and 150 mg/kg were effective; 
however no effect was observed for 1 mg/kg, suggesting that the antinociceptive effect 
is induced above of this dose, with a threshold for effect between 1 and 5 mg/kg. The 
linear regression analyses of the effect of all HC doses tested, indicated that there was 
dose-response until 15 mg/kg, however this effect reached maximal efficacy between 
this dose and 45 mg/kg, becoming saturated. As described in the introduction (Section 
1.4.3), there are eight previous antinociceptive studies that evaluated the activity of 
three other Hyptis species (Bispo et al., 2001; Lisboa et al., 2006; Marcal et al., 2006; 
Menezes et al., 2007; Santos et al., 2007b; Arrigoni-Blank et al., 2008; Franco et al., 
2011; Raymundo et al., 2011); the acetic acid inducing writhing was used in all these 
studies. Four of these studies evaluated Hyptis essential oil and the others evaluated an 
extract and fractions. The dose used in these studies ranged from 10 to 400 mg/kg for 
the essential oils studies, 100 to 400 mg/kg in the aqueous studies and 25 to 400 mg/kg 
for extractions using organic solvents studies. The essential oils evaluated were from the 
H. pectinata and H. fruticosa species, one of these studies reported saturation in the 
effect of essential oil at 50 mg/kg (i.p.) (Franco et al., 2011), while for the other studies 
it was not possible to indicate which dose reached the maximum response since the 
lowest dose used was already effective (Arrigoni-Blank et al., 2008). For the aqueous 
extract that would be more comparable with this H. crenata study, as this experiment 
also used aqueous extraction, it is not very clear if there was dose-dependency of the 
observed writhing effect. However, it appears that H. suaveolens treatment reached its 
maximum effect between 200 and 400 mg/kg (p.o.) (Santos et al., 2007b) and 
H.pectinata was still showing an increase in effect at the highest dose tested that was 
400 mg/kg (p.o.) (Bispo et al., 2001). If compared, the predicted maximum effect 
occurred with a dose of H. crenata that is between 15 and 150 mg/kg (p.o.), while these 
other Hyptis studies occurred at much higher doses. There are a number of reasons for 
this including the fact that the active compounds may be more efficacious or occur at 
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higher concentrations or that H. crenata compounds have a lower “first-pass loss” when 
passing through sites like gastrointestinal tissues and the liver than the compounds 
present in these other species, therefore a smaller amount of treatment is needed to 
induce the effect (Rowland and Tozer, 2011). However, because in these other reports 
on Hyptis aqueous extracts the dose-dependency effect was not properly calculated, it 
could be that the effect was already saturated in the lowest dose tested (100 mg/kg) 
which in any case is still very high when compared to the present H. crenata study. 
The results of this experiment also showed that the most active fraction from H. crenata 
decoction extract was the hexane fraction, with no significant effect observed for the 
other fractions. One of the previous Hyptis genus antinociceptive studies also 
investigated the effect using fractions from H. pectinata, however the difference was 
that the organic solvents (MeOH, hexane, chloroform and ethyl acetate) were added 
directly to the plant powdered leaves (Lisboa et al., 2006) while the present study first 
produced a decoction which was then fractionated. In contrast with H. crenata results, 
all these fractions from H. pectinata were effective in decreasing writhing, indicating 
the possibility of a more diverse class of compounds being active on antinociception. 
But this does not mean that this range of diverse compounds were absent in H. crenata 
species, it is possible that the decoction extract did not select these compounds. It could 
be argued that a study like that of Lisboa et al., 2006 produces fractions that do not 
reproduce the profile of compounds that would be selected in a traditional use method. 
Therefore there is a potential risk for some of these compounds to be toxic, assuming 
that they have never been “clinically tested” by the medicinal plant users (Fabricant et 
al., 2001). In comparing the percentage inhibition of writhing between the H. crenata 
and H. pectinata studies, it appears that H. crenata hexane fraction appeared to be more 
effective in reducing writhing since 2.1 mg/kg of the fraction was able to reduce 
writhing by 68% compared to control (present study), whereas 100 mg/kg of the hexane, 
ethyl acetate and chloroform fractions from H. pectinata  achieved 62%, 67% and 84%, 
respectively. Another interesting outcome from the present study  is that H. crenata 
decoction extract was as effective as indomethacin, although this was not surprising, 
since similar results were also found using H. pectinata species using aqueous extract as 
treatment (Bispo et al., 2001). However, after HC fractionation the results showed that 
hexane fraction was more effective than indomethacin. 
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When comparing the type of behaviour observed before and after the injection of acetic 
acid, as expected writhing behaviour only appears for mice after they have received the 
acetic acid injection. However, what was also noted was that all mice after acetic acid 
injection, independent of treatment received, displayed a slight tremor designated as 
twitching behaviour. In addition, animals receiving acetic acid displayed a considerably 
increased time stationary. A literature search was made to examine if other authors have 
noted or measured these variables during the acetic acid test. Although an increase in 
time stationary after acetic acid injection has been described by Le Bars et al. (2001) 
there is no mention of twitching during the acetic acid test. The possibilities for these 
results could be that because twitching is not a major change in behaviour it was not 
measured in previous studies. Considering that these two behaviours (time stationary 
and twitching) could measure the level of pain during the acetic acid test, analyses were 
carried out comparing H. crenata decoction doses, its fractions and indomethacin 
against the control (vehicle). None of these treatments were significant in decreasing 
twitching or time stationary, even indomethacin. This could suggest that these 
behaviours are not caused by pain but it could be associated with some stress or anxiety 
(Morgan et al., 1999). 
4.7 Conclusions 
The data presented in this chapter supports the antinociceptive effect of H. crenata 
decoction extract at doses of 5, 15, 45 and 150 mg/kg (p.o.) and its hexane fraction on 
visceral pain caused by acetic acid. There is a dose-dependent effect observed for the 
doses 0, 1, 5 and 15 mg/kg. The saturation in the effect occurred at 15 mg/kg or 
between 15 and 45 mg/kg (p.o.). Therefore, these results support the antinociceptive 
effect of dose 15 mg/kg (p.o.) which was derived from reports of traditional use. H. 
crenata decoction extract and its fractions do not affect locomotor and ethological 
behaviours. Also the twitching and the increase of time stationary induced by acetic acid 
are not affected by Hyptis crenata treatments or by indomethacin. 
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5.1 Overall Procedures 
5.1.1 Flowchart 
 
 
 
Evaluation of decoction 
extract at doses 0, 15 
and 150 mg/kg and 
group treated with 
indomethancin 
Analyses of c-fos expression 
of mice after acetic acid test, 
group treated with HC 0, 15 
and 150 mg/kg 
Chapter 6 
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5.2 Introduction 
In addition to behavioural indices of antinociceptive action described in the preceding 
chapters, an aim of these studies was to obtain other evidence that Hyptis extract was 
able to modulate pain pathways. This chapter describes a study in which the expression 
of the immediate early gene product, Fos, was used to determine neural activation in the 
brains of animals from the acetic acid test described in Chapter 4. 
The use of the protein Fos as a neuron marker for analysing the response to pain stimuli 
has been used by several research studies. The advantage of this technique is that it is 
relatively simple to carry out and would give an unbiased measure of the pain response. 
In addition, the reduction of pain-induced expression of this protein in a specific part of 
the pain pathway can contribute to the understanding of the pharmacodynamic action 
and mechanism of a drug. However the disadvantage of this immediate early gene is 
that it is not only expressed in response to pain stimuli but also to other stimuli like 
stress (Harris, 1998; Herdegen and Leah, 1998; Hoffman and Lyo, 2002; Sinniger et al., 
2004). 
The injection of acetic acid used in the acetic acid test as noxious stimulus will induce 
chemical irritation in the peritoneum area increasing the level of pain mediator 
substances such as prostaglandin. This has the ability to activate nociceptors, therefore 
lowering its threshold and transmitting signals to second-order neurones in the spinal 
cord. From the spinal cord these signals are sent through the anterolateral system 
towards the thalamus, and from the ventral posterior thalamus the somatosensory 
information is transmitted to the cortex via third-order neurons. These sensory signals 
will be processed in the cortex and will generate the perception of pain (Dickenson and 
Suzuki, 2005; Toates, 2007). 
In response to this pain stimulus, the immediate early gene c-fos is expressed and will 
increase the Fos protein level 40-120 min after acetic acid injection (Harris, 1998). This 
increase of protein level due to the acetic acid stimulus has been reported to be found in 
the spinal cord (e.g. superficial laminae of the dorsal horn), forebrain (e.g. 
hypothalamus), midbrain (e.g. periaqueductal gray matter), as described in Table 37 
which shows these different regions with specifics parts analysed for c-fos expression 
after visceral pain induced by acetic acid. Regarding the function for some of these 
brain areas, the hypothalamus is an area of the brain that is mainly involved in 
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homeostasis and emotion; this emotion can be related to fear and anxiety. In regard to 
periaqueductal gray (PAG), it has an important role in the descending control pathway, 
and reports have suggested that PAG is the main site of action for analgesic drugs like 
morphine. It has also been reported that inhibitory control from PAG mainly affects 
transmission of C fibres nociception (Jacquet and Lajtha, 1974; Matthews, 2001; 
Heinricher et al., 2009). 
 
Authors Anatomical locations 
Methods of 
visualisation Animal 
(Nakagawa et al., 
2003) 
Amygdale central nuclei C-fos mRNA Rats 
(Bianchi et al., 
2003) 
Periaqueductal gray matter 
(PAG) 
Immunohistochemistry Rats 
(Taylor et al., 
1998) 
Spinal cord Immunohistochemistry Mice 
(Huang et al., 
2010) 
Spinal cord, superficial 
dorsal horn 
Immuno and western 
blot 
Mice 
(Sinniger et al., 
2004) 
Paraventricular nucleus of 
the hypothalamus (PVN) 
C-fos mRNA Rats 
(Bonaz et al., 
2000) 
Nucleus tractus solitarius, 
and paraventricular nucleus 
of the hypothalamus 
Immunohistochemistry Rats 
(Snowball et al., 
2000) 
Paraventricular nucleus of 
the hypothalamus (PVN), 
the supraoptic nucleus 
(SON), ventral regions of 
the anterior hypothalamus 
(PVA) and periaqueductal 
gray (PAG). 
Immunohistochemistry Rats 
(Jiao and Xie, 
2004) 
Limbic system and anterior 
cingulate cortex 
Immunohistochemistry Rats 
(Mitsui et al., 
2003) 
Midbrain periaqueductal 
gray matter 
Immunohistochemistry Rats 
(Hammond et al., 
1992) 
Spinal cord and the nucleus 
tractus solitarii 
Immunohistochemistry Rats 
(DeLeo et al., 
1991) 
Thoraco-lumbar region of 
the spinal cord 
Immunohistochemistry Rats 
Table 37 - Regions of the central nervous system where c-fos or Fos was observed 
after intraperitoneal injection of acetic acid 
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5.2.1 Fos expression for measurement of antinociceptive properties of medicinal 
plants and other drugs studies 
Searches were made to find studies that evaluated medicinal plant antinociceptive 
effects and also used c-fos expression as a measurement tool for pain response. 
Examining the databases in Medline, Web of Knowledge and Scopus, only one study 
was found published by Peng et al. (2009). This study reported the effects of Ligustici 
chuanxiong Hort essential oil in reducing c-fos expression in cells localised in the brain 
stem and the hypothalamus of rats after performing the nitroglycerin-induced headache 
test. However, in relation to conventional analgesic drugs studies and methods of 
evaluation involving c-fos measurements, there are a number of articles. In these articles 
drugs have been reported for their ability to suppress c-fos expression in specific areas 
of the central nervous system using several animal models of pain. These drugs can be 
divided into two categories; drugs suppressing c-fos at the trigeminal nuclear complex 
and suppressors of c-fos at the spinal cord and dorsal horn. 
5.2.2 Suppressors of c-fos at the trigeminal nuclear complex 
The trigeminal nerve carries sensory information from the head and the trigeminal 
nuclear complex has been described to be associated with pain mechanisms involved in 
primary headaches (Evers, 2010; Fernandez-De-Las-Peas, 2010; Edvinsson, 2011; 
Hargreaves, 2011; Kelman, 2011). Sumatriptan, a triptan sulfa used for the treatment of 
migraine, has been reported to reduce c-fos in the trigeminal nucleus caudalis of rats 
performing a test that consisted of injecting carrageenan into the cisterna magna to 
induce inflammation (Nozaki et al., 1992). Similarly, the drug dihydroergotamine, an 
ergot alkaloid also used to treat migraines has been reported to reduce c-fos expression 
at the superior local superficial laminae of the trigeminal nucleus caudalis (Hoskin et al., 
1996), and also in the dorsal horn at levels C1 and C2. 
Fentanyl, an agonist at the μ-opioid receptor, also suppresses c-fos in the trigeminal 
nuclear complex at the transitional region between subnucleus interpolaris and caudalis 
and within the subnucleus caudalis after noxious stimulation of the dental pulp 
(Chattipakorn et al., 1999). Finally, celecoxib a sulfa non-steroidal anti-inflammatory 
drug, selective COX-2 inhibitor and acetaminophen, which is classified as a non-
steroidal anti-inflammatory drug, both decreased c-fos expression in the caudalis 
© Newcastle University 2013 135 
subnucleus in a rat model of orthodontic pain involving incisor movement (Stabile et al., 
2009). 
5.2.3 Suppressors of c-fos at the spinal cord 
Another drug that has been reported for suppressing c-fos is morphine. This drug is a 
potent opiate analgesic medication and researchers suggest that its effects decrease c-fos 
in the dorsal horn neurons (Burkey et al., 1996). Remifentanil, which is also an opioid 
and lidocaine, a common local anesthetic and antiarrhythmic drug, have been reported 
to inhibit c-fos in the spinal cord during the formalin test (Abbadie et al., 1997). 
Sevoflurane, a halogenated ether, also inhibits c-fos cells in the spinal cord after the 
formalin test (Hao et al., 2002). However, it should not be concluded that the spinal 
cord is the sole site of action for these drugs, as in most cases only the spinal cord was 
examined. 
5.2.4 Suppressors of c-fos at the cingulate cortex 
The cingulate cortex has been described to be specially activated by muscle pain, and it 
was also reported that pain cognition and emotion is segregated in this area (Maeda et 
al., 2011; Shackman et al., 2011; Takahashi et al., 2011). The drug Milnacipran, which 
is a serotonin-norepinephrine reuptake inhibitor used in the clinical treatment of 
fibromyalgia, has the ability to suppress c-fos expression in the anterior cingulate cortex 
(Takeda et al., 2009). 
5.3 Aim of this experiment 
Evidence shows that the Fos protein can be used as a valid tool for the study of the 
neural activities correlating with nociception, and research has reported its expression in 
some areas of the forebrain and midbrain of mice, induced by intraperitoneal injection 
of acetic acid. Therefore, this experiment aimed to investigate whether H. crenata 
decoction extract, which was effective in reducing acetic acid writhing, would also 
reduce Fos expression localised in the forebrain and midbrain of the mouse after this 
noxious stimulus. 
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5.4 Material and methods 
5.4.1 Experimental design 
In this experiment the Fos analyses were carried out on mice tissue after performing the 
acetic acid test (Chapter 4). The forebrain and midbrain were the parts of the central 
nervous system used for Fos expression analyses. The reason for not analysing the 
spinal cord was because there was an uncertainty regarding which level of the spinal 
cord the acetic acid stimulus was acting, therefore it would be difficult to select and 
analyse precisely the Fos active section and make valid comparisons between treatment 
groups. 
Because the brain is a very large area, it was necessary to decide which specific areas 
would be the focus of this experiment. A literature search was made to investigate in 
which areas of the brain the Fos protein is expressed after acetic acid injection in mice. 
The results of this search showed that the main areas were the forebrain and midbrain, 
specifically the area of PVA, PVN, SON and PAG (Table 37). Therefore these were the 
target areas for this study. 
The immunohistochemistry technique was the chosen method for Fos protein detection. 
The reason for choosing immunohistochemistry is due to the fact that it allows using 
fixed tissue, which is easier to handle for the large number of sections generated. In 
addition, with this technique it would be possible to integrate the response to a pain 
stimulus that occurred over a longer period, and it would give a potentially larger signal 
than the c-fos mRNA transcription technique. Furthermore, this technique has been 
widely used for studies using Fos as the method for neural marker (Bonaz et al., 2000; 
Bianchi et al., 2003; Nakagawa et al., 2003). 
The details of the animals and the treatments are reported in Section 4.4. This 
experiment analysed the treatments HC 15 mg/kg (p.o.), HC 150 mg/kg (p.o.) and 
vehicle, water for injection (p.o.) after the acetic acid test. Note that all animals received 
the acetic acid injection and the hypothesis being tested was whether H. crenata would 
reduce the level of Fos expression compared with vehicle, there was no comparison 
made with conventional anaesthetic. 
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5.4.2 Brain collection and fixation 
Ninety min after the injection of acetic acid animals were moved sequentially in their 
individual cages to a room for fixation and collection of the brain tissue. Animals were 
not moved until ready for the fixation in order to prevent any additional stimulus. 
The mouse was placed in a small plastic chamber (approx. 5 x 5 x 10 cm) containing a 
tissue on which 1 ml of fluothane had been added. The animal remained in the chamber 
for approx. 2 min until breathing had ceased and spontaneous recovery could not occur. 
The animal was removed and quickly dissected. The pelt over the chest was removed 
and the rib cage removed by cutting across the line of the diaphragm and, holding the 
xiphoid process, the anterior chest was dissected. The left jugular was cut and the 
descending aorta clamped with a small, curved hemostatic clamp. 
Gently holding the right ventricle with Watchmakers forceps, approx. 10 ml of 
heparinised PBS at 4°C was infused into the right ventricle using a 20 ml syringe and 
23-gauge needle. The infusion took approx. 1 minute and the paws could be seen to 
visibly blanch as the blood was removed. The animal was then fixed with 10-15 ml of 
4% paraformaldehyde (PFA) at 4°C. Good fixation was indicated by muscular twitching 
and stiffening of the forelimbs. 
After fixation the head was removed, the scalp dissected and the cranial bones peeled 
off using the hemostatic clamp. The brain was placed in a 5 ml labelled specimen tube 
containing 4 ml PFA and post fixed at 4°C for 48 h. The PFA was removed and 
replaced by a solution of 30% sucrose in PBS containing 1 mg/ml sodium azide as an 
anti-microbial agent and stored at 4°C. 
5.4.3 Tissue sectioning 
Each brain was sectioned using the cryostat (Microm HM 560). A razor blade was used 
to make a coronal cut through the cerebellum and the caudal surface of the brain was 
mounted and fixed on a cryostat chuck using tissue-tek (MICROM international GmbH). 
The chuck was then fixed to the head stage of the cryostat. The cryostat chamber was 
maintained at a temperature of -22ºC specimen and -20ºC knife. The tissue excess was 
trimmed until the anterior commissure was no longer continuous across the midline. 
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For collecting the tissue sample the free floating plate technique was used, which 
consisted of allocating the brain sections into wells of a multiwell plate filled with PBS 
0.1M, pH 7.4. 
When the anterior commissure was no longer continuous 22 sections were collected (50 
µm thick) from the forebrain region. These sections were collected in two sets (11 slices 
in each well for sample duplication). After the forebrain, 56 sections were cut and 
discarded until the midbrain was reached. In this area 40 sections were collected (20 
slices each well). 
During the sectioning, the atlas ‘Mouse Brain in Sterotaxic Coordinates’ (Paxinos, 
1996) was used as reference for the structures. The forebrain sections were collected 
from interaural line 3.58 mm/bregma -0.22 mm until interaural line 2.10 mm/bregma -
1.70 mm and for midbrain collected from interaural line 1.26 mm/bregma 2.54 mm until 
interaural line 1.40 mm/bregma 5.20 mm. 
The tissues samples were transferred from PBS into 5 ml labelled specimen tubes with 
cryoprotectant (150 ml ethylene glycol, 150 ml glycerol, 100 ml of 0.3 M (PBS) PH 7.2 
and 100 ml of deionised water) and stored in a freezer (-24ºC). 
5.4.4 Immunocytochemistry for visualising Fos protein expression 
Immunocytochemistry was carried out on one duplicate of the forebrain sections (11 
sections) and midbrain sections (20 sections) for each mouse. These sections were 
collected from the cryoprotectant liquid and washed with PBS 0.1M three times for 5 
min each. Next the sections were permeabilized for 30 min with 0.1% Triton X -100 
(Molekulay). After, the sections were placed for overnight incubation with polyclonal 
rabbit anti-Fos antiserum (Sc-52 Santa Cruz Biotechnology), diluted 1:300 in PBS 
containing 3% bovine albumin (Sigma Aldrich) and 0.1 M Lysine, (L-2,6 
Diaminohexanoic acid, monohydrochlorid FW 182.6) in a large cold room (4ºC). 
After overnight incubation, the sections were placed for warming back to room 
temperature (20ºC) for 30 min. Then the sections were washed three times for 5 min 
each. After, they were incubated for 2 h with biotinylated goat anti-rabbit secondary 
antibody affinity purified (1:100, Vector laboratories, UK). 
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Sections were washed again with PBS three times (10 min each) followed by 1 h 
incubation with Fluorescein Avidin D concentration 1:100 (Vector laboratories). During 
Fluorescein incubation the plate was covered with aluminium foil to protect it from the 
light. Finally, the sections were washed (three times for 10 min each). 
The sections were collected with a fine paint brush from the wells and mounted on to 
coated microscope slides and left to dry under aluminium foil for 15 min. The sections 
on the slide were then covered with a fine layer of Vectashield (hard set mounting 
medium containing the nuclear stain DAPI H-1500 from Vector Laboratories) followed 
by a cover glass (25x60 mm, 0.13-0.17 mm thick) and left to dry for 15 min. The 
mounted slides were then stored in plastic slide storage boxes in a fridge (4º). 
All washing was performed using a polystyrene plate with wells that were filled with 
PBS 0.1M (500 µl/well) using a glass Pasteur’s pipette whose sucking edge was 
narrowed with a Bunsen burner to avoid damaging the tissues. After filling with PBS 
the plate was covered with its lid and placed in a 3D Rocking Platform STRA (Stuart 
Scientific) at 30 revolutions/min. The brain slices were washed having a maximum of 3 
sections in each well. 
All the incubation procedures were performed with the plate placed on a 3D Rocking 
Platform STRA (Stuart Scientific) 30 revolutions/min. 
5.4.5 Image processing, visualization Fos detection and counting process 
For detecting and counting the number of Fos- positive neurones, a Leica DMRA 
fluorescence microscope model C4742-80-12AG was used, using filter set Cy7 and a 
digital image processing software for microscope, Axiovision 4.8. 
Firstly, the sections were observed in the microscope to detect where Fos was expressed. 
In the forebrain Fos protein expression was detected in the PVA, PVN and SON area. In 
the midbrain Fos was also detected in the PAG, but due to the inconsistent and small 
signal it was not counted. The PVA and SON were counted using 20x magnification 
and PVN using 10x magnification. In order to have the same size area counted, each 
structure was measured as shown in Figure 29 (PVA: 0.35 mm x 0.2 mm (A), PVN: 
0.75 mm x 0.25 mm for each side (B) and SON: length of area 0.3 mm and 0.01, 0.04 
and 0.02 widths). 
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All sections with Fos expression in the PVA, PVN and SON areas were counted. There 
were no more than four sections for each mouse containing Fos expression in the PVA 
and PVN, and no more than two sections for SON. The statistical analyses were carried 
out from the sum of expression contained in these sections. Therefore the results show 
total PVA, PVN and SON expression. ‘The Mouse Brain in Sterotaxic Coordinates’ 
(Paxinos, 1996) was used as a guide to confirm the identity of the structure being 
examined. Due to the thickness of the sections, the stained nuclei appeared in different 
focal planes. To solve this problem the counting was carried out twice for the same 
location using a different focus. When counting, the nuclei were marked with a cross 
using the computer program tool, therefore avoiding double-counting the neurones 
when changing the focus. 
 
 
 
 
 
 
 
Figure 29 - Surface area counted for c-fos expression. Paraventricular thalamic 
nucleus, anterior PVA: 0.35 mm x 0.2 mm (A), paraventricular nucleus of 
hypothalamus PVN: 0.75 mm x 0.25 mm for each side (B) and supraoptic nucleus SON: 
length of area 0.3 mm and and 0.02 width. 
 
5.4.6 Statistical analyses 
The statistical analyses was carried out for the forebrain areas, comparing the total 
number of Fos-positive nuclei with one way ANOVA for PVA, PVN, SON compared to 
vehicle (control). Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05. SigmaPlot 11. 
 
A B C 
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5.5 Results 
The immunohistochemistry analyses of the forebrain and midbrain showed the presence 
of Fos-positive neurones. However, in the midbrain Fos expression was not consistent 
and the signal was very small, which would make the counting potentially inaccurate. 
For this reason it was decided only to present qualitative analyses indicating the parts of 
the midbrain where the Fos protein was expressed. In the midbrain sections the Fos 
expression was observed for all treatments, but not for all individuals in the group 
(Table 38), and expression was located in the midbrain areas of dorsomedial 
periaqueductal grey (DMPAG), dorsal lateral periaqueductal grey (DLPAG) and 
ventrolateral periaqueductal grey (VLPAG) (Figure 30). 
The forebrain sections showed more consistent expression of Fos-positive neurones and 
for this reason it was possible to carry out quantitative analyses. Figure 31, Figure 32 
and Figure 33 show the regions analysed for the forebrain, which are the ventral regions 
of the paraventricular thalamic nucleus, anterior (PVA) (Figure 31), paraventricular 
nucleus of hypothalamus (PVN) (Figure 32) and the supraoptic nucleus (SON) Figure 
33). In each case expression was quantified for both sides of the brain. Analyses of Fos-
positive neurones in these parts showed a significant decrease of the expression of cells 
in the paraventricular nucleus of hypothalamus (PVN) for the groups treated with H. 
crenata 150 mg/kg (p.o.) after being through the acetic acid test (Figure 35, Table 39 
and Table 40). This reduction of Fos protein in the PVN is illustrated in Figure 37 
where it shows the difference in Fos expression when comparing mice treated with 
vehicle, HC 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.). However, for the other brain 
parts, PVA and SON, there was no significant difference in the level of expression 
when compared with the vehicle (Table 41 and Table 42). 
 PAG area (number of mice with detectable Fos expression) 
Treatments N DMPAG DLPAG LPAG VLPAG 
Vehicle 8 3 5 5 6 
HC 15 mg/kg 8 1 5 4 4 
HC 150 mg/kg 8 1 6 5 6 
Table 38 - Qualitative analysis of Fos expression observed in the mouse midbrain. 
Analysis in areas of dorsomedial periaqueductal grey (DMPAG), dorsal lateral 
periaqueductal grey (DLPAG) and ventrolateral periaqueductal grey (VLPAG), 
indicating number of mice with detectable Fos expression.  
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Figure 30 – Photomicrograph of midbrain areas. Photomicrograph of DAPI nuclear 
staining (A) and c-fos protein expression (B) observed in the DMPAG (1), DLPAG (2), 
LPAG (3) and VLPAG (4) FITC labelled (10 x magnification)  
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Figure 31 - Photomicrograph of paraventricular thalamic nucleus, anterior (PVA). 
DAPI nuclear staining (A) (10x magnification) and c-fos protein expression FITC 
labelled (B) (10x magnification) from the paraventricular thalamic nucleus, anterior 
(PVA) 
  
 
 
  
A 
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Figure 32 - Photomicrograph of paraventricular nucleus of the hypothalamus 
(PVN). DAPI nuclear staining (A) (10x magnification) and c-fos protein expression 
FITC labelled (B) (10x magnification) from the Paraventricular nucleus of the 
hypothalamus (PVN) 
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Figure 33 - Photomicrograph of supraoptic nucleus (SON). DAPI nuclear staining 
(A) (10x magnification) and c-fos protein expression FITC labelled (B) (10x 
magnification) from the supraoptic nucleus (SON) 
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Figure 34 – Number of c-fos positive neurons in the forebrain paraventricular 
thalamic nucleus, anterior (PVA). Mean ± S.E.M. of c-fos positive neurons in the 
forebrain paraventricular thalamic nucleus, anterior (PVA), of mice treated with vehicle 
(p.o.), H. crenata decoction extract dose 15 mg/kg (p.o.) and H. crenata decoction 
extract dose 150 mg/kg (p.o.).  
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Figure 35 – Number of c-fos positive neurons in the forebrain paraventricular 
nucleus of the hypothalamus (PVN). Mean ± S.E.M. of c-fos positive neurons in the 
forebrain Paraventricular nucleus of the hypothalamus (PVN), of mice treated with 
vehicle (p.o.), H. crenata decoction extract dose 15 mg/kg (p.o.) and H. crenata 
decoction extract dose 150 mg/kg (p.o.). * Analysis of Variance (ANOVA), multiple 
comparisons versus vehicle (Holm-Sidak method): Overall significance level = 0.05. 
SigmaPlot 11. 
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Figure 36 – Number of c-fos positive neurons in the forebrain supraoptic nucleus 
(SON). Mean ± S.E.M. of c-fos positive neurons in the forebrain supraoptic nucleus 
(SON), of mice treated with vehicle (p.o.), H. crenata decoction extract dose 15 mg/kg 
(p.o.) and H. crenata decoction extract dose 150 mg/kg (p.o.). 
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Treatment comparison Diff of Means t Unadjusted P Critical Level 
Vehicle vs. HC 150 mg/kg 156.5 2.668 0.014 0.025 
Vehicle vs. HC 15 mg/kg 29.875 0.509 0.616 0.05 
Table 39 - Multiple comparisons statistic of one way ANOVA for analyses of Fos 
expression in the PVN of mice after acetic acid injection. Animals treated with H. 
crenata (HC) decoction extract 15 and 150 mg/kg (p.o.) compared with vehicle (p.o.). 
 
Source of Variation  DF   SS   MS   F   P  Power 
Between Groups 2 110449.8 55224.875 4.014 0.033 0.515 
Residual 21 288932.3 13758.679    
Total 23 399382     
Table 40 - Output of one way ANOVA for analyses of c-fos expression in the PVN 
of mice after acetic acid injection. Animal groups treated with H. crenata (HC) 
decoction extract 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.) compared with vehicle (p.o.). 
 
 
Figure 37 - Effect of H. crenata decoction extract on Fos protein expression in the 
paraventricular nucleus of the hypothalamus (PVN) after noxious stimuli of acetic 
acid. Groups treated with vehicle (A), HC 15 mg/kg (B) and HC 150 mg/kg (C). 
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Source of 
Variation 
 DF   SS   MS   F   P  Power 
Between Groups 2 0.0248 0.0124 0.422 0.661 0.049 
Residual 21 0.617 0.0294    
Total 23 0.642     
Table 41 - Output of one way ANOVA for analyses of c-fos expression in the 
paraventricular thalamic nucleus, anterior (PVA) area of mice after acetic acid 
injection. Animal groups treated with H. crenata (HC) decoction extract 15 mg/kg 
(p.o.) and HC 150 mg/kg (p.o.) compared with vehicle (p.o.). All data points are n=8. 
 
Source of 
Variation 
 DF   SS   MS   F   P  Power 
Between Groups 2 0.0129 0.00644 0.186 0.832 0.049 
Residual 21 0.729 0.0347    
Total 23 0.741     
Table 42 - Output of one way ANOVA for analyses of c-fos expression in the SON 
area of mice after acetic acid injection. Animal groups treated with H. crenata (HC) 
decoction extract 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.) compared with vehicle (p.o.). 
All data points are n=8. 
 
5.6 Discussion 
The aim of this chapter was to investigate if the H. crenata decoction extract that 
previously showed significant effects in reducing writhing in the acetic acid test could 
also reduce the expression of Fos in specific areas of the midbrain and forebrain. 
In the midbrain, Fos expression was observed for all treatments, in a small number of 
neurones located in the dorsal lateral periaqueductal grey (DLPAG), dorsomedial 
periaqueductal grey (DMPAG) and ventrolateral periaqueductal grey (VLPAG). 
Observation of Fos in the periaqueductal grey was also reported by a number of groups 
(Snowball et al., 2000; Bianchi et al., 2003; Mitsui et al., 2003) using acetic acid to 
induce pain. In their study of Fos expression in the periaqueductal grey (PAG) of rats, 
Keay and Bandler (1993) described that deep noxious stimulation can lead to fos-
positive cells in the VLPAG while superficial noxious stimulation can led to fos-
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positive cells predominantly in the LPAG. Therefore we could suggest that, based on 
this information, the c-fos neurons present in the midbrain PAG ventrolateral areas of 
the mice in the present study indicated that they suffered deep noxious stimulation. 
In the forebrain, Fos expression was observed in the paraventricular thalamic nucleus, 
anterior part (PVA), paraventricular nucleus of hypothalamus (PVN) and supraoptic 
nucleus (SON). According to Ab Aziz and Ahmad (2006) the thalamus has a specialised 
structure that connects with multiple ascending pain pathways. It is involved in 
processing of nociceptive information before transmitting the information to various 
parts of the cortex. The hypothalamus is also involved in the sensory discrimination and 
motivational components of pain, and has substantial importance in modulation of stress 
activity (Fontes et al., 2011; Peter, 2011; Ueta et al., 2011). This study showed that the 
level of Fos expression in the PVA and SON was not affected by H. crenata extract. 
However, the higher dose of H. crenata extract significantly reduced Fos expression in 
the PVN (43% reduction). Thus, it is possible that H. crenata compounds could be 
decreasing the visceral pain that is transmitted to the PVN. However, the decrease of 
Fos in the PVN area was not significant for the lower dose of HC (15 mg/kg) that was 
effective in reducing writhing during the acetic acid test. The fact that PVN is also 
involved in stress activity could suggest that this c-fos decrease could be due to a 
potential anxiolytic effect induced by a particular compound that requires a higher dose 
in order to be active (Gao et al., 2010). 
Regarding conventional anaesthetic or other antinociceptive drugs acting to reduce c-fos 
in the PVN, there are several studies reporting such effects, including the results 
reported by Peng et al. (2009) described in the introduction of this chapter. The Peng 
group observed that Ligustici chuanxiong Hort essential oil was effective in reducing 
Fos expression in the brain stem and hypothalamus of mice that demonstrated an 
antinociceptive effect in the acetic acid inducing writhing test. However examination of 
the photomicrographs of Fos-immunoreactivity suggests that their data may have been 
compromised by an artefact of staining of red blood cells which contain a high level of 
endogenous peroxidase activity and can appear as a series of dark “immunoreactive” 
elements closely lined up. Therefore, the present study is the first to accurately measure 
the effect of a phytochemical on nociceptice responses using Fos expression. The study 
by Peng et al. (2009) also reported the effect of the treatment on prolonging the sleeping 
time induced by sodium pentobarbital, therefore suggesting that the plant compounds 
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also have sedative effect. The substances opiates, ethanol, cannabinoids, nicotine, 
cocaine and amphetamines have been described for inducing activation of the 
hypothalamic-pituitary-adrenal axis, with the consequent release of adrenocorticotropic 
hormone and glucocorticoids (Armario, 2010). Regarding reports about Fos expression 
in hypothalamic regions by cocaine and ethanol, contrary to H. crenata 150 mg/kg 
(p.o.), cocaine and ethanol increases c-fos expression in this forebrain area (Torres and 
Rivier, 1992; Westerman et al., 2010). Local anaesthetics, like lidocaine and 
bupivacaine, were reported for their inability to reduce c-fos expressed in the PVN after 
surgery, despite being able to reduce c-fos expression in the spinal cord (Stenberg et al., 
2005). This could indicate that although the H. crenata extract lower dose (HC 15 
mg/kg) did not reduce c-fos in the PVN area it could be reducing c-fos in the spinal cord 
area. However, because the spinal cord was not analysed in this study, this hypothesis 
could not be examined. 
Fos expression in the PVA and SON were unaffected by treatment with HC extract. 
Regarding the function described for these structures, there is mention that the PVA is 
involved in central sleep and circadian regulation (Salazar-Juarez et al., 2002) and its 
activation by acetic acid may relate to an arousal effect of this nociceptive agent. The 
SON is largely known for its role in water balance, through the release of vasopressin, 
and the control of sodium excretion (natriuresis) through release of oxytocin. It is likely 
that acetic acid represents an osmotic stimulus as well as a stress and pain stimulus that 
may underlie its activation. In relation to the SON, studies in rats described its 
functional connections with the stomach. In relation to antinociception it was reported 
that SON plays an important role in pain modulation and the hormone oxytocin secreted 
is involved in this effect (Lu et al., 2011; Yang et al., 2011). However it seems that the 
antinociceptive effects observed for H. crenata are not in connection with the pathway 
that would affect c-fos expression in these structures. 
The fact that these areas analysed, especially the PVN, are involved in multifunction 
activities raises doubt as to whether the c-fos expression observed was due to the pain 
induced by the acetic acid. This expression could be related to several activities, mainly 
because c-fos is not uniquely expressed in the pain condition; therefore this experiment 
would have more robust results if the experiment design had a group that did not receive 
the noxious stimulus by acetic acid. 
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5.7 Conclusions 
In conclusion, the present study demonstrated that, compared to the vehicle group, mice 
treated with H. crenata decoction extract at 150 mg/kg (p.o.) showed decreased c-fos 
protein expression in the paraventricular nucleus of the hypothalamus (PVN) following 
injection of acetic acid, a model of visceral nociception. This significant reduction of c-
fos expression was not observed for the lower dose 15 mg/kg (p.o.). 
So far, there is no conclusive study of a conventional antinociceptive drug that is 
effective in reducing c-fos expression in the PVN area. Therefore, the fact that there was 
a trend for dose dependence for c-fos reduction from H. crenata doses, but not a 
significant effect of c-fos reduction from 15 mg/kg that was effective in writhing 
reduction, could suggest that the c-fos reduction observed may not be due to 
antinociception but to another activity, probably anxiolytic or sedative. 
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Chapter 6. Analysis of COX Inhibition Activities from Hyptis crenata 
Decoction Extract 
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6.1 Introduction 
Some analgesic drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) have 
their effect through inhibition of the fatty acid cyclo-oxygenase enzyme (COX). The 
different variety of COX enzyme and its mechanisms on pain relief are described in 
Chapter 1. 
In order to investigate if the H. crenata antinociceptive effect is also related to COX 
inhibition, a COX inhibitor assay was performed. In this assay inhibition of COX-1 and 
2 was analysed. 
6.2 Material and methods: 
6.2.1 COX Inhibitor Screening Assay 
The samples were evaluated with a commercial kit, the Cayman chemical COX 
Inhibitor screening assay kit, item nº 560131. 
According to the Cayman description about this assay, the COX (ovine) inhibitor 
screening assay directly measures PGF2α (Prostaglandin F2α) by SnCL2 (Stannous 
Chloride) reduction of COX-derived PGH2 produced in the COX reaction. The 
prostanoid product is quantified via enzyme immunoassay (EIA) using a broadly 
specific antiserum that binds to all the major PG compounds. The assay includes both 
ovine COX-1 and human recombinant COX-2 enzymes. 
6.2.1.1 COX reaction procedure 
The first step in this assay was to aliquot the background samples in the test tubes 
(inactivate COX-1 and COX-2) and mix with heme. Next, heme was also added in the 
100% COX-1 and COX-2 tubes and the same procedure was carried out for the COX-1 
and COX-2 tubes with H. crenata extraction. The tubes were incubated for ten minutes 
at 37°C, the reaction was initiated by adding arachidonic acid to the tubes, and it was 
vortex and incubated for two min. The next procedure was to add HCl (1M) to the tubes 
in order to stop the enzyme catalysis, the tubes were removed from the bath and 
stannous chloride was added to set-up the reaction product and reduce it in a form to be 
analysed. After, the tubes were incubated for five minutes at room temperature. 
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6.2.1.2 Enzyme immunoassay procedure (EIA) 
Firstly, the EIA buffer, wash buffer and standards were prepared. Then, the background, 
COX 100% initial activity and HC extract previously prepared in the COX reaction 
procedure were diluted . The background samples were diluted by adding 10 µl of the 
previously prepared background samples (Background COX-1 or COX-2) to a tube 
containing 990 µl of EIA buffer (BC1 or BC2). The BC1 or BC2 tube contained a 1:100 
dilution of the original sample. 
The COX 100% Initial Activity samples were diluted by adding 10 µl of the previously 
prepared COX 1 or COX 2 100% Initial Activity sample to 990µl of EIA buffer (IA1). 
Next 50 µl of IA1 dilution was added to another tube containing 950µl of EIA buffer 
(IA2). Then, 500 µl of tube IA2 was added to another tube containing 500 µl. Therefore, 
tube IA2 contained 1:2000 dilution of the original sample and tube IA3 contained 
1:4000 dilution of the original sample (IA1). 
The COX inhibitor samples (H. crenata samples), previously prepared were diluted 
following the same procedure for COX 100% Initial Activity, however its dilutions 
were called C1, C2 and C3. The C2 and C3 tubes contained 1:2000 and 1:4000 dilution 
respectively of the original sample (C1). 
The next procedure was to add the samples to the plate well coated with mouse anti-
rabbit IgG. The plate wells were composed of blank, non-specific binding, maximum 
binding, PG standards, background COX-1 and COX-2, 100% initial activity samples 
and the HC extract dilutions (88 wells, Figure 38). Finally, the AChE tracer and 
antiserum were added to the specific wells. The Plate was incubated at room 
temperature for eighteen hours on an orbital shaker, rinsed five times with wash buffer, 
developed with Ellman’s Reagent and read on a microplate reader (Thermo Lab 
Systems, Multiscan Asent) at 410 nm. 
The percent inhibition was calculated using the Cayman analysis tool spreadsheet, the 
calculation was also checked by Brooke Kilyanek, M.S. Cayman technical support 
representative. 
There were some samples that were not calculated due to high % B/B0 
(%Bound/Maximum Bound). For this reason the number of samples per group is 
different. 
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Figure 38 - Layout of the samples set on the plate for which the absorbance was 
measured for the COX inhibition assay. COX 1 and COX 2 inhibitors evaluated 
(Hyptis crenata decoction (HC) samples and HC fractions containing dilution of 
C2=1:2000 and C3=1:4000), COX1 and COX 2 background (dilution of 1:100), COX 1 
and COX 2 100% activity (dilution of 1:2000 and 1:4000), Blank, NSB=non-specific 
binding, BO=maximum binding, TA=total activity and Std=standards. 
 
6.2.2 H. crenata samples concentration 
The same decoction extract and fractions of decoction extract that were used in the 
antinociceptive test carried out on the mice were also used in this assay. The procedures 
for the H. crenata decoction extraction and fractions are described in the methodology 
section of Chapter 3. 
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6.2.3 H. crenata decoction extract 
The concentration used to start the assay and the final concentration applied in the well, 
presented in Table 43, were based on the same concentration given to the mice in the 
antinociceptive tests (HC 1500 µg /10 ml and HC 15000 µg /10 ml). However instead of 
using water as a solvent, the reaction buffer provided in the COX inhibition kit was 
used. 
 
H. crenata treatments 
Start concentration HC 
µg/10 ml reaction buffer 
Final concentration of 
HC µg per 50 µl 
applied in the well 
Decoction extract lower 
dose (HCl) 1500 µg 0.00097µg 
Decoction extract higher 
dose (HCh) 15000 µg 0.00978 µg 
Table 43 - Start concentration for performing COX reactions and final 
concentration of H. crenata decoction applied in the plate wells in the COX 
inhibition screening assay 
 
In addition, HC fractions were evaluated, the concentration used to start the assay and 
the final concentration applied in the well, presented in Table 44, were based on the 
same concentration given to the mice in the antinociceptive tests (HC Hexane fraction 
210 µg/10 ml, HC DCM fraction 400 µg/10 ml, HC Methanol 1480 µg/10 ml and HC 
Water fraction 2300 µg/10 ml). The water and Tween 80 used as a solvent in the animal 
experiment were substituted by the reaction buffer provided in the COX inhibition kit. 
 
© Newcastle University 2013 159 
H. crenata treatments, 
Fractions/Solvent 
Start concentration HC 
fractions µg/10 ml 
reaction buffer 
Final concentration of 
HC µg per 50 µl 
applied in the well 
Hexane fraction 210 µg 0.00013 µg 
DCM fraction 400 µg 0.00026 µg 
Methanol fraction 1480 µg 0.00096 µg 
Water fraction 2300 µg 0.0015 µg 
Table 44 - Start concentration for performing COX reactions and final 
concentration of H. crenata decoction fractions applied in the plate wells in the 
COX inhibition screening assay 
 
The data were analysed using one-way ANOVA and when the overall P-value was 
<0.05 Tukey’s multiple pairwise comparison test was used to test if any of the results 
for any extracts or fractions were different from others. 
6.3 Results 
In general the results of this assay showed imprecise data due to problems with the 
sensitivity of the test that was caused by the samples’ dilution (too diluted) and low 
inhibition by the positive control 100% initial activity. The problem was mainly 
observed for the evaluation of COX-1 inhibition where the ANOVA was non-
significant (Table 45) and none of the samples presented any difference from the control 
value (see Figure 39). If anything the lower HC concentration, hexane, DCM and 
methanol fractions seemed to be activating COX-1 instead of inhibiting it. 
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Source of 
Variation 
 DF   SS   MS   F   P  Power 
Between Groups 6 33665.91 5610.985 1.141 0.381 0.075 
Residual 17 83602.31 4917.783    
Total 23 117268.2     
Table 45 - Multiple comparisons statistic of one way ANOVA for COX-1 inhibition. 
Control group (100% initial activity) n=4 versus H. crenata decoction 1500 µg/ml 
(HCl) N=3, H. crenata decoction 15000 µg/ml (HCh) N=3 and H. crenata decoction 
fractions hexane 210 µg/ml (HexFrac) N=4, DCM fraction 400 µg/ml (DCMFrac) N=3, 
methanol fraction 1480 µg/ml (MetFrac) N= 4 and water fraction 2300 µg/ml (WatFrac) 
N=4. One way ANOVA (Holm-Sidak method), overall significance level = 0.05. 
 
Figure 39 – Effect of HC decoction fractions on COX-1 inhibition. Mean+ standard 
deviation of COX-1 inhibition for the control (100% initial activity) n=4, H. crenata 
decoction 1500 µg/ml (HCl) n=3, H. crenata decoction 15000 µg/ml (HCh) n=3 and H. 
crenata decoction fractions hexane 210 µg/ml (HexFrac) n=4, DCM fraction 400 µg/ml 
(DCMFrac) n=3, methanol fraction 1480 µg/ml (MetFrac) n= 4 and water fraction 2300 
µg/ml (WatFrac) n=4. 
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Regarding COX-2 the ANOVA did show significance (Table 46), so even though none 
of the samples showed difference from the control, all H. crenata treatments seemed to 
inhibit COX-2 but it is not possible to suggest which of the samples is more effective or 
if there is a dose dependence effect from the higher and lower dose of the decoction 
(Figure 40). For example, while the H. crenata decoction extracts in a start 
concentration of 1500 µg inhibited 41% of COX-2 and the higher concentration 15000 
µg inhibited 83%, as shown in Figure 40, the standard deviations were too high to 
distinguish between the two doses. The corresponding inhibition values for the fractions 
were: hexane (61%), DCM (56%), methanol (72%) and water (63%). 
 
Source of 
Variation 
 DF   SS   MS   F   P  Power 
Between Groups 6 13731.2 2288.533 3.31 0.046 0.525 
Residual 10 6914.477 691.448    
Total 16 20645.68     
Table 46 - Multiple comparisons statistic of one way ANOVA for COX-2 inhibition. 
Control group (100% initial activity) N =4 versus H. crenata decoction 1500 µg/ml 
(HCl) N=3, H. crenata decoction 15000 µg/ml (HCh) N=3 and H. crenata decoction 
fractions hexane 210 µg/ml (HexFrac) N=4, DCM fraction 400 µg/ml (DCMFrac) N=5, 
methanol fraction 1480 µg/ml (MetFrac) N = 3 and water fraction 2300 µg/ml 
(WatFrac) N=2. One way ANOVA (Holm-Sidak method), overall significance level = 
0.05. 
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Figure 40 - Effect of HC decoction fractions on COX-2 inhibition. Mean+ standard 
deviation of COX-2 inhibition for the control (100% initial activity) N=4, H. crenata 
decoction 1500 µg/ml (HCl) N=3, H. crenata decoction 15000 µg/ml (HCh) N=3 and H. 
crenata decoction fractions hexane 210 µg/ml (HexFrac) N=4, DCM fraction 400 µg/ml 
(DCMFrac) N=5, methanol fraction 1480 µg/ml (MetFrac) = 3 and water fraction 2300 
µg/ml (WatFrac) N=2. 
 
6.4 Discussion 
The aim of this experiment was to investigate whether H. crenata compounds that 
showed to have demonstrated antinociceptive properties would affect prostaglandin 
levels in a COX inhibitor screening assay. Despite the problems with the sensitivity of 
this assay, the results indicate that H. crenata treatments may be effective to inhibit 
COX-2, while the results for COX-1 showed that none of the fractions or extracts had 
any inhibitory effect, although for most of them some of the samples showed negative 
inhibition. According to an explanation from a Cayman technician, the negative 
inhibition values may mean that the H. crenata compound is actually activating COX-1. 
Treatments
Control HCl HCh HexFrac DCMFrac MetFrac WatFrac
%
 i
n
h
ib
it
io
n
 o
f 
C
O
X
2
0
20
40
60
80
100
© Newcastle University 2013 163 
However, it may also mean that there was something in the H. crenata decoction 
sample that interfered with the assay. There are no reports in the literature about Hyptis 
increasing or decreasing COX-1 activity. 
In contrast, the inhibition of COX-2 seems to be more plausible, and there are reports 
about Hyptis compounds inhibiting COX-2 activity (Kuhnt et al., 1995b; Raymundo et 
al., 2011). However, all H. crenata fractions induced this effect at a similar level, in 
contrast to the antinociceptive results observed in the animal test which shows that 
hexane fraction was the most active fraction and DMC fraction, which obtained COX 
inhibition value of 56% in this assay, was inactive in the antinociceptive tests. There are 
two possible explanations for this result; firstly this assay may not have been sensitive 
enough to detect the difference between the fractions. It is also possible that even if 
compounds with COX-2 inhibition activity are present in the extracts and fractions, the 
antinociceptive properties observed for H. crenata in the in vivo experiment may not be 
due to COX-2 inhibition, or at least this may not be the main mechanism responsible for 
the effect, for example if COX-2 inhibitors have low oral bioavailability or are degraded 
during digestion.  
When considering the possibility of all fractions to inhibit COX-2, it could indicate that 
there are several H. crenata compounds that are able to induce this effect or that the 
effect is produced by one particular compound that is present in all decoction fractions. 
The compounds that appear in all decoction fractions and could be involved in the COX 
- 2 inhibition are: rosmanol isomer nº 53, carnosic acid nº 66, methyl epirosmanol nº 71 
and 72 (Chapter 7, Table 48). Besides, some of these compounds, carnosol and carnosic 
acid, have already been reported for inhibiting COX-2 (Lai et al., 2009; Bauer et al., 
2012). 
Other compounds that are present in the decoction extract and distributed in its fractions 
have been reported for inhibiting COX-2, these compounds are vicenin-2 isomer, 
apigenin isomer, scutellarein O-methyl ether isomer, and carnosol isomer (Kim et al., 
2004; Lai et al., 2009; Dos Santos et al., 2010; Suou et al., 2011; Bauer et al., 2012; Oh 
et al., 2012). It is possible that the compound inhibiting COX-2 in these non-
antinociceptive active fractions could be compounds that have low bioavailability and 
absorption in the animal gut, but could be effective when evaluated in the COX 
inhibition in vitro assay (Hu, 2007). 
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Regarding the COX-1 activation, supposing that it actually occurred, there is a possible 
explanation for this activity based in the results of the traditional use survey (Chapter 2). 
The main use of H. crenata decoction was for stomach pain, this could indicate that 
there are compounds in the extract that are increasing COX-1 and enhancing 
endogenous prostaglandin production, since it has been shown in the literature that it 
induces gastric protection (Kleine et al., 1993). Therefore, it could contribute to the 
stomach pain relief, and this could also explain the gastroprotective effects reported for 
the species H. spicigera and H. mutabilis (Barbosa and Ramos, 1992; Takayama et al., 
2011). In addition, if considering that this COX 1 activation would be occurring, the 
COX assay result presented in this thesis suggested that the majority of these 
theoretically gastroprotective compounds, or the most active compounds for this effect, 
may be in the hexane, DCM and methanol fractions.  
Although these results for COX-1 should be interpreted with caution as the findings 
might not be reliable, the fact that there is an indication that H. crenata inhibits COX-2 
and not COX-1, could indicate a positive potential for H. crenata, since there is a great 
interest in COX-2 selective compounds for clinical use (Baykal and Gök, 2002). 
However, it is important to emphasize that overall, the COX assay result presented in 
this thesis is very preliminary and might not be reliable, therefore it should be repeated. 
6.5 Conclusions 
The results for this assay suggest that H. crenata extract dose at concentration of 1500 
µg/ml and 15000 µg/ml and its decoction fractions may be inhibitors of COX-2. In 
addition, the extract and mainly the water fractions could be increasing COX-1 
activities. However, it may also mean that there are compounds in the sample that are 
interfering with the assay and giving false-positive results, for this reason a repetition of 
this experiment would be highly recommended to confirm this results. 
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Chapter 7. Chemical analyses of Hyptis crenata decoction and its 
fractions 
 
 
© Newcastle University 2013 166 
7.1 Introduction 
As described in Section 1.4.4, the only chemical information reported about H. crenata 
species is related to its volatile compounds. However for the studies reported in this 
thesis the volatile compounds were not tested since the treatments used were from 
lyophilised hot water extract and the fractions were also prepared from this lyophilised 
extract which had lost almost all the volatile compounds present in the plant material. 
Other reasons for not evaluating the extract with volatile compounds was that the 
volatiles have been reported to have considerable variation according to the place that 
Hyptis plants grow, as described in the traditional use chapter (Section 2.3.3). In 
addition it was reported in the traditional use survey that the plant could be collected at 
any time of the year. Together with information about the common preparation methods 
(which do not retain the volatiles) this indicates, that the volatile compounds were not 
crucial for the plant’s possible antinociceptive effects. Evaluation of the lyophilised 
extract and its fraction on two animal models for antinociceptive response demonstrated 
antinociceptive effects for the decoction extract and the hexane fraction had enhanced 
bioactivity. In order to find out which chemical compounds were present in the H. 
crenata decoction extract and its fractions, chemical analysis was carried out using 
liquid chromatography–mass spectrometry (LC-MS). 
7.2 Material and methods 
7.2.1 LC-MS 
The analysis was carried out by Dr Melanie Jayne Howes and her plant chemistry 
analytical team at Jodrell Laboratory in Kew Gardens, Richmond, Surrey. The 
equipment used was a High-performance liquid chromatograph machine, thermo 
Scientific Surveyor and Mass spectrum Pump (HPLC-MS), Thermo Scientific ‘LTQ-
Orbitrap XL’ Linear Ion Trap-Orbitrap, with full scan m/z 250-2000, equipped with an 
electrospray ionisation unit (positive model). The LC column was a Phenomenex Luna 
C18, 150 mm x 3 mm, 3 μm. The column was eluted by using gradient of water : 
methanol : acetonitrile containing 1% formic acid [400 μl/min: 90:0:10 (t=0min), 
0:90:10 (t=20min), 0:90:10 (t=25min), 90:0:10 (t=27min), 90:0:10 (t=30min)], column 
temperature 30°C. 
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For the analyses, H. crenata decoction lyophilised extract and its dried fractions 
(hexane fraction, DCM fraction, methanol fraction and water fraction) were used. Due 
to the potential for some solvents to affect the LC column and chromatography, 
dichloromethane and hexane were not used to reconstitute the HC decoction fractions; 
100% water was also not used to reconstitute the HC decoction and HC decoction 
fractions, due to the potential for microbial contamination prior to analysis. 
Concentrations were based on the amount available and solubility. The preparation 
details were as shown in Table 47. The injection volume for all samples tested was 5µl. 
 
Extract / fraction solvent concentration (mg/ml) 
HC decoction extract 50% methanol 10 
HC hexane fraction 70% ethanol 4 
HC DCM fraction 70% ethanol 9 
HC methanol fraction 100% methanol 6 
HC water fraction 50% methanol 10 
Table 47 - Concentration of HC treatments analysed in the HPLC-MS 
 
The result of the hexane fraction was chosen for comparing with the decoction extract in 
order to find out which compounds were enriched after the fractionation process. To 
make this comparison the chromatograms graph (Figure 41 and Figure 42) and the 
detection table report (Table 48) were used. The reason for selecting the hexane fraction 
rather than the other fractions is because it was the most active which gave a maximum 
bioactivity by weight of dry material, as shown in the Hargreaves test and acetic acid 
test results. 
7.2.2 Calculation of compound concentration and enrichment % 
The compounds’ peaks were measured from chromatograms printed on A3 size paper, 
the areas under the peaks were calculated considering the shape of each peak as a 
triangle, therefore the area was calculated as ½ x base x height. When more than one 
compound was present within a single peak due to them having the same or similar 
retention times, and they were therefore not distinguishable from each other, the total 
area of the peak was divided by the number of compounds in order to obtain an estimate. 
In order to calculate the % of weight, the molecular weights were corrected for cations 
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(Na+, NH4+ or H+), and then the proportion of weight was calculated (=compound 
area/total area of compounds x compound molecular weight). The enrichment of the 
fraction was calculated as = (amount of extract /amount of fraction) x (concentration of 
compound in the fraction/concentration of compound in the extract). 
7.3 Results 
In total 91 compounds, including their isomers, were detected from the HPLC-MS 
analyses for HC decoction extract and its fractions. In the decoction extract 88 
compounds were detected. For the fractions; 16 compounds were detected in the hexane 
fraction, 31 compounds in the DCM fraction, 53 compounds in the methanol fraction 
and 25 compounds in the water fraction (Table 48). 
As shown in Table 48, the five most prevalent compounds in the decoction were the 
diterpene trilobiol (nº 64) which accounted for 30.4% of the total mass, the isomers of 
phenolic terpene methyl epirosmanol (nº 71,72,74,75 and 80; 17,5% of mass), the c-
glycosylflavonoid, isoshaftoside (nº 10; 4.5% of mass) and an unidentified diterpenoid 
(nº 58; 4.4% of mass). In the hexane fraction the major compounds were: the isomers of 
phenolic compound carnosol/hyptol (nº 76,78 and 84; 34.5% of mass), methyl rosmanol 
isomers (nº 71 and nº 72; 30.6%), rosmanol and its isomers (nº 52,53,63;15.6% of mass), 
and isomers of a derivative of hydroxylabdanolidoic acid (nº 83 and 85; 18% of mass). 
When comparing the HC decoction fraction with the hexane fraction, there are some 
compounds that were enriched with the hexane fractionation process. The compound 
phenolic diterpene (nº 84) was the most enriched with this fractionation, since in the 
decoction results it appears as trace and in the hexane chromatogram it is one of the 
major compounds. Another compound enriched by this process was 
hydroxylabdanolidoic acid derivative (nº 85), although not as much as phenolic 
diterpene (nº 84). There is an unassigned compound (nº 4) that is only detected in the 
hexane fraction although this only composed 0.6% of the mass. The compound trilobiol 
(nº 64), dominant in the decoction extract, was not present in the hexane fraction 
(Figure 41 and Figure 42). 
The only compound that appears in the HC decoction and in all fractions is methyl 
epirosmanol isomers (nº 71 and 72), although it only appears as a trace in the DCM 
fraction. 
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The majority of different compounds present in the DCM fraction are terpenoid 
derivative, although the most concentrated compounds are carnosol isomers (67.2% of 
the mass) and rosmanol isomers (23.1% of mass) (Table 48). The carnosol isomers (nº 
81 and nº 82) were enriched by the DCM fractionation and were not detected in other 
fractions. Another interesting observation about this fraction is that the compound 
salviregnone (n
o
 90) was identified in this sample but not in the decoction extract, this 
could indicate that this compound was just a trace and was enriched with the 
fractionation. 
The methanol fraction contained a wide variety of compounds present in the original 
decoction extract. The most prevalent compounds were: Rosmanol and its isomers (nº 
52 and 53; 32.1% of mass), trilobiol (nº 65; 23% of mass), methyl epirosmanol (nº 71, 
72, 74 and 75; 11.8% of mass), isoschaftoside (nº 10; 5.9% of mass). The greatest 
enrichment occurred for one of the rosmanol peaks (nº 53; 12.3 x enrichment over the 
decoction) and a trace compound clemomandshuricoside B (nº 38) which only 
comprised 0.4% of the mass but was 6.9 times enriched over the decoction. 
For the water fraction the most prevalent compounds were: trilobiol (nº 64; 29.7% of 
mass), the flavonoid glycoside, vicenin-2 (nº 6; 27.7% of mass) and 
shaftoside/isoschaftoside (nº 10 and 11; 14.4% of mass). The greatest enrichement was 
observed with vicenin-2 which was 8.5 x enriched over the decoction. 
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Figure 41 - HPLC-MS chromatogram of decoction extract. Chromatogram showing relative abundance, retention time and mass-to-charge (m/z) of 
compounds 
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Figure 42 - HPLC-MS chromatogram of HC hexane fraction. Chromatogram showing relative abundance, retention time and mass-to-charge (m/z) 
of compounds 
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1 6.5 Coumaroyl hexoside 2.0 ND ND 0.5 ND 0.2 0.0 0.0 0.0 0.0 0.074 0.000 0.000 0.000 0.000 0.0 0.0 0.2 0.0 
2 6.7 Creoside I (or isomer)  1.0 ND ND 0.5 ND 0.1 0.0 0.0 0.0 0.0 0.035 0.000 0.000 0.000 0.000 0.0 0.0 0.3 0.0 
3 6.9 Unassigned compound 0.5 ND 1.5 0.5 ND 0.0 0.0 0.1 0.0 0.0 0.013 0.000 0.004 0.000 0.000 0.0 3.4 0.7 0.0 
4 7 Unassigned compound ND 3.1 ND ND ND 0.0 0.6 0.0 0.0 0.0 0.000 0.013 0.000 0.000 0.000 ND NC ND ND 
5 7.2 Unassigned compound 0.5 ND 2.5 ND ND 0.0 0.0 0.2 0.0 0.0 0.013 0.000 0.006 0.000 0.000 0.0 5.6 0.0 0.0 
6 7.4 Vicenin-2 (or isomer) 21.8 ND ND 9.0 49.0 3.3 0.0 0.0 4.7 27.7 1.468 0.000 0.000 0.693 6.365 0.0 0.0 1.4 8.5 
7 7.5 Unassigned compound 21.8 3.0 3.5 9.0 ND 1.3 0.3 0.2 1.8 0.0 0.563 0.007 0.009 0.266 0.000 0.3 0.2 1.4 0.0 
8 7.9 Benzyl disaccharide  0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.2 0.0 0.023 0.000 0.000 0.026 0.000 0.0 0.0 3.5 0.0 
9 8 Vicenin-2 (or isomer) 0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.3 0.0 0.034 0.000 0.000 0.038 0.000 0.0 0.0 3.5 0.0 
10 8.2 Isoschaftoside 31.5 ND ND 12.0 13.0 4.5 0.0 0.0 5.9 7.0 2.018 0.000 0.000 0.877 1.603 0.0 0.0 1.3 1.6 
11 8.5 Schaftoside 13.0 ND ND 5.0 13.8 1.9 0.0 0.0 2.5 7.4 0.833 0.000 0.000 0.365 1.696 0.0 0.0 1.3 4.0 
12 8.9 Unassigned compound 1.1 ND 0.5 ND ND 0.1 0.0 0.0 0.0 0.0 0.037 0.000 0.002 0.000 0.000 0.0 0.5 0.0 0.0 
13 8.9 Benzyl pentoside derivative 1.1 ND ND 0.5 1.5 0.1 0.0 0.0 0.1 0.3 0.031 0.000 0.000 0.016 0.079 0.0 0.0 1.5 5.0 
14 9.1 Neoisoschaftoside 0.5 ND ND 0.5 0.5 0.1 0.0 0.0 0.2 0.3 0.032 0.000 0.000 0.037 0.062 0.0 0.0 3.5 3.8 
15 9.3 Neoschaftoside 20.0 ND ND 8.0 11.0 2.8 0.0 0.0 3.9 5.9 1.281 0.000 0.000 0.585 1.357 0.0 0.0 1.4 2.1 
16 9.6 Apigenin methyl ether pentosyl hexoside 0.5 ND ND ND 0.5 0.1 0.0 0.0 0.0 0.3 0.033 0.000 0.000 0.000 0.063 0.0 0.0 0.0 3.8 
17 9.7 Vitexin  6.0 ND ND 0.5 1.5 0.7 0.0 0.0 0.2 0.6 0.294 0.000 0.000 0.028 0.142 0.0 0.0 0.3 0.9 
18 10 Isovitexin 2.5 ND ND ND 0.5 0.3 0.0 0.0 0.0 0.2 0.123 0.000 0.000 0.000 0.047 0.0 0.0 0.0 0.8 
19 10.3 Luteolin glycoside derivative 2.5 ND ND 0.5 0.5 0.4 0.0 0.0 0.3 0.3 0.173 0.000 0.000 0.040 0.067 0.0 0.0 0.7 0.8 
20 10.4 Sesquiterpenoid derivative 2.5 ND 0.5 0.5 ND 0.2 0.0 0.0 0.1 0.0 0.072 0.000 0.001 0.016 0.000 0.0 0.2 0.7 0.0 
21 10.4 Apigenin dipentoside 2.5 ND ND 0.5 2.0 0.3 0.0 0.0 0.2 1.0 0.152 0.000 0.000 0.035 0.234 0.0 0.0 0.7 3.0 
22 10.5 Apigenin acetyl-hexoside derivative  10.0 ND ND 4.5 4.5 1.6 0.0 0.0 2.5 2.7 0.722 0.000 0.000 0.371 0.626 0.0 0.0 1.6 1.7 
23 10.7 Apigenin methyl ether pentosyl hexoside  0.5 ND ND 0.5 0.5 0.1 0.0 0.0 0.3 0.3 0.033 0.000 0.000 0.037 0.063 0.0 0.0 3.5 3.8 
24 10.9 Apigenin dipentoside 1.1 ND ND 0.5 0.5 0.2 0.0 0.0 0.2 0.3 0.068 0.000 0.000 0.035 0.058 0.0 0.0 1.5 1.7 
25 11.2 Hydroxyluteolin pentoside 6.0 ND ND 3.0 1.9 0.7 0.0 0.0 1.1 0.8 0.296 0.000 0.000 0.169 0.178 0.0 0.0 1.7 1.2 
26 11.6 Rosmarinic acid 0.5 ND ND 0.5 0.5 0.0 0.0 0.0 0.2 0.2 0.020 0.000 0.000 0.023 0.039 0.0 0.0 3.5 3.8 
27 11.6 Apigenin O-glycoside 0.5 ND ND ND ND 0.1 0.0 0.0 0.0 0.0 0.023 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
28 11.7 Sesquiterpenoid derivative 0.6 ND 0.5 ND ND 0.0 0.0 0.0 0.0 0.0 0.017 0.000 0.001 0.000 0.000 0.0 1.0 0.0 0.0 
29 11.8 Diterpenoid derivative  0.6 ND 0.5 0.5 ND 0.0 0.0 0.0 0.1 0.0 0.022 0.000 0.002 0.021 0.000 0.0 1.0 3.0 0.0 
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30 11.8 Megastigmenone glycoside derivative 0.6 ND ND 0.5 0.5 0.1 0.0 0.0 0.2 0.2 0.025 0.000 0.000 0.024 0.041 0.0 0.0 3.0 3.2 
31 12 Salvianolic acid B, E or L (or isomer) 0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.3 0.0 0.041 0.000 0.000 0.047 0.000 0.0 0.0 3.5 0.0 
32 12.1 Megastigmenone glycoside derivative 0.5 ND ND 0.5 ND 0.0 0.0 0.0 0.2 0.0 0.021 0.000 0.000 0.024 0.000 0.0 0.0 3.5 0.0 
33 12.2 Epoxylignan derivative 1.3 ND 4.0 0.5 0.5 0.1 0.0 0.4 0.2 0.2 0.049 0.000 0.016 0.023 0.038 0.0 3.6 1.4 1.5 
34 12.5 Megastigmene glycoside derivative 0.5 ND ND 0.5 ND 0.0 0.0 0.0 0.2 0.0 0.022 0.000 0.000 0.025 0.000 0.0 0.0 3.5 0.0 
35 12.6 Labdanone / kaurenone diterpenoid 0.5 ND 0.5 ND ND 0.0 0.0 0.1 0.0 0.0 0.021 0.000 0.002 0.000 0.000 0.0 1.1 0.0 0.0 
36 12.9 Sesquiterpenoid derivative 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 0.014 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
37 13.1 Labdanone / kaurenone diterpenoid 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 0.021 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
38 13.2 Clemomandshuricoside B (or isomer) 0.5 ND ND 1.0 ND 0.1 0.0 0.0 0.4 0.0 0.029 0.000 0.000 0.065 0.000 0.0 0.0 6.9 0.0 
39 13.5 Diterpenoid 2.3 ND 6.3 2.0 ND 0.2 0.0 0.6 0.6 0.0 0.081 0.000 0.022 0.082 0.000 0.0 3.1 3.1 0.0 
40 13.7 5-Deacetoxy-5'-epiolguine (or isomer) 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 0.018 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
41 13.8 Megastigmadienone glycoside derivative 0.5 ND ND ND ND 0.1 0.0 0.0 0.0 0.0 0.023 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
42 13.9 Germacradiene derivative (salviadienol B or isomer) 0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.2 0.0 0.031 0.000 0.000 0.036 0.000 0.0 0.0 3.5 0.0 
43 14.1 Pervoside B (or isomer) 9.0 ND ND 0.8 3.0 0.8 0.0 0.0 0.2 1.0 0.364 0.000 0.000 0.035 0.234 0.0 0.0 0.3 1.3 
44 14.2 Scutellarein O-methyl ether 9.0 ND 8.1 3.0 ND 0.7 0.0 0.7 0.8 0.0 0.307 0.000 0.028 0.117 0.000 0.0 1.0 1.2 0.0 
45 14.4 Nonyl hydroxybenzoate derivative 0.5 ND 0.5 ND ND 0.0 0.0 0.0 0.0 0.0 0.015 0.000 0.001 0.000 0.000 0.0 1.1 0.0 0.0 
46 14.5 Martiusane (or isomer) 4.5 ND 0.5 0.5 ND 0.4 0.0 0.0 0.1 0.0 0.163 0.000 0.002 0.021 0.000 0.0 0.1 0.4 0.0 
47 14.7 Diterpenoid  1.4 ND ND 0.5 ND 0.1 0.0 0.0 0.1 0.0 0.053 0.000 0.000 0.022 0.000 0.0 0.0 1.2 0.0 
48 14.8 Diterpenoid 1.4 ND ND 0.5 ND 0.1 0.0 0.0 0.2 0.0 0.059 0.000 0.000 0.024 0.000 0.0 0.0 1.2 0.0 
49 14.9 Diterpenoid  1.4 ND 2.8 0.5 ND 0.1 0.0 0.3 0.1 0.0 0.053 0.000 0.010 0.022 0.000 0.0 2.2 1.2 0.0 
50 14.9 Labdenone diterpenoid  1.4 ND 2.8 2.0 ND 0.1 0.0 0.3 0.6 0.0 0.056 0.000 0.011 0.091 0.000 0.0 2.2 4.9 0.0 
51 15.3 Hydroxylabdanolidoic acid derivative (norambreinolide-18,6-olide or isomer) 9.4 ND ND 2.0 ND 0.7 0.0 0.0 0.5 0.0 0.296 0.000 0.000 0.072 0.000 0.0 0.0 0.7 0.0 
52 15.5 Rosmanol / isorosmanol / epi-rosmanol / epi-isorosmanol 9.0 24.0 42.0 2.0 ND 0.8 3.9 4.1 0.6 0.0 0.354 0.082 0.164 0.090 0.000 5.0 5.2 0.8 0.0 
53 16.1 Rosmanol / isorosmanol / epi-rosmanol / epi-isorosmanol 29.3 49.5 111.0 104.0 ND 2.6 8.1 10.9 31.5 0.0 1.153 0.170 0.434 4.663 0.000 3.2 4.2 12.3 0.0 
54 16.2 Rosmanol / isorosmanol / epi-rosmanol / epi-isorosmanol 29.3 ND ND ND 4.5 2.6 0.0 0.0 0.0 1.5 0.000 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.6 
55 16.3 Maoecrystal V (or isomer) 29.3 ND ND ND ND 2.4 0.0 0.0 0.0 0.0 1.153 0.000 0.000 0.000 0.341 0.0 0.0 0.0 0.0 
56 16.9 Scutellarein di-O-methyl ether 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 1.100 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
57 17.1 Rosmaquinone (or isomer) 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 0.018 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
58 17.2 Diterpenoid  46.3 ND ND ND 10.0 4.4 0.0 0.0 0.0 3.6 0.020 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.8 
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59 17.5 Eudesmenone or labdanolide derivative 0.5 0.5 ND ND ND 0.0 0.1 0.0 0.0 0.0 1.976 0.000 0.000 0.000 0.822 1.9 0.0 0.0 0.0 
60 17.5 Epoxyabietrienone methyl ether derivative 0.5 ND ND 0.5 ND 0.0 0.0 0.0 0.2 0.0 0.000 0.000 0.000 0.000 0.000 0.0 0.0 3.5 0.0 
61 17.6 Diterpenoid  0.5 ND 0.5 ND ND 0.0 0.0 0.0 0.0 0.0 0.017 0.001 0.000 0.000 0.000 0.0 1.1 0.0 0.0 
62 17.6 Epoxyabietrienone methyl ether derivative 0.5 ND ND ND ND 0.0 0.0 0.0 0.0 0.0 0.021 0.000 0.000 0.024 0.000 0.0 0.0 0.0 0.0 
63 17.8 Rosmanol / isorosmanol / epi-rosmanol / epi-isorosmanol 11.0 22.0 52.5 ND ND 1.0 3.6 5.1 0.0 0.0 0.019 0.000 0.002 0.000 0.000 3.7 5.3 0.0 0.0 
64 18.2 Trilobiol (or isomer)  154.5 ND ND 33.8 40.0 30.4 0.0 0.0 23.0 29.7 0.021 0.000 0.000 0.000 0.000 0.0 0.0 0.8 1.0 
65 18.4 Diterpenoid  0.5 ND 0.5 ND ND 0.0 0.0 0.0 0.0 0.0 0.432 0.076 0.205 0.000 0.000 0.0 1.1 0.0 0.0 
66 18.4 Carnosic acid / 7,20:11,20-diepoxy-7,8-seco-8,11,13-abietatriene-7,14-diol / 
horminone (or isomer)  
0.5 0.5 0.5 0.5 0.5 0.0 0.1 0.0 0.1 0.2 13.691 0.000 0.000 3.411 6.824 1.9 1.1 3.5 3.8 
67 18.6 Diterpenoid  0.5 ND 33.0 ND ND 0.0 0.0 3.1 0.0 0.0 0.019 0.000 0.002 0.000 0.000 0.0 73.9 0.0 0.0 
68 18.6 Triterpenoid  0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.2 0.0 0.019 0.002 0.002 0.022 0.036 0.0 0.0 3.5 0.0 
69 18.7 Methyl epirosmanol / oxoinuroyleanol (or isomer) ND ND ND ND 4.0 0.0 0.0 0.0 0.0 1.4 0.019 0.000 0.125 0.000 0.000 ND ND ND NC 
70 18.8 Rosmaquinone A or B (or isomer) 0.5 ND ND 0.5 ND 0.0 0.0 0.0 0.2 0.0 0.029 0.000 0.000 0.034 0.000 0.0 0.0 3.5 0.0 
71 19 Methyl epirosmanol / oxoinuroyleanol (or isomer) 61.0 90.0 0.5 16.0 6.8 5.5 15.3 0.1 5.0 2.3 0.000 0.000 0.000 0.000 0.315 2.8 0.0 0.9 0.4 
72 19.1 Methyl epirosmanol / oxoinuroyleanol (or isomer) 61.0 90.0 0.5 16.0 6.8 5.5 15.3 0.1 5.0 2.3 0.020 0.000 0.000 0.023 0.000 2.8 0.0 0.9 0.4 
73 19.3 Salvidorol (or isomer) 0.5 ND 17.0 ND ND 0.0 0.0 1.5 0.0 0.0 2.495 0.322 0.002 0.746 0.532 0.0 38.1 0.0 0.0 
74 19.4 Methyl epirosmanol / oxoinuroyleanol (or isomer) 34.7 ND ND 3.0 ND 3.2 0.0 0.0 0.9 0.0 2.495 0.322 0.002 0.746 0.532 0.0 0.0 0.3 0.0 
75 19.5 Methyl epirosmanol / oxoinuroyleanol (or isomer) 34.7 ND ND 3.0 ND 3.2 0.0 0.0 0.9 0.0 0.018 0.000 0.061 0.000 0.000 0.0 0.0 0.3 0.0 
76 19.6 Carnosol / hyptol (or isomer) 34.7 76.0 ND ND ND 2.9 11.9 0.0 0.0 0.0 1.418 0.000 0.000 0.140 0.000 4.1 0.0 0.0 0.0 
77 19.6 Epoxykaurene derivative 34.7 ND ND 3.0 ND 3.6 0.0 0.0 1.1 0.0 1.418 0.000 0.000 0.140 0.000 0.0 0.0 0.3 0.0 
78 19.7 Carnosol / hyptol ( or isomer) 34.7 76.0 180.3 ND ND 2.9 11.9 16.8 0.0 0.0 1.300 0.249 0.000 0.000 0.000 4.1 5.8 0.0 0.0 
79 19.8 Abietadi- or tri-ene derivative  34.7 ND ND 3.0 ND 3.4 0.0 0.0 1.0 0.0 1.599 0.000 0.000 0.158 0.000 0.0 0.0 0.3 0.0 
80 19.9 Methoxynepetaefolin derivative (or isomer) 0.5 ND ND 0.5 ND 0.1 0.0 0.0 0.2 0.0 1.300 0.249 0.673 0.000 0.000 0.0 0.0 3.5 0.0 
81 20 Carnosol / hyptol (or isomer) 0.5 ND 180.3 ND ND 0.0 0.0 16.8 0.0 0.0 1.536 0.000 0.000 0.152 0.000 0.0 403.8 0.0 0.0 
82 20.1 Carnosol / hyptol 0.5 ND 180.3 ND ND 0.0 0.0 16.8 0.0 0.0 0.025 0.000 0.000 0.028 0.000 0.0 403.8 0.0 0.0 
83 20.5 Hydroxylabdanolidoic acid derivative 11.5 68.7 ND ND ND 0.8 9.0 0.0 0.0 0.0 0.019 0.000 0.673 0.000 0.000 11.2 0.0 0.0 0.0 
84 20.6 Carnosol / hyptol (or isomer) 0.5 68.7 180.3 ND ND 0.0 10.7 16.8 0.0 0.0 0.019 0.000 0.673 0.000 0.000 257.2 403.8 0.0 0.0 
85 20.7 Hydroxylabdanolidoic acid derivative 9.0 68.7 ND ND 10.0 0.6 9.0 0.0 0.0 2.6 0.363 0.190 0.000 0.000 0.000 14.3 0.0 0.0 4.2 
86 20.8 Methyl pisiferate (or isomer) 0.5 0.5 ND ND ND 0.0 0.1 0.0 0.0 0.0 0.019 0.225 0.673 0.000 0.000 1.9 0.0 0.0 0.0 
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87 20.8 Arucadiol / hydroxy-miltirone (or isomer) 8.5 ND ND ND ND 0.6 0.0 0.0 0.0 0.0 0.284 0.190 0.000 0.000 0.608 0.0 0.0 0.0 0.0 
88 21.5 Ethylrosmanol / epi-ethylrosmanol (or isomer) 0.5 ND 28.0 ND ND 0.0 0.0 3.0 0.0 0.0 0.019 0.002 0.000 0.000 0.000 0.0 62.7 0.0 0.0 
89 21.7 Abietane diterpenoid derivative 0.5 0.5 0.5 ND ND 0.0 0.1 0.0 0.0 0.0 0.288 0.000 0.000 0.000 0.000 1.9 1.1 0.0 0.0 
90 22.1 Salviregnone (or isomer) ND ND 21.8 ND ND 0.0 0.0 1.7 0.0 0.0 0.021 0.000 0.118 0.000 0.000 ND ND NC ND 
91 22.8 Esquirolin B / suaveololi (or isomer) 0.5 0.5 0.5 0.5 ND 0.0 0.1 0.0 0.1 0.0 0.000 0.000 0.000 0.000 0.000 1.9 1.1 3.5 0.0 
Table 48 - Concentration of compounds present in the H. crenata decoction extract and enrichment of its fractions (hexane, DCM, methanol 
and water). DecExt= Decoction extract, HexFrac= Hexane fraction, DCMFrac=DCM fraction, MetFrac=Methanol fraction, WatFrac=Water fraction. 
ND= Compound not detected, NC= Not calculated due not detection of compound in the decoction extraction. Area mm
2 
= Measurement of compound 
peak’s area on the HPLC-MS chromatogram. Amount % weight = Percentage of compound amount according to the total mass of compounds in the 
sample. Conc. = Amount of H. crenata’s dry matter in the sample. Enrichement = Proportion of enrichement of the fraction over decoction extract. 
Some of the compounds presented in this table, such as N
o
 53, 54, 71 and 72 have the same molecular formula and molecular weight, however they 
could not be distinguished because no reference compounds were available to compare them with (the retention times and MS data). For this reason 
these compounds appear more than once in the table. 
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7.4 Discussion 
This study investigated which compounds are present in the H. crenata preparations 
tested. The results have shown the presence of 91 compounds, some of which were also 
reported in other Hyptis species. These compounds are apigenin, carnosic acid, carnosol, 
esquirolin B, hyptol, martiusane, methoxynepetefolin derivative, rosmarinic acid and 
salvigenin, as shown in the Hyptis genus compounds table in Appendix A. Therefore, 
through the results of this project 82 compounds were described that are unknown to the 
knowledge of the Hyptis genus chemical profile. 
The compounds present in the hexane fraction will be the main focus of this discussion 
since this fraction was the most potent treatment tested. There were 15 compounds 
enriched by this fractionation. The highest enrichment observed was for carnosol/hyptol 
followed by hydroxylabdanolidoic acid and rosmanol. However if compared with other 
fractions tested, which were less active than the decoction itself, there are 7 compounds 
that are more enriched by hexane fractionation. These compounds are eudesmenone (n
o 
59), methyl epirosmanol (n
o 
71 and n
o 
72), carnosol/hyptol (n
o 
76), 
hydroxylabdanolidoic acid derivative (n
o 
83 and n
o 
85) and methyl pisiferate (n
o 
86). 
With the exception of compounds 71, 72 and 85, the other compounds are only present 
in the hexane fraction. It is possible that one compound, some compounds or the entire 
hexane composition could be contributing to the antinociceptive effect observed, in 
particular those selectively enriched by the hexane fractionation. Therefore, the next 
step of this study should be to isolate these compounds and test them separately, using 
the hexane fraction as a positive control. The results might indicate if any of these 
isolated compounds would be more potent than the hexane fraction. If the fraction were 
to be the most potent, then it could be proposed that compounds are enhancing each 
other’s effects, therefore it could be a synergistic activity.  
The fact that in the thermal antinociceptive test the water fraction was significantly 
effective, but the methanol fraction was not, could eliminate the possibility that 
compounds 71 and 72 were the ones responsible for the antinociceptive effect, since 
their concentration in the methanol fraction is higher than in the water fraction. 
Therefore, it could be suggested that the effect observed from the water fraction could 
be induced by other compounds such as vicenin-2 (n
o
 6), which had a high enrichment 
within the water fraction. Besides, vicenin-2 has been already reported for this effect 
(Gorzalczany et al., 2011). Another potential compound that might be inducing the 
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effect observed from both fractions is hydroxylabdanolidoic acid derivative (n
o
 83), 
since it is present in both fractions but with higher concentration in the hexane fraction. 
Among these compounds described in the hexane fraction, carnosol derivative followed 
by rosmanol derivative are the most mentioned compounds in the literature. The 
compound carnosol was first observed in the species Rosmarinus officinalis L as well as 
the compound rosmanol (Wenkert et al., 1965; Nakatani and Inatani, 1981). After these 
reports, carnosol has been described in several species, some of these species are Salvia 
officinalis, Origanum majorana, Origanum vulgare, Dorystoechas hastate and Sphacele 
chamaedryoides (Abreu et al., 2008; Areche et al., 2009b; Farhat et al., 2009; Erkan et 
al., 2011; Bauer et al., 2012; Cui et al., 2012; Hossain et al., 2012; Walch et al., 2012). 
The compound rosmanol, which is a abietane diterpene, is also commonly found in the 
Salvia species (Djarmati et al., 1992; Miura et al., 2001; Guerrero et al., 2006; Máthé et 
al., 2007; Cui et al., 2012). These two compounds are also mentioned in the literature 
for their pharmacological activities as antidepressant, gastroprotective, neuroprotective 
and anti-inflammatory effects (Izumi et al., 2007; Areche et al., 2009a; Beninca et al., 
2011). However only carnosol is reported for antinociceptive activities (Rodrigues et al., 
2012). 
As shown in Table 48, compound n
o 
76 may be a hyptol rather than a carnosol 
derivative. Hyptol is not widely known in relation to its pharmacology, so far there is no 
report about it. However its structure is described from chemical studies with the 
species H. fructicosa (Monache et al., 1977). 
Hydroxylabdanolidoic acid derivative, one of the most enriched compounds in the 
hexane fraction, as well as the other less enriched compounds methyl pisiferate (n
o 
86) 
and eudesmenone (n
o
 59), are also not widely known. Hydroxylabdanolidoic acid was 
reported for the Lamiaceae subfamilie nepetoideae (CCD, 2012), the name labdane 
comes from the Mediterranean shrub Cistus ladaniferus which secretes a dark brown 
resin containing α-pinene and 8β hydroxyl labdan -15-oic acid (Breitmaier, 2006). 
Labdanoic acid is found in high concentrations in the leaves of Aristolochia giberti 
which is widely used in Brazilian tradition medicine (Marchesini et al., 2009). Methyl 
pisiferate had been reported as a diterpene from the Chamaecyparis pisifera species 
(Yatagai and Takahashi, 1979), whereas eudesmenone compounds have only been 
reported as components of vetiver oil. 
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7.5 Conclusions 
Based on the enrichement calculation for the hexane fractionation, it can be concluded 
that there are possible compounds that might play a important role in the antinociceptive 
effect observed. These compounds are hydroxylabdanolidoic acid, methyl epirosmanol, 
carnosol or hyptol and methyl pisiferate derivative. 
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Chapter 8. General Discussion, concluding remarks and 
recommendations 
 
 
© Newcastle University 2013 180 
8.1 General discussion 
8.1.1 Medical plants, past and future 
Plants and man, through the process of evolving, have always kept a close relationship. 
There are many ways that man uses the benefits offered by plants and one of them is the 
medicinal properties obtained from metabolites of defence against environmental 
conditions produced in the plant. Over the years mankind learned about which species 
could be used and their activities, therefore there are thousands of medicinal plants that 
are traditionally used and thousands of different uses. Because the effects obtained 
could not be reasonably explained, throughout history they have been associated with 
magic, god beliefs and mysticism. However, with the evolution of medicine and 
chemistry the medicinal properties of plants are finally being properly explained. This 
started with the discovery of morphine in 1804, unveiling the main key behind the effect 
of Papaver somniferum (Klockgether-Radke, 2002). After this event, the interest grew 
in screening medicinal plants for therapeutic compounds, however the aim was 
primarily towards compound synthesis (Borris, 1996). 
Therefore, this era of synthesis left a legacy of drugs in the market for which the active 
compound is based on a medicinal plant substance. However, in more recent years, 
there has been a new focus on the use and commercialisation of medicinal plants in the 
form of developing phythotherapeutics and perhaps this is the future for the use of 
medicinal plants as medication (Desmarchelier, 2008). A phythotherapeutic product is 
the result of preparation of a medicinal plant using standard methods and controlling the 
quality and quantity of compounds in order to deliver safer and more efficient plant 
medication (Calixto, 2000). The use of phythotherapeutics and nutraceutics, which is 
also part of herbal therapy, has been widely accepted in the United States, Europe and 
Asia (Iriti et al., 2010). In Brazil, since 2008, the Brazilian National Health System 
(Sistema Unico de Saude -SUS) has included phythotherapeutics as part of their list of 
medication to be distributed in sixteen federal states, which contains six medicinal 
plants for producing these phythotherapeutics (SUS, 2010). However, the number of 
plants included on the list is very small when compared to the diversity of medicinal 
plants found in Brazil (da Cunha and Bortolotto, 2011). The main reason why there is 
not a larger number of medicinal plants that can be used as phythotherapeutics is due to 
a lack of pharmacological information about the species. One such species is Hyptis 
crenata Pohl. 
© Newcastle University 2013 181 
8.1.2 The traditional use survey and its contribution to this study 
Species from the Hyptis genus have been in traditional use for generations and some 
Hyptis species have shown pharmacological activities in pre-clinical trials. However, 
there has been no pharmacological study of H. crenata, and the fact that it was used 
traditionally as medicine could indicate potential therapeutic activities. Considering the 
benefits of knowing details about its use and method of preparation, before carrying out 
pharmacological trials, the first step of this project was to carry out a small traditional 
use survey. The results showed that this plant is mainly used for the relief of pain and 
there are seven different ways to prepare the plant, with each method extracting a 
different concentration and type of compounds, in this case volatile and phenolic 
compounds. Despite there being a previous survey about the traditional use of H. 
crenata published during the course of this thesis (De Jesus et al., 2009), the researchers 
only reported one method of preparation and without details of its procedure. Therefore, 
this thesis is the first to suggest that temperature and solvent, which varied according to 
the different method of preparation, have an important role in determining the amount 
and type of H. crenata compounds obtained. 
The next step of this project was to choose which of these extracts would be suitable to 
test for its antinociceptive properties. Although it could be interesting to investigate 
whether all these different methods would induce antinociception, in order to minimise 
the number of animals used and because it was a proof of principle investigation, it was 
decided to test the method of preparation that was the most recommended by the 
interviewees. For this study it was decided not to test the volatiles due to their low level 
in the decoction when compared with other extraction methods mentioned in the 
traditional use survey. This could indicate a preference by the users for the lowest 
amount of this type of compound in the preparation. This preference could suggest that 
these compounds are not important for the effect or there is a risk of toxicity related to 
them. This theory may be more likely when the reports of poisoning caused by camphor, 
which was one of the main volatiles found in these different preparations, are taken into 
consideration (Manoguerra et al., 2006; Bhaya and Beniwal, 2007a). Although volatile 
compounds in Hyptis have been demonstrated to induce antinociception (Menezes et al., 
2007; Arrigoni-Blank et al., 2008; Franco et al., 2011; Raymundo et al., 2011), the data 
presented in this thesis clearly demonstrated that H. crenata treatment not containing 
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volatile compounds efficiently induced antinociception from thermal and chemical 
noxious stimuli. 
8.1.3 The antinociceptive effect of H. crenata and possible anxiolytic effect 
This study showed that H. crenata extract dose-dependently increased the threshold for 
peripheral thermal stimuli and visceral chemical stimuli, but it is still unclear where the 
site of action for the active compounds is. However, the fact that H. crenata was shown 
to be effective in both of these animal models could suggest that its treatment can 
inhibit pain transmitted through Aδ and C fibres, as Aδ is especially involved in the 
thermal pain response measured in the Hargreaves test and C fibres are the main pain 
connection for the animal model of peritoneo-visceral chemical stimuli (Calvino et al., 
1984; Le Bars et al., 2001). Because C fibres are also the main fibres involved in 
chronic pain sensation (Ørstavik et al., 2003), for future studies it would be interesting 
to evaluate H. crenata treatment for chronic pain symptoms. Indeed, the fact that this 
plant treatment dose-dependently decreased c-fos in the hypothalamus after acetic acid 
stimulus would make this prospect for a chronic pain trial even more attractive, since 
this decrease in neurone activity in the hypothalamus suggests that H. crenata 
effectively reduced the stress caused by the pain sensation (Galli et al., 2009). Another 
recommendation for the future evaluation of H. crenata would be to investigate its 
effect against headache like migraine, since the hypothalamus plays an important role in 
the mechanism for this symptom (Matharu, 2007). In addition, the fact that headache 
was one of the symptoms that are treated with H. crenata reported in the traditional use 
survey further supports this proposal. 
The fact that only the higher dose tested (HC 150 mg/kg (p.o.)) significantly reduced c-
fos activity could indicate that the compound(s) responsible for this effect has a lower 
concentration compared to the others that compose the chemical profile of H. crenata. 
Because anxiety stimuli increase c-fos in the PVN (see Chapter 5), while anxiolytic 
compounds decrease this expression (Zahner et al., 2007), this compound may be 
decreasing c-fos through an anxiolytic effect, since the antinociceptive action in the 
acetic acid test HC 15 mg/kg (p.o.) was as effective as the higher dose, therefore in 
theory both should have the same effect if only pain was influencing the c-fos level. The 
compound that was observed in H. crenata samples, and that would most likely fit these 
descriptions is the derivative of flavonoid shaftoside, which is also found in the species 
Passiflora incarnata L and has been described as an anxiolytic and sedative (Wohlmuth 
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et al., 2010). A simple approach for future study to find out if this compound or other 
compounds is/are responsible for the c-fos activity decrease, would be to analyse the 
brain of animals treated with H. crenata fractions after performing the acetic acid test. If 
the effect only appears for the methanol and water fractions, and the effect of the water 
fraction is stronger than that of the methanol fraction, it is likely that shaftoside 
derivative could be the compound involved, since this compound is more concentrated 
in the water fraction. Although shaftoside derivative has been reported as a sedative, it 
seems that it is not having this effect according to the behavioural results presented in 
this thesis from animals treated with the H. crenata extract. However, the anxiolytic 
effect of the extract was not analysed, therefore from these results it is not possible to 
affirm if this plant does or does not induce this activity, although is possible to propose 
a likelihood based on the c-fos reduction induced by the extract and supported by the 
fact that there is another species of Hyptis that was confirmed to have this effect in a 
pre-clinical trial (Bueno et al., 2006). 
8.1.4 Possible H. crenata compounds involved in the antinociceptive effect 
The results in this thesis showed that in both animal models for thermal and visceral 
nociception the most active H. crenata treatment was the hexane fraction. Interestingly, 
this fraction was the one with the smallest amount of dry material (2.1 mg/kg (p.o.)), 
and this suggests that the compounds that constitute the hexane fraction are more 
involved in the mechanism of pain relief. The compounds that have the highest 
enrichment in the hexane fraction were carnosol (nº 84), hydroxylabdanolidoic acid (nº 
85) and rosmanol (nº 52). 
Previous work evaluating rosmanol derivatives suggested that it performs an important 
role as an anti-inflammatory agent by inhibiting the activity of transcription factors NF-
κB and STAT3 that play a key role in regulating COX-2 and inducible nitric oxide 
synthase (INOs) gene expression. It was also proposed that this inhibition is through 
suppression of phosphorylation and degradation of IκB, which is part of the NF-kB 
transduction cascade (Lai et al., 2009). The enzyme COX-2 catalyses prostaglandin E2 
production and INOs synthetises nitric oxide, both molecules are pro-inflammatory and 
pain mediators (Koch et al., 2007; Tassorelli et al., 2007). Hence, these reports imply 
that the antinociceptive effect observed from H. crenata treatment could involve 
inhibition of both these enzymes, but mainly COX-2 since its activity increases during 
the acetic acid test. In addition, carnosol also has been reported as a COX-2 inhibitor. 
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The mechanism of COX-2 inhibition by carnosol has been clearly elucidated in the 
literature. This compound inhibits microsomal prostaglandin E Synthase-1 (mPGES-1), 
which is a COX-2 promoter. This process is achieved by interruption of the protein 
kinase C signalling which consequently affects the binding of the activator protein-1 
(AP-1) to the cyclic adenosine monophosphate response for mPGES-1 (Subbaramaiah 
et al., 2002; Samuelsson et al., 2007; Bauer et al., 2012). However, when considering 
the fact that the concentrations of carnosol (nº 84) and rosmanol derivatives (nº 52) 
were higher in the DCM fraction sample than the hexane fraction and the fact that 
thermal and visceral antinociception evaluations showed that the DCM fraction was 
much less active than the hexane fraction, it could indicate that although these 
compounds might be having some effect, they are not the most important compounds in 
the sample responsible for the antinociceptive effect observed. On the other hand, it is 
likely that this role might be played by eudesmenone (nº 59), methyl epirosmanol (nº 71 
and nº 72), carnosol/hyptol isomer (nº 76), hydroxylabdanolidoic acid derivative (nº 83 
and nº 85) and methyl pisiferate (nº 86), since the concentrations of these compounds 
are higher in the hexane fraction when compared to the DCM fraction. 
Searches of the literature were made to identify whether there were biological activities 
reported for these compounds. There are reports of methyl epirosmanol identified in 
other Hyptis species (Urones et al., 1998; Araujo et al., 2005), as well as a report of an 
antioxidant and anti-inflammatory study from Salvia namaensis containing this 
compound (Kamatou et al., 2010). However, there were no reports about the biological 
activities of the other compounds. Regarding the Salvia namaensis anti-inflammatory 
study, in contrast to rosmanol as discussed earlier, the treatment containing methyl 
epirosmanol was uneffective against inflammation. Therefore, it could indicate that this 
compound might be a specific antinociceptive agent. 
In hypothesis that these compounds might be the ones responsible for the 
antinociceptive effect and that the concentration of compound enrichment might play an 
important role in the antinociceptive effect, the enrichement of these compounds in the 
hexane, methanol and water fractions were compared. As the hexane fraction was the 
most potent in the Hargreaves test, and the water fraction was also effective, it could be 
expected that concentration of the active compounds should be highest in the hexane 
fraction, less high in the water fraction and lowest in the methanol fraction. Therefore, 
the only compound that would fit this profile is hydroxylabdanolidoic acid (nº 85). 
© Newcastle University 2013 185 
On the other hand, it is also possible that the effect induced by the water fraction could 
be induced by a compound not present in the hexane fraction. In this case, the most 
likely compounds inducing the antinociceptive effect observed in the hexane fraction 
would be compounds nº 59, nº 71, nº 72, nº 76, n
o 
83, n
o 
85 and n
o 
86. 
However, there is another possibility that involves the potential of carnosol (which had 
the highest concentration in the hexane fraction and has been reported as having 
antinociceptive effect) being the active compound if considering the fact that the hexane 
fraction had fewer compounds than the other inactive fractions. It is possible that the 
fact that the DCM fraction also had this compound in such a high concentration, but not 
the effect, could be due to another compound that is inhibiting or antagonizing the 
action of carnosol (Rowland and Tozer, 2011). Therefore, perhaps other compounds 
present in hexane fraction are not playing an important role as antinociceptive, they are 
just being inactive, allowing rosmanol and carnosol to induce their effect. Alternatively 
it could be that a number of compounds in the hexane fraction are active, but because 
they are pain specialised they would work in a synergetic way amplifying the 
antinociception effect that was slightly observed in the water fraction. 
It is also possible that the effect observed in the Hargreaves test and in the acetic acid 
test could be obtained by two different mechanisms that were induced by different 
compounds. Carnosol and rosmanol for example, could be inhibiting PGE 2 in the 
peritoneal fluid in the acetic acid test and the other compounds could be acting to inhibit 
the withdrawal reflex promoted by Aδ fibres in the Hargreaves test. A future 
methodological consideration would be to measure the level of prostaglandin in the 
peritoneal fluid of mice treated with the hexane fraction and its isolated compounds 
after injection of acetic acid. In addition it would be recommended to evaluate these 
treatments together with naloxone to examine if this opioid antagonist would reverse the 
antinociceptive effects (Chahl, 1996; Dawood and Khan-Dawood, 2007). An opioid 
effect was suggested for other Hyptis species using this approach (Bispo et al., 2001; 
Santos et al., 2007b), although it was not shown which Hyptis compounds might be 
inducing this effect. 
8.1.5 Possible anti-inflammatory effect of H. crenata 
When searching in the literature for antinociceptive and anti-inflammatory effects 
reported for the compounds presented in the H. crenata treatments, it was found that 
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there are eleven compounds (vicenin-2, apigenin, vitexin, luteolin, rosmarinic acid, 
salvianolic acid, scutellarein, rosmanol, carnosic acid, suaveolol and carnosol) that have 
been reported as anti-inflammatory agents (Hu and Kitts, 2004; Van Dross et al., 2005; 
Chen et al., 2006b; Scheckel et al., 2008; Lai et al., 2009; Marrassini et al., 2011). The 
fact that 12 % of H. crenata compounds are reported to have anti-inflammatory effects 
indicates the possibility for H. crenata treatment to have this activity. In addition, 
carnosic acid and suaveolol have already been reported as responsible for the anti-
inflammatory effect observed in H. verticillata and H. brevipes (Shenoy and Shirwaikar, 
2002; Grassi et al., 2006; Raederstorff et al., 2008). For this reason, it would be 
recommended to investigate H. crenata treatment in an animal model to evaluate its 
anti-inflammatory effect. 
8.1.6 Contribution of this thesis to the chemistry of Hyptis genus  
So far, the majority of chemical compounds reported for the Hyptis genus, and 
especially for H. crenata, are volatile compounds obtained from essential oils. One of 
the motives for mainly studying volatile compounds is due to the fact that they are 
relatively easy to be identified, since the equipment most commonly used is GC-MS 
which is more accessible than HPLC-MS. For this reason, 82 compounds reported in 
this study were not available in the literature for Hyptis species. Therefore, knowledge 
of the chemistry of this genus has been improved. 
8.2 Concluding remarks and recommendations 
As the current pain relief treatments available in the market are still failing to treat some 
pain symptoms (Jensen and Finnerup, 2007), and the fact that people are looking for 
more “natural” treatments for symptoms like menstrual pain which is suffered by 50% 
of worldwide female population (Dawood, 2006), it might be recommended to evaluate 
H. crenata as a possible phytotherapeutic in a clinical trial for this symptom, since it 
was effective against visceral pain and it has indicated to inhibit prostagladin E2, which 
is one of the pain mediators amplified during this symptom (Hayes and Rock, 2002). 
If H. crenata would be evaluated as a possible phytotherapeutic in a clinical trial, firstly 
it would be recommended to carry out a detailed toxicology analysis of the plant. 
Secondly, the treatment to be evaluated should be the hexane fraction for its potency or 
the aqueous decoction extract, prepared at a concentration of 50g/l, heating it until it 
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boiled (5 min boiling). In addition, the compounds hydroxylabdanolidoic acid 
derivative, methyl epirosmanol isomer, rosmanol isomer, eudesmenone derivative, 
methyl pisiferate and carnosol isomer present in the hexane fraction are the possible 
compounds to be used as markers for the extract standardisation. 
Taken together, H. crenata has potential as a pain relief treatment and also as a potential 
anti-inflammatory treatment. Its effect and mechanism should be further investigated in 
order to find out its site of action in the pain and anti-inflammatory pathways and to 
investigate which specific compounds are responsible for this effect. Therefore for 
future studies it would be recommended to test each of those compounds that are in the 
hexane fraction and evaluate their activities. 
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Appendix A – Hyptis crenata Chemical Compounds 
 
 
  
Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Abietadi- or tri-ene 
derivative 
C22H30O6 Not found 390.1936 H. crenata (present work) Anti-inflammatory 
activities(Pferschy-Wenzig et al., 
2008) 
Abietane diterpenoid 
derivative 
C21H28O3 Not found 328.193 H. crenata (present work) Not described
A 
Apigenin acetyl-hexoside 
derivative 
C29H32O16 
 
636.1761 H. crenata (present work) Not mentioned 
Apigenin dipentoside C25H26O13 
 
534.1445 H. crenata (present work) Not mentioned 
Apigenin methyl ether 
pentosyl hexoside 
C27H30O14 Not found 578.1713 H. crenata (present work) Not mentioned 
Apigenin O-glycoside C20H18O9 
 
402.1024 H. crenata (present work) Not mentioned 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Apigenin C15H10O5 
 
270.2 H. albida 
H. capitata 
(Peredamiranda and Delgado, 
1990; Almtorp et al., 1991) 
H. crenata (found in the 
present work but with different 
molecular weight). 
Antinociceptive and Anti-
inflammatory (Magalhaes et al.) 
Arucadiol / hydroxy-
miltirone (or isomer) 
C19H22O3 
 
298.1459 H. crenata (present work) Not mentioned 
Benzyl disaccharide C18H26O10 
 
402.187 H. crenata (present work) Not mentioned 
Benzyl pentoside derivative C12H16O5 Not found 240.0891 H. crenata (present work) Not mentioned 
Borneol 
endo-1,7,7-Trimethyl- 
bicyclo[2.2.1]heptan-2-ol 
C10H18O 
 
154.2 H. emoryi 
H. crenata 
(Sheth et al., 1972; Pino et al., 
2002) and present work. 
Convulsant* (Quintans et al.) 
Anti-inflammatory (Juhas et al., 
2008) 
Antinociceptive (Martinez et al., 
2009) 
Modulator of GABA action* 
(Granger et al., 2005) 
HA and 5-HT in rat's hypothalamus 
(Li et al., 2004) 
Inhibitors on N-(3,5-
dichlorophenyl) succinimide 
nephrotoxicity* (Hong et al., 1999) 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Camphor 
1,7,7-
Trimethylbicyclo[2.2.1]hep
tan-2-one 
C10H16O 
 
152.2 H. suaveolens 
H. emoryi 
H. crenata 
(Sheth et al., 1972; Scramin et 
al., 2000; Joy et al., 2008; 
Rebelo et al., 2009) and 
present work. 
Hypotension and myocarditis 
(Hempel et al., 2005; Bhaya and 
Beniwal, 2007b) 
Antinociceptive (Taniguchi et al., 
1994) 
Anti-inflammatory (Yoon et al.) 
Antiproliferative and antitumor 
(Loizzo et al.) 
Antispasmodic activity (Astudillo et 
al., 2004) 
Enhancement of neutrophil activity 
(Chao et al., 2005) 
Carnosic acid C20H28O4 
 
332.4 H. dilatata 
(Urones et al., 1998) 
H. crenata (present work) 
Antinociceptive and Anti-
inflammatory (Qnais et al.) 
NF Kappa B Activities (anti-
inflammatory)* (Yu et al., 2009) 
Cytotoxic activities (Costa et al., 
2007; Nga et al., 2007) 
Activators of the human 
peroxisome proliferator-activated 
receptor gamma (Rau et al., 2006) 
Carnosol  
1,3,4,9,10,10aS-hexahydro-
5,6-dihydroxy-1,1-
dimethyl-7-isopropyl-2H-
9S,4aR-
(epoxymethano)phenanthre
n-12-one 
C20H26O4 
 
330.4 H. dilatata 
H. martiusii 
(Urones et al., 1998; Costa-
Lotufo et al., 2004) 
H. crenata (present work) 
Anti-inflammatory (Poeckel et al., 
2008) 
NF-Kappa B inhibition* (Anti-
inflammatory) (Lian et al.) 
Neuroprotective effects (Tamaki et 
al.; Izumi et al., 2007)* 
(Glutathione metabolism) 
Inhibitor of transporter P-
glycoprotein* (Nabekura et al.) 
Prostate cancer* (Johnson et al., 
2008) 
Gastroprotective (Areche et al., 
2009a) 
Activation of gamma receptor 
(implying an anti-inflammatory 
potential) (Poeckel et al., 2008)* 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Clemomandshuricoside B 
(or isomer) 
C22H30O13 
 
Not found 502.2 H. crenata (present work) Not mentioned 
Coumaroyl hexoside C15H18O8 Not found 326.1 H. crenata (present work) Anti-inflammatory and 
antinociceptive activities (Kupeli et 
al., 2007) 
Creoside I (or isomer) C14H24O7 Not found 304.2 H. crenata (present work) Not mentioned 
5-Deacetoxy-5'-epiolguine 
(or isomer) 
C16H20O7 Not found 324.11 H. crenata (present work) Not mentioned 
Diterpenoid derivative C19H22O5 Not described
A 330.1546 H. crenata (present work) Not describedA 
Diterpenoid derivative C20H30O4 Not described
A 334.2216 H. crenata (present work) Not describedA 
Diterpenoid C20H28O3 Not described
A 316.2112 H. crenata (present work) Not describedA 
Diterpenoid C20H32O6 Not described
A 368.2 H. crenata (present work) Not describedA 
Diterpenoid C20H30O4 Not described
A 334.2 H. crenata (present work) Not describedA 
Diterpenoid C20H24O7 Not described
A 376.1414 H. crenata (present work) Not describedA 
Diterpenoid C20H32O4 Not described
A 336.2191 H. crenata (present work) Not describedA 
Epoxyabietrienone methyl 
ether derivative 
C21H28O6 Not found 376.1774 H. crenata (present work) Not described
A 
Epoxykaurene derivative C22H30O7 Not found 406.188 H. crenata (present work) Not mentioned 
Epoxylignan derivative C18H20O7 Not found 348.126 H. crenata (present work) Cytotoxic and Antioxidative 
activities(Duan et al., 2009) 
Esquirolin B / suaveololi 
(or isomer) 
C20H34O2 Not found 306.2633 H. dilatata (Urones et al., 
1998) 
H. crenata (present work) 
Not mentioned 
Ethylrosmanol / epi-
ethylrosmanol (or isomer) 
C22H30O5  Not found 374.1983 H. crenata (present work) Anti- HIV activities(Paris et al., 
1993) 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Eucalyptol 
(1,8 cineole ) 
C10H18O 
 
154.2 H. recurvata 
H. emoryi 
H. fruticosa 
H. crenata 
H. martiusii 
H. mutabilis 
H. spicigera 
H. suaveolens 
(Fragoso-Serrano et al., 1999; 
Leclercq et al., 2000; Scramin 
et al., 2000; Azevedo et al., 
2001; Azevedo et al., 2002; 
Campos et al., 2002; Aguiar et 
al., 2003; Araujo et al., 2006; 
Koba et al., 2007; Menezes et 
al., 2007; Ngassoum et al., 
2007; Noudjou et al., 2007b; 
Botrel et al., 2009; Rebelo et 
al., 2009) 
H. crenata (present work) 
Antinociceptive* (Bastos et al., 
2009; Martinez et al., 2009) 
Anti-Inflammatory* (Bastos et al.; 
Juergens et al., 2003) 
Sedating and antipyretic activity 
(Ortiz de Urbina et al., 1989) 
Eudesmenone or 
labdanolide derivative 
C17H26O4 Not found 294.1722 H. crenata (present work) Not mentioned 
Germacradiene derivative 
(salviadienol B or isomer) 
C28H42O11 Not found 554.2621 H. crenata (present work) Not mentioned 
Hydroxylabdanolidoic acid 
derivative 
(norambreinolide-18,6-
olide or isomer) 
C16H22O4 Not found 278.1589 H. crenata (present work) Not mentioned 
Hydroxyluteolin pentoside C20H18O11 
 
434.092 H. crenata (present work) Not mentioned 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Hyptol C20H26O4 
 
 H. fructicosa(Monache et al., 
1977) 
H.crenata (present work) 
Not mentioned 
Isoschaftoside C26H28O14 
 
564.1551 
 
H. crenata (present work) Not mentioned 
Isovitexin C21H20O10 
 
432.1132 
H. crenata (present work) Antinociceptive and anti-
inflammatory(Rabelo et al., 2013) 
Labdanone / kaurenone 
diterpenoid 
C20H32O6 Not found 368.2273 H. crenata (present work) Not mentioned 
Labdenone diterpenoid C20H32O5 Not found 352.2324 H. crenata (present work) Not mentioned 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Luteolin glycoside 
derivative 
C27H30O16 
 
610.2 H. crenata (present work) Neuroprotective, antinociceptive 
and anti-inflammatory(Guo et al., 
2013; Rabelo et al., 2013) 
Maoecrystal V (or isomer) C19H22O5 
 
330.1358 H. crenata (present work) Not mentioned 
Martiusane (or isomer) C20H30O3 Not found 318.2269 H. crenata (present work) 
H. martiusii (Cavalcante Da 
Cruz Aragao et al., 2004) 
Not mentioned 
Megastigmene glycoside 
derivative 
C19H30O8 Not found 386.2016 H. crenata (present work) Not mentioned 
Megastigmenone glycoside 
derivative 
C19H32O7 Not found 372.2 H. crenata (present work) Not mentioned 
Megastigmadienone 
glycoside derivative 
C19H30O9 
 
Not found 402.1786 H. crenata (present work) Not mentioned 
Methoxynepetaefolin 
derivative (or isomer) 
C23H32O8 Not found 436.199 H. crenata (present work) 
H. fasciculata (Ohsaki et al., 
2005) 
Not mentioned 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Methyl epirosmanol / 
oxoinuroyleanol (or 
isomer) 
C21H28O5  
 
360.1834 H. crenata (present work) Not mentioned 
Methyl pisiferate (or 
isomer) 
C21H30O3 Not found 330.2085 H. crenata (present work) Not mentioned 
Neoisoschaftoside C26H28O14 
 
564.2 H. crenata (present work) Not mentioned 
Nonyl hydroxybenzoate 
derivative 
C16H24O3 
 
264.2 H. crenata (present work) Not mentioned 
Pervoside B (or isomer) C16H20O9 Not found 356.0997 H. crenata (present work) Not mentioned 
Rosmanol C20H26O5 
 
346.4 H. dilatata 
(Urones et al., 1998) 
H. crenata (present work) 
Inhibits lipopolysaccharide-induced 
inos and COX-2 expression through 
downregulating MAPK, NF-
Kappab, STAT3 and C/EBP 
signaling pathways* (Anti-
inflammatory) (Lai et al., 2009) 
Neuroprotective effects (Park, 
2009) 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Rosmaquinone (or isomer) C20H24O5 
 
344.2 H. crenata (present work) Not mentioned 
Rosmaquinone A or B (or 
isomer) 
C21H26O5 
 
358.2 H. crenata (present work) Not mentioned 
Rosmarinic acid 2R)-2-
[[(2E)-3-(3,4-
Dihydroxyphenyl)-1-oxo-2-
propenyl]]oxy]-3-(3,4-
dihydroxyphenyl) 
propanoic acid 
C18H16O8 
 
360.3 H. capitata 
H. verticillata 
(Heinrich et al., 1992; Kuhnt 
et al., 1995b; Heinrich, 2003) 
H. crenata (present work) 
Antinociceptive (Park, 2009) 
Anti-inflammatory* (Park, 2009; 
Rocha et al., 2009; Sahu and 
August, 2009) 
Anticancer (Feng et al.; Nabekura 
et al.; Nabekura et al.; Stanojkovic 
et al.; Yesil-Celiktas et al.; 
Scheckel et al., 2008; Koeberle et 
al., 2009; Kwak et al., 2009; Xavier 
et al., 2009) 
Suppresses retinal 
neovascularisation (Kim et al., 
2009) 
Salvianolic acid B, E or L 
(or isomer) 
C36H30O16 
 
718.2 H. crenata (present work) Neuroprotective, anti-inflammatory 
and antidepressant(Chen et al., 
2011; Ye et al., 2011; Feng et al., 
2012) 
Salvidorol (or isomer) C19H26O4 Not found 318.2 H. crenata (present work) Not mentioned 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Salvigenin 
(4H-1-benzopyran-4-one, 
5-hydroxy-6,7-dimethoxy-
2-(4-methoxyphenyl)- 
 
C18H16O6 
 
328.3 H. urticoides 
(De Vivar et al., 1991) 
H. crenata (present work) 
Anticholinesterase (Kolak et al., 
2009) 
Anticancer (Kamatou et al., 2008) 
Salviregnone (or isomer) C19H24O2 Not found 284.2 H. crenata (present work) Not mentioned 
Schaftoside C26H28O14 
 
564.2 H. crenata (present work) Antihepatotoxic 
effects(Hoffmannbohm et al., 1992) 
Scutellarein O-methyl ether C16H12O6 
 
300.1 H. crenata (present work) Anti-inflammatory(Rao et al., 
2009) 
Scutellarein di-O-methyl 
ether 
C17H14O6 Not found 314.1 H. crenata (present work) Anti-inflammatory(Williams et al., 
1999) 
Sesquiterpenoid derivative C15H26O3 Not found 254.1779 H. crenata (present work) Not mentioned
A 
Sesquiterpenoid derivative C15H24O3 Not found 252.1802 H. crenata (present work) Not mentioned
A 
Thymol 
(Phenol, 5-methyl-2-(1-
methylethyl)- 
C10H14O 
 
150.2 H. mutabilis 
H. verticillata 
(Kuhnt et al., 1995a; Aguiar et 
al., 2003; Heinrich, 2003) 
H. crenata (present work) 
Antinociceptive (Angeles-Lopez et 
al.; Angeles-Lopez et al., 2010) 
Anti-inflammatory (Braga et al., 
2006; Monteiro et al., 2007) 
Gastroprotective (Monteiro et al., 
2007) 
Cytotoxic (Ersev et al., 1999) 
Acetylcholinesterase* (Andres and 
Narayanaswamy, 1997; Jukic et al., 
2007) 
Trilobiol (or isomer) C21H26O7 Not found 780.3 H. crenata (present work) Not mentioned 
Triterpenoid C30H46O7 Not found 518.3 H. crenata (present work) Not described
A 
 Compound Molecular 
formula 
Structure Molecular 
weight/ 
(g/mol) 
Hyptis 
Species/Author 
Pharmacological effects 
Applied for the compound 
published. 
Unassigned compound C12H20O4 Not described
A 228.1 H. crenata (present work) Not mentionedA 
Unassigned compound C21H32O8 Not described
A 412.2 H. crenata (present work) Not describedA 
Unassigned compound C12H20O4 Not described
A 228.1258 H. crenata (present work) Not describedA 
Unassigned compound C12H20O4 Not described
A 228.1258 H. crenata (present work) Not describedA 
Unassigned compound C19H16O3 Not described
A 292.1176 H. crenata (present work) Not describedA 
Vicenin-2 (or isomer) C27H30O15 
 
594.1652 H. crenata (present work) Antinociceptive and anti-
inflammatory(Gorzalczany et al., 
2011{Marrassini, 2011 #1779)} 
Vitexin  C21H20O10 
 
432.1131 H. crenata (present work) Antinociceptive and anti-
inflammatory(Rabelo et al., 2013) 
Not described
A
 =Not possible to describe due to unspecific identification of the compounds 
Table appendix A – Compounds identified in the Hyptis crenata decoction extract and fractions that were tested in this PhD project  
 
  
 
 
 
 
 
 
 
 
Appendix B – Traditional Use Questionnaire 
 
 
 Questionnaire applied in the traditional use survey 
I – When did you first use H.crenata? 
II – How often do you use it? 
III – Do you think of H.crenata as a regular drink or tonic (like coffee)? 
IV – What are the situations when you use or are using H.crenata? 
V – What effects do you think that H.crenata has?  
VI – How do you feel after you have consumed it? 
VII – Are you using H.crenata to treat an illness, if so which and is it proving an 
effective treatment? 
VIII – Did you take or are you taking any other medication when you were or are using 
H.crenata? If yes, which kind? E.g. herbal 
IX – How much are you taking? How many times are you taking H.crenata per day? 
What time of the day do you use H.crenata?  
X – How frequently and over what time scale have you been using it? Days, weeks, 
months or years? 
XI – Describe any symptoms or side effects you may experience through use of 
H.crenata? 
XII – Description of preparation process and utilisation: 
XIII – How do you use H.crenata? e.g.: decoction (tea), tinctures, syrup, paste, infusion, 
ointment, salad (e.g. eat the leaves). 
XIV – Which part of the plant is used? e. g. stems, leaves, flowers, whole plant, roots. 
XV – How much material is used during preparation? E.g. numbers or grams of leaves, 
stems or flowers. 
XVI – How do you use the material collected? E.g. fresh, dried 
 XVII – Do you store the material for use? If yes, how do you store it? How long do you 
store it for? 
XVIII – Is there any particular time of the day that you collect the plant? E.g. morning, 
afternoon or evening. 
XIX – Is there any particular time of the year that you collect the plant? E.g. 
January…December 
XX – Where did you get the H.crenata from? 
XXI – From whom did you learn how to prepare H.crenata? 
XXII – Which type of solvent is used? e.g water, alcohol, honey… sugar. 
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